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CHAPTER I 
 
INTRODUCTION 
 
Autism and the Broader Autism Spectrum 
 Autism (OMIM #209850) is a devastating neurological disorder in which 
affected individuals have life-long deficits related to three core phenotypic 
areas/domains:  deficits in the development of language; inappropriate social 
understanding, interactions, and behavior; and patterns of repetitive, restrictive, 
and compulsive interests and behaviors. Classic autism, or autistic disorder, is 
distinguished from other Pervasive Developmental Disorders (PDDs), including 
Asperger’s syndrome, Rett syndrome, and PDD not otherwise specified (PDD-
NOS) through the use of diagnostic instruments that rate various aspects of the 
broader autism phenotype (BAP) [1]. These instruments include the DSM-IV, the 
Autism Diagnostic Interview (ADI) and its revision (ADI-R), and the Autism 
Diagnostic Observation Schedule (ADOS) [2-4]. The ADI and ADOS are used 
universally to obtain a research diagnosis of autism. A small percentage (~10%) 
of patients presenting with autistic features can be ascribed to single-gene 
disorders, such as fragile X syndrome, tuberous sclerosis complex [5], Angelman 
syndrome [6], and Rett syndrome [7]. Prominently identified features in patients 
with autism include mental retardation (~70%), macrocephaly (~20%), epilepsy 
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and/or seizures (~15-30%), gastrointestinal abnormalities, hypotonia, and motor 
stereotypies [8, 9]. 
 
History and Epidemiology 
 The term “autism” was coined by Eugen Bleuler, a Swiss psychiatrist and 
psychologist, around 1912 and originally referred to “an escape from reality”. In 
his 1943 article entitled “Autistic Disturbances of Affective Contact” in the journal 
Nervous Child, Leo Kanner adapted this term to describe children he believed to 
be afflicted with a syndrome not previously described. Kanner remarked that 
affected children  “have come into the world with innate inability to form the usual, 
biologically provided affective contact with people”. His observations describe 
specific features of the clinical presentation: “extreme autistic aloneness”; 
delayed and abnormal speech with echolalia, pronominal reversal, literalness and 
inability to use language for communication; and monotonous, repetitive 
behaviors with an “anxiously obsessive desire for the maintenance of sameness”. 
Many children were believed to be deaf or hard of hearing due to their lack of 
response to questions or commands. Kanner indicates: “Everything that is 
brought to the child from the outside, everything that changes his external or 
even internal environment, represents a dreaded intrusion”. These intrusions may 
often be ignored. If persistent, however, they cause panic, stress, and despair, 
often being expressed as temper-tantrums [10, 11].  
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Physically, the eleven children Kanner originally reported were normal, 
however, he noted that five had enlarged heads. Three of the eleven were mute. 
He also noted that only three of the eleven were female. Other anecdotal 
observations included a curious commonality of backgrounds for these children. 
Kanner writes “It is not easy to evaluate the fact that all of our patients have 
come of highly intelligent parents. This much is certain, that there is a great deal 
of obsessiveness in the family background. One other fact stands out 
prominently. In the whole group, there are very few really warmhearted fathers 
and mothers. For the most part, the parents, grandparents, and collaterals are 
persons strongly preoccupied with abstractions of a scientific, literary, or artistic 
nature, and limited in genuine interest in people”  [10]. These observations of 
non-autistic family members would later prove to be genetically important. At the 
time, the bias in psychiatry attempted to explain psychiatric disorders as a result 
of poor parenting, leading society to believe this was the cause of autism. Later 
studies disproved this by demonstrating no significant difference in the parents of 
autistic individuals to those of non-autistic children [8, 12].  
Despite that fact that “classic autism” as we know it today was not formally 
described until 1943 by Leo Kanner, a few accounts of conditions in the 
eighteenth and nineteenth centuries are similar in nature. One case described by 
Uta Frith described 39 year-old Hugh Blair. When he appeared in court for a 
1747 trial, witness depositions described him as lacking common sense and 
having a “silent madness”. More specific descriptions led Frith to believe this to 
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be an early report of autism. Other early cases reports by John Haslam, Henry 
Maudsley, and Jean Itard are thought to represent case descriptions of 
individuals with pervasive developmental disorders (PDDs) (i.e. the broader 
autism spectrum), likely including Asperger syndrome. Kanner never believed 
these to meet his description of “autism”, while others argue these cases could 
have been autism. Regardless, over time many noteworthy investigators have 
refined Kanner’s description of autism. In doing so, they have shown that the 
clinical diagnosis and description for autism presents across a spectrum of 
severity involving the three core phenotypic domains [11].  
 Autism epidemiology is quite complex. Surveys of autism prevalence 
started in the mid-1960s in England and have since been conducted worldwide. 
Original surveys were based on a narrow definition of autistic disorder 
representing severe impairment of language, social interaction, and repetitive 
behaviors. Over time, diagnostic criteria have evolved to include cases on both 
less severely and more severely affected ends of the spectrum. This has 
complicated efforts to establish precise estimates of autism prevalence within 
and across populations over time [13]. Fombonne points out that rates for a 
narrow diagnosis of autism disorder in recent surveys has been consistently 
higher than 10/10,000 whereas previous prevalence estimates were on the range 
of ~4-5/10,000. For a broader diagnosis of autism spectrum disorder, the 
prevalence is ~60/10,000. The ratio of affected males to affected females is 4:1 
for classic autism, and even higher in the broader spectrum. He concludes that 
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available evidence suggests that rates of autism spectrum disorders (ASDs) and 
autistic disorder appear 3 to 4 times higher now than rates estimated in the 
1970s [9, 14-16]. Fombonne outlines other confounding factors that may help 
explain some or all of this apparent increase in prevalence [17]. 
 Although classic autism is a distinct syndrome, current literature supports 
the description of autism as more appropriately presenting across a spectrum. 
DSM-IV-defined autistic disorder represents one slice of this spectrum of 
behavioral restriction and social and communication impairment [9].  
 
Genetics 
There has been long-standing support from twin, family, and segregation 
studies providing evidence of a substantial genetic component in the etiology of 
autism. Twin studies have shown a 60% to 90% concordance rate for classic 
autism among monozygotic (MZ) twins depending on use of narrow or broad 
diagnostic criteria, respectively. Dizygotic (DZ) twins, in contrast, show a 0-10% 
concordance under the same models [9, 18, 19]. Studies have estimated the 
recurrence risk for siblings of a child with autism to be anywhere from ~50-100 
times greater than the population prevalence [19, 20]. Current estimates of the 
sibling recurrence risk are 6 to 8% for autistic disorder [8, 9]. The heritability, or 
the proportion of the total phenotypic variation due to genetic variation, of 90% 
indicates that autism is among the most genetic of neuropsychiatric conditions [8, 
14]. Various studies indicate that between five and fifteen (and possibly more) 
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genes contribute to overall genetic risk for idiopathic autism. Models support 
oligogenic inheritance within individual families with locus heterogeneity resulting 
in different families possessing a different collection of susceptibility alleles [20, 
21]. Traits or milder phenotypes presenting in relatives of individuals with autism 
may reflect inheritance of allelic subsets of those present in the affected 
individual [8]. Thus, autism is not merely a genetic disease, but a disorder with a 
complex genetic architecture. Despite such strong support for a genetic etiology, 
no autism susceptibility gene has been definitively identified. 
Alternative hypotheses regarding the genetics of autism have been put 
forward. Some have proposed that epigenetic effects at susceptibility genes play 
an important role in autism etiology [22]. Epigenetics relates to alterations in gene 
expression without a necessarily accompanying sequence variation. Genomic 
imprinting is an example of an epigenetic phenomenon. There has also been 
substantial discussion involving environmental risk factors such as the Measles-
Mumps-Rubella (MMR) vaccine or the earlier (higher mercury-containing) 
formulations of the vaccine preservative thimerosal [23]. The MMR hypothesis 
has been widely disproved [24]. While the case for thimerosal is less certain, 
studies are underway to evaluate the potential epidemiological effects for 
exposure to these older vaccine preservatives that contained relatively higher 
levels of mercury.  
To identify autism susceptibility genes, several groups have undertaken 
unbiased, genome-wide linkage screens using varying numbers of families with 
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multiple affected individuals (e.g. affected sibling pairs) [21, 25-33]. These 
studies have identified numerous linkage peaks on many chromosomes. 
Comparison of these results indicates linkage on 7q and 2q as being most 
consistently replicated. However, no single gene has been convincingly 
demonstrated to underlie increased risk for autism on these or other 
chromosomes. Numerous candidate gene studies have been conducted in 
autism on the basis of available information concerning chromosomal 
abnormalities, linkage, altered neurobiology and neuropathology seen in autism 
[8]. 
 
Neurobiological Candidate Systems 
While there are several neurobiological systems that are potentially 
involved with genetic risk for autism, the main focus of this dissertation is on the 
serotonin (5-hydroxytryptamine, 5-HT) and GABA (γ-aminobutyric acid) systems. 
Multiple lines of investigation point to abnormalities in both of these systems as 
being involved in autism. Several genes within these systems have been 
examined for involvement in disease risk, although no consistent results implicate 
common alleles at any particular gene. 
Well-replicated observations of elevated platelet serotonin in ~20-25% of 
people with autism and first-degree relatives implicates serotonin as being 
relevant to autism etiology [34-36]. Selective serotonin reuptake inhibitors 
(SSRIs), preferentially targeting the serotonin transporter (SLC6A4), are often 
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effective in treating anxiety, rituals and aggression in autism and related 
disorders [37, 38]. Numerous association studies in autism have failed to yield 
consistent findings with serotonin-related genes in general and SLC6A4 in 
particular. However, most of these studies have focused on 5-HTTLPR, an 
insertion/deletion polymorphism in the promoter of SLC6A4. 
GABA is the major inhibitory neurotransmitter in the adult brain although it 
mediates excitatory transmission during development. Recent publications have 
shown: (1) the number of GABAA receptors are significantly decreased in brains 
of children with autism [39]; (2) plasma GABA, and its essential precursor 
glutamate, are elevated in children with autism [40-42]; (3) benzodiazepines, 
which are effective in treating seizures, anxiety, and social phobia that are seen 
in autism, bind to and act, on GABAA receptors [43]; (4) GABA-ergic transmission 
has important trophic actions during development; (5) genetic evidence points to 
the 15q11-q13 region in general and the GABRB3 gene in particular [31, 44-47].  
Based on these data, the GABAA receptor subunit genes, particularly those in 
15q11-q13, represent excellent candidates, allelic variants of which could confer 
genetic susceptibility for development of autism. 
 
Genomic Candidate Regions 
Though there are multiple regions of interest based on linkage findings or 
chromosomal abnormalities  (e.g. 7q, 2q), the first part of this dissertation will be 
focused on examination of candidate genes in two specific regions: 17q11.2 and 
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15q11-q13. The former region has been identified by ongoing linkage studies that 
are also part of this work. Initial linkage analysis of 158 multiplex autism families 
revealed a multipoint heterogeneity LOD (HLOD) score of 2.74 under a dominant 
model at ~53 cM on 17q11.2. This score increased to 3.65 when the families 
were analyzed separately based on relative affection for rigid-compulsive 
behaviors, a sub-phenotype of autism. The International Molecular Genetic Study 
of Autism Consortium (IMGSAC) has also observed suggestive linkage at this 
site [48]. The serotonin transporter locus (SLC6A4), long considered a functional 
candidate in autism, maps directly underneath the linkage peak. Given multiple 
lines of evidence, one aim of this thesis project is to test the hypothesis that 
SLC6A4 is involved in autism susceptibility. 
The second region, 15q11-q13, was hypothesized to harbor an autism 
susceptibility locus based on observations of duplications and triplications 
affecting this region in a small percentage of people with autism (reviewed in 
Veenstra-VanderWeele et al.) [9, 49, 50]. While not universally observed by all 
groups [30, 51, 52], both linkage and association have been observed in this 
region [31, 44-47]. Our group and Shao et al. have documented increased 
linkage in trait-based subsets of autism in a region containing a cluster of GABAA 
receptor subunit genes [53, 54]. Several groups have detected association at 
microsatellite and SNP markers in the GABRB3 gene, and the data presented in 
this dissertation substantially extends these findings. A detailed analysis of allelic 
association throughout the GABA cluster, as well as the interval involved in 
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genomic imprinting control and that containing maternally-expressed genes 
(UBE3A and ATP10A) 5’ of the GABAA receptor subunit gene cluster will be 
presented. 
The final part of the dissertation describes a series of genome-wide 
analyses for autism and quantitative traits, representing subsets of the broader 
autism phenotype. These analyses point to additional potential candidate regions 
that may harbor autism-related risk factors. Regions showing significant or highly 
suggestive linkage were further investigated by analysis of additional markers to 
refine linkage data and test a limited number of promising candidate gene loci. 
 
Genetic Analysis of Complex Disease 
Three common approaches are used to facilitate identification of genes for 
complex genetic disorders. These are as follows: (1) Genome-wide linkage 
analysis, a biologically unbiased method for detecting regions of the genome 
more frequently inherited in common by affected individuals in a family than 
predicted by chance; (2) Test candidate systems likely to be involved in disease 
etiology identified based on altered physiology or pathology seen in patients with 
the disorder. Such information can then be used in speculation concerning 
particular biological systems or pathways, and ultimately specific proteins in 
those systems. Thus, by being well informed about altered biology in a disease 
condition, one may test specific genes, in a hypothesis-driven manner, directly for 
involvement in disease risk; (3) Examination of rare cases or families with the 
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disorder presenting with chromosomal abnormalities that may identify a relevant 
genomic interval or gene locus.  Co-localization with linkage and/or functional 
candidate genes makes such findings even more compelling to investigate. 
The purpose of a genomic linkage screen is to identify regions in the 
genome that are more frequently inherited by affected family members than 
would be expected by chance. The amount of allele-sharing within and across 
families is measured in LOD (logarithm of odds) score units. This is calculated 
based on the relationship between recombinant and non-recombinant alleles at a 
given marker and across nearby markers [55]. Traditional genome-wide analyses 
have exploited highly polymorphic microsatellite markers with an average 
genome-wide spacing of 10 cM or less to provide sufficient coverage and 
information content to identify regions for more detailed analysis. These intervals, 
which harbor potential functional (and by definition positional) candidate genes, 
may be selected for detailed study. Often, the first step in such efforts involves 
higher resolution genotyping to improve information content and refine genetic 
linkage data; this often has the effect of narrowing a candidate interval.  
Identification of disease-related alleles within a targeted candidate region 
should be informed by at least two possible allele-disease risk paradigms. 
Common genetic markers (e.g. SNPs) may be employed to test for the presence 
of allelic association to detect the presence of common alleles. This may be done 
in an unbiased manner across the entire candidate interval, or within specific 
functional candidate genes, located within the candidate interval of linkage. 
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Alternatively, a variant screening-type approach may be used to test for possible 
heterogeneous disease-related variants. Such an approach is quite labor 
intensive and expensive, and in practice is generally reserved for a very small 
number of candidate loci. If more discreet genomic regions (in the case of a 
chromosomal abnormality) or specific genes (in the case of a functional 
candidate approach) are chosen, these methods permit a bypass of the genome-
wide linkage process, by directly testing the hypothesis that a particular gene 
and/or functional candidate is involved in the disease. 
Association studies test whether a common and specific allele is either 
present more often in cases than controls, or is more frequently transmitted to 
affected individuals within a family (i.e. exhibiting allelic transmission distortion). 
Thus, the two basic frameworks for association analysis are case-control and 
family-based studies. The case-control approach is generally regarded as more 
powerful and sensitive than family-based tests [56], although it can produce 
spurious associations due to population stratification [57]. Failure to match cases 
and controls for the same underlying population, ethnicity, and other factors, can 
lead to false positive or false negative results due to recent admixture and 
selection or drift between unlinked loci [58-60]. Historically, association tests 
have depended on the availability of numerous polymorphic markers in a given 
candidate region and the availability of abundant SNP markers makes this 
approach viable. It is estimated that SNPs occur on average every 500-1,000 
base pairs and have a low mutation rate, both of which are advantageous in 
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association studies [61-64]. To avoid false negative results from an association 
study, it is important to perform a thorough analysis of linkage disequilibrium 
patterns and haplotype structures across a candidate locus or region to provide 
sufficient information content with which to detect and localize genetic effects. 
Without using multiple polymorphisms, any association study is likely to be 
vulnerable to type II error by failing to adequately cover the gene of interest [65, 
66]. A current disadvantage of association studies is the need to identify a 
substantially narrowed genomic interval of interest or selected a candidate gene 
based on a priori  knowledge.  Recent technological advances will make the idea 
of genome-wide association studies a reality. However, as outlined in a recent 
review by Hirschhorn and Daly, there are multiple details that must be worked out 
before this can truly become practical [67]. These issues include but are not 
limited to; (1) the cost of such an experiment; (2) the criteria for choosing 
markers; (3) the limitation of false positive results.  
Although, standard genetic analyses can detect genes of moderate to 
strong main effect, they have no ability to detect purely interactive effects. It is 
very likely that complex genetic disease in general and autism in particular will 
involve, at least in part, epistatic effects on disease risk. In fact, many 
researchers suggest that epistasis may be the rule in common complex disease 
and not the exception [68, 69]. This may be especially true given the lack of 
replication of single-locus results in association studies reviewed by Hirschhorn 
et al. [70]. In fact, Moore and Williams hypothesize that epistatic effects will prove 
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more important than independent main effects in complex disease [71]. Epistatic 
effects among multiple genes may play an important role in determining risk of 
autism, or broader phenotypes, and for some genes the interactive effects may 
be stronger than the independent single-gene effects. The Multifactor 
Dimensionality Reduction (MDR) method was developed by Moore and 
colleagues as a new approach to examine allelic interaction [72-74]. These kinds 
of new and innovative methods for examination of gene-gene interactions will 
play a key role in the future examination of complex disease. 
A refinement of linkage and association strategies in genetic analysis of 
complex disease is to use trait-based phenotypic subsets and relevant statistical 
methodologies to identify susceptibility genes. These subsets can include 
endophenotypes, measurable components of the disease that become 
recognizable through detailed examination, and other intermediate quantitative 
traits [75]. Standard linkage and association analyses seek to identify genes of 
main effect and are typically employed using a global diagnosis for the disorder.  
Given the clinical and genetic heterogeneity in autism, I proposed to maximize 
use of available phenotypic data. Two recent reports describe trait subsets of 
autism derived from ADI information using a principal components analysis to 
identify clusters of ADI responses. This strategy has provided a means for 
performing genetic analyses using phenotypic subsets of autism.  Our 
collaborator Dr. Susan Folstein and her group identified six distinct clusters of 
highly correlated variables from the Autism Diagnostic Interview (ADI): (1) spoken 
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language, (2) social intent, (3) compulsions and rigidity, (4) developmental 
milestones, (5) savant skills and (6) sensory aversions. Most of these are highly 
correlated between sibs and within affected sib-pair families, suggesting genetic 
relevance [76].  Calculation of scores for each of these sub-phenotypes would 
provide quantitative variables suitable for quantitative trait locus (QTL) analysis 
and quantitative trait association studies. Hauser and colleagues described an 
Ordered-Subsets Analysis (OSA) method that allows families to be ranked 
according to a family-specific (and genetically-relevant) covariate value. OSA 
starts with the (e.g.) highest or lowest ranked family, calculates an allele-sharing 
LOD score, subsequently adds families by rank and recalculates the LOD score 
with each addition until it defines the division in the dataset at which a maximum 
LOD score is reached [77]. These families, producing the maximum LOD score, 
are then defined as a subset for that covariate and can be used for subsequent 
analyses. I will describe application of these strategies for genome-wide and 
region/gene-specific studies. 
Other endophenotypes in disease useful in homogenizing a sample 
include anatomical, biochemical, and neuropsychological measures. Several of 
these quantitative traits relevant to autism are reviewed by Veenstra-
VanderWeele et al. and include: “level of intellectual functioning, degree of social 
or communication impairment, presence of seizure disorder, dysphmorphology, 
savant abilities, restrictive and repetitive behaviors”, and most notably “head 
circumference and whole blood serotonin” [9]. 
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As mentioned by Weiss et al. another confounding effect of complex 
disease may be the presence of sex-specific genetic effects [78]. They suggest 
that failing to model for sex-specific architecture may limit the ability to detect 
“true” susceptibility loci in genome-wide analyses. Given that autism has roughly 
a 4:1 ratio of male to female-affected individuals, it may prove imperative to 
examine families with only male-affected individuals given that families containing 
female-affected individuals may have a different underlying landscape for genetic 
susceptibility.  A recent study provides support that such a course may be 
warranted in autism [79]. 
Another innovation in the examination of candidate genes or regions 
potentially involved in complex disease involves applying the rapidly emerging 
availability of sequences from different genomes to identify regions of 
conservation that may harbor non-coding but regulatory functionality. A traditional 
bias in direct screening of candidate regions/genes, for rare mutations or to 
follow-up associated markers or haplotypes, is to focus on coding exons. Given a 
significant potential for complex disease-associated variants to affect expression, 
it is vitally important to represent potential regulatory sequences when designing 
genetic or variant screening strategies. If the alternative hypothesis of 
heterogeneous variation is involved in complex genetic disease, it is unlikely that 
coding variation will account for all disease alleles.  It will be more likely that 
variation within conserved non-coding and/or promoter and enhancer regions of 
the genome will play a role in disease susceptibility. The web-based program 
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VISTA (Visualization Tools for Alignment) (www-gsd.lbl.gov/vista/) is a useful tool 
that allows identification of conserved, and therefore potentially functional, 
sequences. VISTA performs comparisons of sequences across species, and 
plots homology relationships as a function of nucleotide sequence identity. This is 
an important tool for identifying non-coding regions that should be targeted for 
genetic analysis and potentially by re-sequencing efforts to directly identify 
potential disease-associated variants. 
Finally, many researchers seek to examine animal models to help explain 
the biology underlying complex diseases including autism [80]. In general, this 
approach can be fruitful in providing hints to gene and protein pathways involved. 
Unless a given gene is demonstrating extremely significant association with the 
human condition, and the nature of the underlying genetic alteration(s) that leads 
to disease risk is clearly understood, correlations between animal models and 
autism are necessarily weak. Even in such a scenario, there is always the caveat 
that the human disorder may be difficult or impossible to parallel in animal 
models. 
With these available tools at our disposal, we must be mindful of the 
multiple complicating factors within complex genetic disease that make our 
endeavors of understanding complex genetic disease extremely difficult. A paper 
by Thornton-Wells et al. addresses numerous issues regarding the complexity of 
common disease and provides suggestion for methods and method development 
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to handle the expanding information required to elucidate a complex disease like 
autism [81]. 
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CHAPTER II 
 
HYPOTHESIS AND SPECIFIC AIMS 
 
In this dissertation, I describe my genome-wide linkage studies of autism 
and traits comprising the aspects of the broader phenotype to identify autism 
susceptibility loci. I further document detailed molecular and genetic analyses of 
candidate genes in regions detected by linkage and specifically in 15q11-q13, 
identified on the basis of chromosomal duplications. Studies focus on genes 
acting within candidate neurobiological systems suspected of involvement in 
autism. Genetic analyses include construction of detailed linkage disequilibrium 
(LD) and corresponding haplotype maps across candidate loci and tests for 
transmission disequilibrium of single markers and haplotypes. Additionally, 
studies test for association to quantitative traits and potential allelic interactions. 
Molecular studies aim to identify functional variations on associated alleles or 
potential rare disease-related variants, and consider evolutionarily conserved 
sequence, in the absence of association. I hypothesize that there are allelic 
variants, which underlie genetic linkage and/or association to autism and related 
traits, and these contribute to autism susceptibility through both direct and 
interactive effects. Towards a genetic and phenotypic dissection of autism, I list 
the following aims for my dissertation: 
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Specific Aim I:  To examine the serotonin transporter (SLC6A4) locus 
within the 17q11.2 autism candidate region 
 
 
a. Identify and genotype single nucleotide polymorphisms (SNPs) across the 
SLC6A4 locus in autism families 
 
b. Characterize inter-marker linkage disequilibrium (LD) and corresponding 
haplotype structures 
 
c. Test single markers and multi-marker haplotypes for evidence of allelic 
association 
 
d. Screen functional/conserved sequences and/or associated allele(s) for 
evidence of disease-related variation 
 
 
 
Specific Aim II:  To examine the 15q11-q13 autism candidate region for 
involvement in inherited susceptibility to autism and related traits 
 
 
a. Examine the GABAA subunit gene cluster for evidence of allelic association 
and disease-related sequence variation using the framework outlined in 
Specific Aim 1  
 
b. Examine the Imprinting Center (IC) and Maternal Expression Domain (MED) 
for association to autism 
 
 
Specific Aim III:  Perform genome-wide linkage analyses of autism and 
individual traits representing autism sub-phenotypes 
 
a. Perform a genomic linkage screen for autism using multiplex families 
b. Perform a follow-up analysis of the most promising linked regions using SNPs 
to refine linkage data and perform limited candidate gene studies 
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CHAPTER III 
 
 
 
GENETICS OF THE SEROTONIN TRANSPORTER (SLC6A4) LOCUS IN 
AUTISM1 
 
 
 
Introduction 
 
 
 Evidence for Serotonin Involvement in Autism 
 Serotonin (5-hydroxytrptamine or 5-HT) has long been considered an 
attractive candidate system for involvement in autism etiology, given well 
replicated observations of elevated platelet serotonin in ~20-25% of probands 
and first-degree relatives [34-36, 82]. Given its role in 5-HT reuptake and 
presence in platelets, the serotonin transporter (SLC6A4) in particular has 
received significant attention as a logical candidate for this effect. Additionally, as 
the primary target for selective serotonin reuptake inhibitors (SSRIs) that are 
effective in treating behavioral symptoms including anxiety, rituals and 
aggression in autism and related disorders, the evidence for the serotonin 
transporter compounds [37, 38, 83-85]. Depleting tryptophan (an essential 
precursor for 5-HT biosynthesis) in adult subjects worsens autistic symptoms 
[86]. 
 In addition to the biological and pharmacological findings providing links 
for serotonin involvement in autism, the emerging understanding of serotonin’s 
                                                
1 Adapted from Am J Med Genet B Neuropsychiatr Genet 2004 May 15, 127B:104-12. 
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general role in behavior supports this premise. Serotonin is now known to affect 
sleep, mood, arousal, aggression, impulsivity, and affiliation, all of which are 
relevant to autism spectrum disorders. In fact, sleep disturbances have been 
observed in autistic individuals [87]. Genetic data from other neuropsychiatric 
conditions, some sharing behavioral traits with autism (mood, obsessive-
compulsivity, anxiety, and social phobia), suggest involvement of multiple genes 
(e.g. MAOA [88], SERT [89, 90], 5-HT receptors [91-94], TPH1 [95], and TPH2 
[96]) in the serotonergic pathway. 
 
Previous Genetic Studies 
Numerous association studies have been performed at this locus using 
two common variants: 5-HTTLPR, an insertion/deletion polymorphism in the 
promoter, and a variable number tandem repeat (VNTR) polymorphism located in 
intron 2. Both variants are proposed to exhibit allelic differences in transcription of 
SLC6A4 message, although the data is more clear for 5HTTLPR  [97-100]. The 
“long” (L) allele shows an approximately 2-fold level increased expression, 
compared to the “short” allele (S). Transmission disequilibrium test (TDT) studies 
in autism have failed to yield any consistent findings of allelic association with 
these markers in autism. This may in part be related to patterns of linkage 
disequilibrium, locus heterogeneity, allelic heterogeneity, or allelic interactions 
within or across loci [81]. Cook and colleagues reported preferential transmission 
of the short allele at 5-HTTLPR in autism [101], while others have reported 
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similar results for the long allele [102-104]. Other groups have failed to detect 
association [51, 105]. A single detailed study reported by the Cook lab describes 
high-density SNP genotyping across the SLC6A4 locus and subsequent TDT 
analysis [106]. They replicate and extend upon previous findings, showing 
nominally significant association of a haplotype containing 5-HTTLPR and the 
VNTR, as well as the VNTR marker alone. Additionally, they identify significant 
linkage disequilibrium (LD) at other SNPs (near the 5′ end of the gene) in their 
dataset of autism families. One other group has recently found association with a 
number of 5′ single-nucleotide polymorphisms [107]. Recent work by both Stone 
et al. and Weiss et al. provide preliminary data suggesting that SLC6A4 may be a 
male-specific susceptibility locus for autism and a sex-specific QTL for whole 
blood serotonin levels [78, 79]. The most recent evidence from Mulder et al. 
demonstrates association of the SERT intron two VNTR (12/12 genotype) with a 
rigid-compulsive domain of the autism phenotype [108]. 
 
Trait-Based Phenotypic Subsets 
 Growing evidence indicates that defining phenotypic subsets may improve 
power to detect genetic effects in complex disorders by identifying genetically 
more homogeneous sub-samples sharing common risk alleles[53, 54, 109-111]. 
To leverage phenotypic heterogeneity in autism for genetic studies, we need 
subsets defined by traits that (a) vary from one autistic person to the next; (b) are 
present, sometimes in milder form, in non-autistic family members much more 
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often than controls; and (c) aggregate in particular autism families. Towards this 
end, our collaborators completed a principal components analysis of items 
common to the Autism Diagnostic Interview (ADI) and its revision (ADI-R) and 
identified six phenotypic subsets, for which significant correlation of items within 
a given factor was observed [76]. These subsets are (1) spoken language, (2) 
social intent, (3) compulsions and rigidity, (4) developmental milestones, (5) 
savant skills and (6) sensory aversions. There was significant inter-sibling 
correlation in multiplex families for five of the six factor subsets, suggesting them 
to be genetically relevant. Social intent was not significantly correlated between 
sibs, but became so when age was covaried. 
 
Study Design 
We analyzed genotype data from an initial genomic screen of multiplex 
families for evidence of linkage using a categorical autism diagnosis. The 
analysis revealed suggestive linkage for autism to chromosome 17, and 
examination of the ADI-based phenotypic subsets revealed increased evidence 
supporting linkage in the families in which affected individuals are comparatively 
more affected for “rigid-compulsive” behaviors. Given that SLC6A4 maps directly 
under the linkage peak, and the nature of the phenotypic subset demonstrating 
increased linkage, we examined this locus for evidence of allelic association. Our 
approach to this study included the use of markers previously shown by Kim et 
al. to associate with autism [106] in parent-child trio families, detailed 
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characterization of LD, and examination of haplotypes across the locus to test the 
hypothesis that common alleles at SLC6A4 confer increased risk for development 
of autism and traits, such as rigid-compulsive behaviors, that are reflected in the 
broader phenotype. 
 
Materials and Methods 
 
Families 
The sample for this initial linkage study consisted of 137 multiplex families. 
A total of 57 multiplex families were recruited from the Tufts/New England 
Medical Center (NEMC) and 80 affected sib-pair families were obtained from the 
AGRE consortium (www.agre.org). Association studies were conducted using a 
dataset of 123 multiplex families, all of which were included in the linkage study. 
All probands were at least four years of age and were clinically assessed with the 
ADI or ADI-R and most with the Autism Diagnostic Observation Schedule 
(ADOS). In multiplex families at least one sib had to meet ADI algorithm criteria 
for an autism diagnosis, while additional siblings may fall only one or two points 
short of meeting full criteria. Probands were excluded from the study if they had a 
known medical or neurological condition suspected to be associated with their 
autistic phenotype (e.g. fragile X syndrome). The procedures for clinically 
evaluating affected individuals for the AGRE families has been previously 
described [30].   
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Molecular Analyses  
DNA was isolated from peripheral blood or lymphoblastoid cells using the 
PureGene kit according to the manufacturer’s recommendations (Gentra 
Systems, Minneapolis, MN). 5-HTTLPR genotypes were determined using size 
discrimination of PCR products on 3% NuSeive (3:1) agarose (FMC Bioproducts; 
Rockland, ME) gels. The short allele corresponds to a product of 484 bp, while 
the longer allele is 528 bp; amplifying PCR primers have been described 
previously [101]. SNPs from the dbSNP and Celera SNP databases were 
selected based on their map position, minor allele frequency, and previous 
findings of allelic association to autism in trio families. Database reference 
numbers and other details for markers are cited in Table 3-1. PCR assays were 
developed and optimized to amplify an ~200 bp region flanking SNPs. Individual 
SNPs were genotyped by either fluorescent polarization template-directed dye 
terminator incorporation assay (FP-TDI) or TaqMan™.  PCR primers and probes 
for assays are listed in Table 3-2. This information is unavailable for marker 
seven, which was obtained from Applied Biosystems (Foster City, CA) as an 
Assay-On-Demand™. 
For FP-TDI genotyping, PCR reaction volumes were 8 µl, employing 10 ng 
genomic DNA template, 0.2 µM primers, 125 µM dNTPs and Applied Biosystems 
AmpliTaq Gold DNA polymerase and buffer (Applied Biosystems). Cycling 
conditions included an initial denaturation at 95 °C for 10 min, followed by 50 
cycles of 94 °C for 15 s, optimal annealing temperature (TA°C) for 30 s, and 72 
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°C for 15 s, and a final extension at 72 °C for 10 min. FP-TDI analysis was 
performed using materials supplied in commercially-available Acycloprime™ kits 
according to the manufacturer’s published protocols (Perkin-Elmer Lifesciences, 
Boston, MA) and as described elsewhere [112]. Samples were analyzed using a 
VICTOR2™ multi-label plate reader instrument (Perkin-Elmer Life Sciences). 
For TaqMan™ genotyping assays reactions were performed in a 5 µl 
volume according to manufacturer’s recommendations (Applied Biosystems) 
[113]. Cycling conditions included an initial denaturation at 95 °C for 10 min, 
followed by 50 cycles of 92 °C for 15 s, 60 °C for 1 min. Samples were analyzed 
using an ABI 7900HT™ Sequence Detection System.  
 
Table 3-1.  SLC6A4 markers.  Alleles are listed major/minor. 
Marker 
No.
Marker 
Type
SLC6A4 
Region
dbSNP rs# 
/Celera hCV#
Alleles
Minor Allele 
Frequency
Intermarker 
Distance (kb)
1 ins/del
Promoter 
1A
5-HTTLPR
528(l)/ 
484(s)
0.45 _
2 SNP Intron 1A
rs2066713/ 
hCV1841702
C/T 0.41 ~12.5
3 SNP Intron 1A
rs2020936/ 
hCV11414119
T/C 0.16 0.851
4 SNP Intron 1A
rs2020937/ 
hCV1841703
T/A 0.41 0.057
5 SNP Intron 2
rs2020942/ 
hCV1841709
G/A 0.4 3.843
6 SNP Intron 5
rs140700/ 
hCV7473202
G/A 0.07 3.525
7 SNP Intron 8
rs140701/ 
hCV7911143
T/C 0.43 4.857
Exon 14
3´ UTR
0.41 13.5218 SNP rs1042173 T/G
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Table 3-2.  SLC6A4 PCR and genotyping primers. Labels are as follows: (F) 
Forward Primer, (R) Reverse Primer, (FP) FP-TDI extension primer, VIC and 
FAM are fluorescent labels for TaqMan™ allelic discrimination probes (Bold 
highlights SNP), AbD is an Assay-By-Design from ABI, AoD is an Assay-On-
Demand from ABI. “Gel” means the product was run out on an agarose gel and 
genotyped through size discrimination. Sequence for primers and probes for AoD 
assays are proprietary information. MGB stands for minor groove binder, and 
NFQ stands for non-fluorescent quencher. 
 
Marker 
No.
Product 
Size (bp)
TA 
(°C)
Assay
F GGCGTTGCCGCTCTGAATGC 484/
R GAGGGACTGAGCTGGACAACCAC 528
F ACTGCTCACTGCTGCTGCTAAATG
R GCATCACCCAAGCGTTCCC
FP-F TTGCTTCTGAGATGGACCGCATTTCCCTTC
F GCCAGGCAGTAGCATAAATGGT
R CAAACACCACTCAGAAGGATATGAA
VIC VIC-AGAGCGGTCTCCATAA-MGB-NFQ
FAM FAM-AAGAGCGATCTCCA-MGB-NFQ
F CATATCCTTCTGAGTGGTGTTTGC
R AATTTTAAAGGGATCGATTGTTGC
FP-F TGTTTGCATTCTTGAGCCTGGGG
F AGGAAGGCCATCACGAGAACAC
R CCTGCAGCCTGAGTTTTTAGCCTA
FP-F AACACATGGTTTTATTCTCGAGCC
F TGCATAGTGGGCTCAGAGGTAGT
R GGAGGTGGGTGAATGGATGTC
FP-F TGATCTTTCTGCCACACCACCTC
7 NA Unavailable NA 60
TaqMan 
(AoD)
F GTAGGAGAGAACAGGGATGCTATC
R CACACTATTTTTCATTTTAGCTTCTTACA
FP-R AGGTTCTAGTAGATTCCAGCAATAAAATT
153 52
FP
1
2
3
4
5
6
8
187 58
FP
151 55
FP
84 60
TaqMan 
(AbD)
181 56
FP
Primer sequences (5´-3´)
63 Gel
127 58
FP
 
 
 
 
Statistical Analyses 
Genotype data from the following chromosome 17 microsatellite markers, 
located between 31cM and 90cM, was included in linkage analyses: D17S1852, 
D17S974, D17S1303, D17S969, D17S947, D17S799, D17S922, D17S900, 
D17S921, D17S839, D17S1857, D17S2196, D17S1850, D17S1871, D17S1824, 
D17S1294, D17S1800, D17S798, D17S1293, D17S1842, D17S933, D17S1867, 
D17S1299, D17S788, D17S957, and D17S916. The deCODE genetic map was 
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used to provide genetic distances for these markers [114].  For a few markers not 
present on the deCODE map, genetic map location was determined by relating 
the deCODE and Marshfield (http://research.marshfieldclinic.org/genetics/) maps. 
Microsatellite genotype data was analyzed following checks for quality control 
and Mendelian inconsistencies.  HLOD values were calculated for the sample as 
a whole and for each subset under recessive and dominant models using 
GENEHUNTER-PLUS [115]. Disease allele frequencies were estimated to be q = 
0.01 or 0.1 for dominant and recessive models, respectively. The phenocopy rate 
was 0.0005, and the penetrance value was set at 0.5 for the analysis. These 
simple models were chosen somewhat arbitrarily, simply making the disease 
allele frequency 10-fold greater under a recessive model than under the 
dominant model. The reduced penetrance value was set at 50% given the 
likelihood of oligogenic inheritance and the possibility of heterogeneity, such that 
not all individuals having the allele would present with disease. These 
parameters, while minimizing our power somewhat, have a smaller impact on the 
lod scores when there is either linkage or no linkage and were therefore selected 
to be robust [116]. 
Families were subdivided into two groups for each of the six factors, 
derived from items common to the ADI and ADI-R. For factors (including rigid-
compulsive behaviors) whose scores had a unimodality of distribution across the 
overall dataset, the mean factor score was calculated for the two (sometimes 
three) probands, and families were split into two groups at the median of the 
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mean probands’ scores for that factor. The two groups for each factor correspond 
to families either “positive” or relatively affected with higher scores on the 
phenotypic domain in question, or “negative” for less affected and lower scores 
for that domain. Linkage was analyzed in both positive and negative subsets for 
each factor as described above. A simulation study to calculate an empiric P-
value for the rigid-compulsive linkage result was performed using SIMULATE 
(http://linkage.rockefeller.edu/ott/simulate.htm) to randomly draw, in each of 
10,000 replicates, 58 (corresponding to the number of rigid-positive) families from 
the overall dataset. Linkage for all markers was calculated separately for this 
group and the remainder of families under both dominant and recessive models 
using GENEHUNTER-PLUS.  
Genotype data from 5-HTTLPR and the seven SNPs were used in LD 
analysis. Initial analysis of SNP genotype data involved quality control checks 
consisting of verification of internal controls and assessment of Mendelian 
inconsistencies, followed by final haplotype consistency analyses using 
Simwalk2 [117]. Conformity with anticipated Hardy-Weinberg equilibrium 
expectations was established for all markers in the association study, and SNPs 
were examined for intermarker LD using both the r2 and D´ measures calculated 
by the GOLD  (Graphical Overview of Linkage Disequilibrium; [118]) software 
package. TD in autism families was determined using the PDT statistic, a variant 
of the transmission disequilibrium test (TDT), developed for use with general 
pedigrees [119]. Common haplotypes were determined using TRANSMIT [120], 
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and analysis of TD was performed using three SNPs (5-HTT-5, 5-HTT-6 and 5-
HTT-7) that define all common (≥5%) haplotypes. Results were considered 
significant at the nominal level for markers or haplotypes with P ≤ 0.05. 
Visualizations Tools for Alignment (VISTA) analysis was performed via 
web-based submission (http://www.gsd.lbl.gov/vista/) of human and mouse 
genomic sequence [121]. 
 
Results 
 To facilitate the identification of genes underlying genetic risk for autism, 
we performed a 10 cM genomic screen of multiplex autism families.  While we 
present the initial details of that study as it relates to chromosome 17 here, the 
completed screen is presented in its entirety in Chapter VIII. We detected 
suggestive evidence for linkage on chromosome 17 (Figure 3-1), with a 
maximum multipoint HLOD of 2.74 at D17S1871 (~50cM) under a dominant 
model in our dataset of families (n = 137). In an exploratory analysis, we used the 
six ADI factors as a basis for subsetting our families for linkage analysis. We 
detected a substantial increase in linkage in the subset of families in which 
probands are relatively affected (positive) by rigid-compulsive behaviors (Figure 
3-1). In the rigid-positive families (n = 58), the dominant HLOD increased to 3.62 
at D17S1294 (~53cM), adjacent to D17S1871 in the genomic screen panel. A 
permutation test showed that linkage in the rigid-compulsive families was 
significant (P = 0.025). Thus, if the rigid-compulsive subsetting scheme had 
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nothing to do with the linkage signal on chromosome 17q, then the probability of 
our observing an HLOD ≥ 3.6 by chance would be ≤ 0.025. 
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Figure 3-1. Linkage analysis of autism for chromosome 17. Dominant 
Multipoint HLOD scores are plotted for the overall (pooled) autism dataset 
(n=137), the rigid-positive (relatively affected; n=58), and the rigid-negative 
(relatively unaffected; n=79). The overall dataset has a peak multipoint HLOD of 
2.74 at D17S1871, and this increase to 3.62 in the rigid-positive subset. 
 
 
We noted that the serotonin transporter (SLC6A4) locus maps adjacent to 
D17S1294 (~140 kb). Given the long-standing hypothesis that 5-HTT is involved 
in serotonin-related autism etiology, we directly tested whether common alleles at 
this gene were associated with autism in our dataset. 5-HTTLPR and seven 
SNPs were initially selected as markers for this study providing an average 
marker density of ~5kb across the transcriptional unit (see Figure 3-2 and Table 
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3-1). Criteria for marker selection included previous evidence for association 
[106], high minor allele frequencies, and uniform spacing across the region. 
Markers were genotyped by PCR and size discrimination (5-HTTLPR), FP-TDI or 
TaqMan™ in a dataset of 123 multiplex families that represent a subset of the 
137 families analyzed for linkage. 
 
 
Figure 3-2. Schematic representation of SLC6A4. The 38kb transcriptional 
unit contains 15 total exons represented by the vertical boxes. Coding regions 
are indicated in black with the untranslated regions in gray. Markers are labeled 
and their positions indicated by arrows. 
 
 
  
Genotypes at individual markers did not deviate from expectations of 
Hardy-Weinberg equilibrium (Data not shown). To discover all common alleles at 
this locus, we characterized intermarker LD to permit identification of haplotype 
blocks and corresponding haplotypes. Intermarker LD was assessed using 
GOLD, and markers 2-8 were found to be in strong LD with one another (Figure 
3-3). By contrast 5-HTTLPR was in relatively weak LD (D´ < 0.5) with these 
markers. These data suggest that at least two distinct haplotype blocks span the 
promoter and transcriptional unit of the SLC6A4 locus. 
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 1 2 3 4 5 6 7 8  D´ Values 
1          [0.76 – 1]  
2          [0.51 – 1]  
3          [0.26 - 0.5]  
4          [0 – 0.25]  
5             
6             
7             
8             
 
Figure 3-3.  Intermarker linkage disequilibrium (LD) at SLC6A4. LD was 
measured for all markers using GOLD. D´ values are represented by shaded 
boxes to display intermarker LD relationships. The major haplotype block 
includes markers 2-8. 5-HTTLPR, for which nominal association is seen, is only 
in weak LD (D´< 0.5) with other markers and is not located in the main haplotype 
block. 
   
 
 
Individual marker association analysis for both the overall and rigid-
compulsive subset was tested using PDT. Nominal association (P ≤ 0.05) was 
seen at 5-HTTLPR (P = 0.01) and 5-HTT-6 (P = 0.02) in the overall dataset (n = 
123). We observed an over-transmission to affected individuals of the short allele 
at 5-HTTLPR (Table 3-3). None of these markers demonstrated evidence of 
association in the smaller rigid-compulsive subset. 
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Table 3-3. PDT analysis of the SLC6A4 locus 
Marker 
No.
Overall 
PDT (P)
Allele
# of Alleles 
Transmitted
# of Alleles   
Not Transmitted
Rigid Subset   
PDT (P)
484(s) 221 180
528(l) 237 278
T 175 188
C 291 278
C 77 89
T 387 375
A 177 189
T 287 275
A 175 184
G 291 282
A 29 49
G 435 415
C 205 184
T 253 274
G 202 185
T 260 277
7 0.22 0.38
8 0.29 0.53
5 0.63 0.88
6 0.02 0.10
3 0.29 0.82
4 0.5 0.50
1 0.01 0.07
2 0.46 0.37
 
 
 
Haplotype frequencies and transmissions were assessed using 
TRANSMIT for the haplotype block defined by markers 2-8.  We identified four 
haplotypes having estimated allele frequencies >5%. These haplotypes represent 
~98% of the haplotypes in our sample. The common haplotypes may be 
differentiated by genotyping only three of the seven SNPs in the block. Using 
SNPs 5-HTT-5, 5-HTT-6, and 5-HTT-7 to represent these haplotypes, 
association analysis was performed on the overall dataset using TRANSMIT 
(Table 3-4). No significant evidence for association was detected with this 
combination of markers. Given the absence of association in the full autism 
dataset, we did not test the rigid-compulsive subset.  
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Table 3-4.  TRANSMIT haplotype analysis for markers 5-6-7 in SLC6A4. 
Gray denotes htSNPs. 
 
Frequency 
Observed 
Transmissions
Expected 
Transmissions
!2
Global 
!2
P
C - T - T - G - G - C - G 0.43 215.5 203.0 2.23
C - C - T - G - A - T - T 0.08 31.0 41.0 5.75
T - T - A - A - G - T - T 0.37 175.0 178.2 0.12
C - C - T - G - G - T - T 0.10 53.5 53.7 0.01
8.00 0.09
2-3-4-5-6-7-8 Haplotype
Overall TRANSMIT analysis
 
 
 
 
VISTA analysis of human and mouse genomic sequence for SLC6A4 
revealed evolutionarily conserved coding and non-coding regions (Figure 3-4). 
Including 20kb of sequence both upstream of the transcriptional start site and 
downstream of the 3´ untranslated region (UTR), we used the web-based VISTA 
program (http://www.gsd.lbl.gov/vista/) to compare the two sequences. Figure 3-4 
highlights the relative positions of SNP markers and the promoter variant on the 
VISTA plot, which shows the location of exons and evolutionarily conserved 
sequence. In addition to coding sequences, several regions of non-coding 
conservation are detected both inside and outside of the main haplotype block. 
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Figure 3-4. Evolutionary conservation at SLC6A4. Output from VISTA 
analysis of the SLC6A4 transcriptional unit (indicated by gray arrow above the 
plot) is shown, with regions of non-coding sequence conservation (>75% identity) 
highlighted by pink shading and coding homology by blue shading. Red vertical 
arrows indicate the position of markers. 
 
 
 
Discussion 
 It is well established that autism is one of the most genetic of 
neuropsychiatric disorders, and that multiple genes are likely involved in its 
etiology. Two complementary approaches for identifying genes underlying 
complex genetic disorders are (1) identification of genomic regions more 
frequently inherited in common by affected individuals in a family through 
genomic linkage screens and (2) analysis of genes in candidate systems 
suspected to be involved in the disease based on altered biology. Linkage-
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oriented efforts to identify susceptibility genes tend to evolve into studies of 
positional candidates, once a region of linkage is identified. These two 
approaches are unified in this study, where an excellent functional candidate 
gene is found in a very strong region of linkage in our dataset. 
 Evaluation of a candidate gene must ultimately be able to detect the 
presence of either common or heterogeneous disease-associated variants. Allelic 
association studies permit identification of common variants at a disease 
susceptibility locus. However, the absence of association does not exclude the 
possibility of heterogeneous variants or rare mutations as underlying increased 
risk associated with a gene.  Therefore, a thorough examination of a candidate 
gene must supplement allelic association analysis with direct screening to identify 
sequence variants. In this report, we identify SLC6A4 as a positional and 
functional candidate in a region of linkage on chromosome 17. The potential for 
this gene as a candidate is strengthened by (1) the nature of the phenotypic 
subset in which we observe increased linkage and (2) the efficacy of SSRIs in 
treating aspects of the autism phenotype such as those present in this subset 
and related phenotypes (e.g. obsessive-compulsive disorder). We did not detect 
association in the main haplotype block corresponding to SNPs 2-8, although we 
saw nominal but not highly significant association at 5-HTTLPR, 5´ to this block. 
Thus, we conclude that a common disease-associated variant does not exist in 
this block.  Future studies will examine the possibility of heterogeneous and/or 
rare variants in the main haplotype block in our dataset. Additionally, regions 5´ 
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or 3´ to this block will be tested for the presence of either common or 
heterogeneous variants. 
 These results must be interpreted in the light of the significant association 
to autism in parent-child trio families reported by Cook and colleagues [106]. The 
comparison of theses studies is aided by a commonality of genetic markers but is 
complicated by the difference in family structure analyzed. With the exception of 
5-HTTLPR, markers demonstrating association in the Kim et al. report do not 
show a similar effect in our dataset [106]. The possibility exists of biases towards 
different genetic mechanisms in multiplex families compared to singleton cases. 
These populations may harbor overlapping but significantly different 
constellations of autism susceptibility alleles. Considering the serotonin 
transporter in particular, it would be interesting to know whether affected 
individuals in multiplex and trio families differ in response to SSRIs. The number 
of transmissions analyzed in this study is slightly larger than that tested by Kim et 
al., so the current study is not limited by power. Ultimately, such detailed studies 
in independent datasets will be required to make a determination of how or if 
these data may be generalized across autism datasets. 
 Given the genetic heterogeneity in autism and other complex disorders, 
the need for approaches to identify genetically more homogeneous sub-samples 
is becoming increasingly apparent. For example, an alternative to the use of a 
categorical autism diagnosis to define affection status is the application of 
individual traits comprising the broader phenotype. There are a variety of ways in 
40 
which phenotype-based subsetting can be applied to genetic studies. In this 
report, we select families that are relatively affected for the previously defined 
ADI factors, and we use them for our analyses. We observed increased linkage 
in a rigid-compulsive subset, and a simulation study suggests this result may be 
significant (P = 0.025). However, this simulation does not account for testing 
multiple subsets, and Bonferroni correction would render this result non-
significant. While we believe it is likely that these subsets are genetically relevant 
and will thus provide increased power to detect risk alleles, we recognize that 
splitting our dataset in this manner may reduce the overall power to detect effects 
due to decreasing the sample size.  
Single marker association studies can be powerful in their ability to detect 
genetic effects. However, it is unlikely that a given polymorphic marker will be a 
disease-susceptibility variant. Rather, a positive finding of association probably 
indicates linkage disequilibrium to a nearby variant. We and others argue that 
characterization of all common haplotypes at a locus is important for meaningful 
association analysis [66]. The absence of strong positive findings may simply be 
the result of failing to test the relevant allele or the potential for allelic 
heterogeneity. Potential susceptibility alleles may exert their effect through 
perturbations in gene expression, and relevant sequences controlling gene 
expression may lay distant 5′ or 3′ to the transcriptional unit. This point highlights 
the utility of identifying conserved sequences around a gene locus under study, 
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so that potential functional sequences may be included in efforts to detect 
disease-associated variants.  
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CHAPTER IV 
 
FOLLOW-UP ANALYSIS OF THE SLC6A4 LOCUS 
 
Introduction 
Our initial analysis of the serotonin transporter lacked strong support for 
direct involvement of this gene in autism susceptibility. Although we saw 
nominally significant association with two of our eight markers, it was clear that 
these results were not explaining the strong evidence for linkage to this region 
seen in our dataset. Given increasing evidence for linkage by our and other 
groups and the significant biological rationale for involvement of this molecule, 
we pursued further examination of the transporter locus. While preliminary 
association studies well represented most of the locus in terms of LD patterns, 
the 5' end (e.g. around 5-HTTLPR and farther upstream in the promoter) was not 
covered. Thus a common allele at an upstream regulatory element, for example, 
would not have been detected. Additionally, some consideration to the alternative 
to the “common disease-common variant” hypothesis deserved consideration. To 
address these scenarios, additional studies of this locus were undertaken. They  
included (1) testing whether known, but otherwise extremely rare non-
synonymous variants might be increased in frequency in autism families, (2) 
screening exons and regions showing high sequence identity between human 
and mouse, and (3) association analysis of markers previously demonstrating a 
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nominal level of significance in a larger dataset. By addressing these issues, we 
sought to further explore the involvement of this gene and the possibility of allelic 
heterogeneity at this locus. 
The absence of highly significant allelic association at this locus led us to 
test the alternate hypothesis that otherwise rare coding variation may be enriched 
in the autism population. In testing a similar hypothesis, Fearnhead et al. present 
evidence suggesting that many rare variants collectively contribute to the 
inherited susceptibility to colorectal adenomas [122]. Glatt et al. reports the most 
detailed study in a non-selected (i.e. “normal”) Caucasian population and 
reported the presence of nine rare non-synonymous variants at the SERT locus, 
with most present only once in 900 chromosomes (minor allele frequency = 
0.0011). The Gly56Ala variant was present on 4/900 chromosomes and 
corresponds to a 56Ala-encoding allele frequency of 0.0044 [123]. Another 
variant, Ile425Val, originally described by Glatt was recently rediscovered by 
Ozaki and colleagues in two unrelated families segregating a complex psychiatric 
phenotype containing Asperger’s syndrome, obsessive-compulsive disorder 
(OCD), and other co-morbid phenotypes [90]. Given the relationship of the 
phenotypes, particularly Asperger’s syndrome to autism, this provides yet further 
suggestion for the role for rare coding variation at SLC6A4 in autism. In our initial 
rigid-compulsive subset we did not find increased evidence for association but 
several rare coding variants, including Ile425Val, might be present in this 
population of families. These families could in turn be those demonstrating 
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increased allele-sharing as detected by our linkage study. We hypothesize that 
one or more of these rare non-synonymous variants, multiple of which have been 
shown by the Blakely laboratory at Vanderbilt (manuscript in preparation) to exert 
functional effects on SERT activity, may be over-represented in the autism 
population.  
 Another hypothesis we aim to test is the influence of common alleles 
within evolutionarily conserved regions across the SLC6A4 locus. Regions 
demonstrating conservation may harbor functional, possibly regulatory, 
sequences. Identifying sequence changes in these regions could uncover 
functionally significant variation. 
Serotonin levels have shown to be sexually dimorphic in previous studies 
[124-127]. Recent evidence of sex-specific risk alleles in autism along with 
evidence of sex-specific whole blood serotonin levels lend more evidence for the 
role of serotonin and the serotonin transporter specifically in autism. Stone et al. 
completed a genome-wide linkage screen subdividing their dataset based on the 
sex of the affected child. They report a major male-specific linkage peak at 53cM 
on chromosome 17, according to the Marshfield map. The location of one of the 
markers (D17S1294) flanking this peak maps only 142 kb away from the SLC6A4 
locus [79]. Weiss et al. have performed a QTL analysis of whole blood serotonin 
levels demonstrating evidence for a male-specific QTL on 17q at the ITGB3 locus 
(~16cM distal to the SLC6A4 locus) in the Hutterite population [78]. Additionally, 
they have seen similar male-specific results near the serotonin transporter gene. 
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We hypothesize that association to autism at the SLC6A4 locus is male-specific 
or at least provides for increased risk in autistic males. In addition, one can 
imagine that families containing autistic females have a different genetic 
architecture (therefore a potentially different set of susceptibility loci) than families 
containing only male-affected individuals. To test this hypothesis we plan on 
examining association within the subset of families containing only male-affected 
individuals. 
 
Materials and Methods 
 
Families 
There are several subsets of samples used in these studies. One sample 
subset is the set of 23 affected but unrelated individuals determined to be the 
most “rigid” based on the “rigid-compulsive” factor score calculated by the 
algorithm obtained through use of a principle components analysis on the ADI-R 
(3 AGRE, 20 TUFTS) [76]. A second subset is the set of 24 affected but 
unrelated individuals (19 AGRE, 5 TUFTS) chosen from 24 strongly linked 
multiplex families (as determined from family-based multipoint LOD scores 
calculated in families demonstrating strongest linkage to the chromosome 17 
peak using ALLEGRO). Both of these subsets were used for screening of exons 
and regions of conserved sequence across the SLC6A4 locus. The larger dataset 
consisting of 384 families (283 AGRE, 98 TUFTS, 3 VANDY) was used for 
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screening of known rare non-synonymous variants, for a replication attempt of 
the nominal associated markers previously shown in Chapter III, and for 
examining SNPs detected through re-sequencing efforts. AGRE samples were 
obtained from the NIMH Center for Collaborative Genetic Studies on Mental 
Disorders (http://nimhgenetics.org/). All probands were at least four years of age 
and were clinically assessed with the ADI or ADI-R and most with the Autism 
Diagnostic Observation Schedule (ADOS). In multiplex families at least one sib 
had to meet ADI algorithm criteria for an autism diagnosis, while additional 
siblings need not meet full criteria. Probands were excluded from the study if they 
had a known medical or neurological condition suspected to be associated with 
their autistic phenotype (e.g. fragile X syndrome). The procedures for clinically 
evaluating affected individuals for the AGRE families has been previously 
described [30].  
  
Molecular Analyses  
DNA was isolated from peripheral blood or lymphoblastoid cells using the 
PureGene kit according to the manufacturer’s recommendations (Gentra 
Systems, Minneapolis, MN). 5-HTTLPR and the intron 2 VNTR genotypes were 
determined using size discrimination of PCR products on 3% NuSeive (3:1) 
agarose (FMC Bioproducts; Rockland, ME) gels. Amplifying PCR primers for 
these two markers have been described previously described [101]. For the 5-
HTTLPR genotyping, the short allele corresponds to a product of 484 bp, while 
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the longer allele is 528 bp.  PCR reaction volumes were 10 µl, employing 12.5ng 
genomic DNA template, 0.22 µl at 10mM of each primer, 1 µl at 2.5mM dNTPs, 
0.08 µl Applied Biosystems AmpliTaq Gold DNA polymerase and buffer (Applied 
Biosystems), and a GC-rich Kit purchased through Roche. For the VNTR 
genotyping, products amplified were 345bp (9 copy repeat), 360bp (10 copy 
repeat), and 390bp (12 copy repeat). PCR reaction volumes were 10 µl, 
employing 5ng genomic DNA template, 0.22 µl at 10mM of each primer, 1 µl at 
2.5mM dNTPs, and Applied Biosystems AmpliTaq Gold DNA polymerase and 
buffer (Applied Biosystems). SNPs were selected based on previous findings of 
allelic association in our initial report, demonstration of association to autism 
through other previous studies, or by discovery through sequencing of exons or 
conserved regions in the lab [128]. In addition, 10 known rare non-synonymous 
variants were also selected for examination. Database reference numbers (both 
dbSNP and Celera IDs when available) and other details for all markers are cited 
in Table 4-1. Individual SNPs were genotyped through the TaqMan™ (Applied 
Biosystems) protocol using either the Assays-On-Demand or Assays-By-Design 
products.  PCR primers and probes for all assays are listed in Table 4-2. This 
information is unavailable for any markers obtained from Applied Biosystems 
(Foster City, CA) as Assays-On-Demand™. When the assay permitted 
(compatible primers were able to be designed within exonic sequence) internal 
site-directed mutant and wild-type cDNA clones (obtained from the laboratory of 
Dr. Randy Blakely) for the rare allele of the non-synonymous variants were used 
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as homozygous (mutant cDNA) and heterozygous (made by using 50/50 mix of 
mutant cDNA with wildtype cDNA) controls to make unambiguous genotype 
when employing the TaqMan™ assays. 
For TaqMan™ genotyping assays [113], reactions were performed in a 5 
µl volume according to manufacturer’s recommendations (Applied Biosystems). 
Cycling conditions included an initial denaturation at 95 °C for 10 min, followed by 
50 cycles of 92 °C for 15 s, 60 °C for 1 min. Samples were analyzed using an 
ABI 7900HT™ Sequence Detection System. 
Variant screening was also performed on both exonic sequence and non-
coding evolutionarily conserved regions across the SLC6A4 locus. Our laboratory 
screened the conserved non-coding regions through direct sequencing efforts. 
Our collaborators in the Blakely laboratory employed the REVEAL System 
(Spectrumedix LLC, State College, PA) for variant screening, followed by 
sequencing confirmation of samples believed to contain real variation. Samples 
for re-sequencing were sent to the Vanderbilt Sequencing Core Facility after 
initial PCR reactions were performed in the lab. PCR reaction volumes were 8 µl, 
employing 10 ng genomic DNA template, 0.2 mM primers, 125 mM dNTPs and 
Applied Biosystems AmpliTaq Gold DNA polymerase and buffer (Applied 
Biosystems). Cycling conditions included an initial denaturation at 95 °C for 10 
min, followed by 50 cycles of 94 °C for 30 s, optimal annealing temperature 
(TA°C) for 30 s, and 72 °C for 1 min, and a final extension at 72 °C for 10 min. 
PCR reaction cleanup was performed using Exo-Sap-It (USB) and then sent to 
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the Vanderbilt Sequencing Core for sequencing using the Big-Dye terminator 
system. Larger regions were amplified from both directions to get complete 
sequence information for the region of interest. Some sequencing reactions were 
carried out with universal primers (M13F (-21) 5′-TGTAAAACGACGGCCAGT-3′ 
and M13R 5′- CAGGAAACAGCTATGAC-3′). Sequencing primers for the regions 
of non-coding evolutionary “conservation” are shown in Table 4-3 along with 
primers used by the Blakely laboratory for screening of exonic sequence. 
 
Table 4-1.  SLC6A4  follow-up markers.  Alleles are listed major/minor. 
Marker No. Marker Type
SLC6A4 
Region
dbSNP rs#/ 
Celera hCV#
Alleles
Minor Allele 
Frequency
Intermarker 
Distance (bp)
rs1050565/
hCV7473213
3 ins/del Promoter 1A 5-HTTLPR 528(l)/ 484(s) 0.44 2,549
9 SNP Exon 2 Thr4Ala A/G _ 157
10 SNP Exon 2 Gly56Ala G/C 0.01 310
9/ 0.02/
10/ 0.39/
12 0.59
12 SNP Exon 4 Lys201Asn G/C _ 40
13 SNP Exon 4 Glu215Lys G/A _ 1,802
15 SNP Exon 6 Ser293Phe C/T _ 505
16 SNP Exon 7 Pro339Leu C/T _ 2,811
17 SNP Exon 8 Leu362Met C/A _ 1,504
18 SNP Exon 9 Ile425Val A/G _ 8,181
19 SNP Exon 13 Lys605Asn A/C _ 4,687
20 SNP Exon 14 Pro621Ser C/T _ _
Promoter 1A T/C 0.32 10,035
2 SNP Promoter 1A G/A 0.03 1,734
1 SNP
4 SNP Intron 1A A/T
5 SNP Intron 1A C/T
Intron 1A T/A
0.07 295
0.47 5
0.07 11,477
7 SNP Intron 1A A/C 0.16 80
6 SNP
931
11 VNTR Intron 2 VNTR 3,269
8 SNP Exon 1B A/C
14 SNP Intron 5 G/A 0.07 195
rs2020930/ 
hCV11424041
rs2020933/ 
hCV11424045
rs2020934/ 
hCV7911197
rs2020935/ 
hCV11424046
rs25528/ 
hCV1841705
rs6354/ 
hCV1841706
rs140700/ 
hCV7473202
0.17
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Table 4-2. Primers and probes for variants in follow-up study of SLC6A4. 
Labels are as follows: (F) Forward Primer, (R) Reverse Primer, VIC and FAM are 
fluorescent labels for TaqMan™ allelic discrimination probes (SNPs highlighted 
by bold text), AbD is an Assay-By-Design from ABI, AoD is an Assay-On-
Demand from ABI. “Gel” means that the product was run out on an agarose gel 
and genotyped through size discrimination. Sequence for primers and probes for 
AoD assays is proprietary information. MGB stands for minor groove binder, and 
NFQ stands for non-fluorescent quencher. 
 
Marker 
No. Primer sequences (5´-3´) 
Product 
Size 
(bp) 
TA 
(°C) Assay 
1 NA Unavailable NA 60 TaqMan (AoD) 
2 F GCTCAAGCAGGTGAACAAAGAAA 
 R CTGGGCAGCTGGGAAGAG 72 60 
 VIC VIC-AACTATTGCTATGCGGTGAT-MGB-NFQ   
 FAM FAM-TTGCTGTGCGGTGAT-MGB-NFQ   
TaqMan 
(AbD) 
3 F GGCGTTGCCGCTCTGAATGC 
 R GAGGGACTGAGCTGGACAACCAC 
484/ 
528 61 Gel 
4 F TGTATGTATTTTTACCATCAGTTTTGTCCAGAA 
 R GAGAGTTAGCTAGCAGGCTCATAAAT 81 60 
 VIC VIC-CATTGACCAGGTTCAC-MGB-NFQ   
 FAM FAM-CATTGACCTGGTTCAC-MGB-NFQ   
TaqMan 
(AbD) 
5 F TTTTCCTGCCACGCACTCT 
 R GCACAAACCTCATAAGAACCTGCTT 80 60 
 VIC VIC-ACCGTTCCAATATGG-MGB-NFQ   
 FAM FAM-CCGTTCCAACATGG-MBG-NFQ   
TaqMan 
(AbD) 
6 F TGGCAGTGACCGTTCCAA 
 R TTGCTCAATTTGCACAAACCTCAT 68 60 
 VIC VIC-CTGCTTCTCACTCATCCA-MGB-NFQ   
 FAM FAM-TGCTTCTCACTCAACCA-MGB-NFQ   
TaqMan 
(AbD) 
7 F CCCAGTGGAGGCACAGG 
 R GAGTGTGCAGGTTACTGATGCT 62 60 
 VIC VIC-TGGTTGGTGTCGCCG-MGB-NFQ   
 FAM FAM-TGGTTGGTTTCGCCG-MGB-NFQ   
TaqMan 
(AbD) 
8 F GGAGGCAAGGCGACCTT 
 R CTGTGGCTAAGCCCCTTGTTATT 58 60 
 VIC VIC-CTTGCCCTCTATTGCAG-MGB-NFQ   
 FAM FAM-TTGCCCTCTCTTGCAG-MGB-NFQ   
TaqMan 
(AbD) 
9 F GTCATTTACTAACCAGCAGGATGGA 62 60 
 R CGCTGATAGCTGCTTCTGAGA   
 VIC VIC-ATTCAAGGGCGTCGTC-MGB-NFQ   
 FAM FAM-CAAGGGCGCCGTC-MGB-NFQ   
TaqMan 
(AbD) 
10 F GGGTACTCAGCAGTTCCAAGTC 
 R GGGATAGAGTGCCGTGTGT 56 60 
 VIC VIC-CTGGTGCGGGAGAT-MGB-NFQ   
 FAM FAM-CTGGTGCGGCAGAT-MGB-NFQ   
TaqMan 
(AbD) 
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11 F TGGATTTCCTTCTCTCAGTGATTGG 
 R TCATGTTCCTAGTCTTACGCCAGTG 
345/ 
360/ 
390 
57 Gel 
12 F GCTATACTACCTCATCTCCTCCTTCAC 
 R TGGTGCAGTTGCCAGTGTT 83 60 
 VIC VIC-CCAGGAGTTCTTGCAGC-MGB-NFQ   
 FAM FAM-CAGGAGTTGTTGCAGC-MGB-NFQ   
TaqMan 
(AbD) 
13 F TCCTGGAACACTGGCAACTG 
 R GAATGGAGGGTCCAGGTGATG 65 60 
 VIC VIC-AATTACTTCTCCGAGGACAA-MGB-NFQ   
 FAM FAM-AATTACTTCTCCAAGGACAA-MGB-NFQ   
TaqMan 
(AbD) 
14 F ACTCCAAGGGTTGTGATCTTTCTG 
 R GGGTGAATGGATGTCAGTGTCTTTT 89 60 
 VIC VIC-ACCACCTCACCCTCCT-MGB-NFQ   
 FAM FAM-CACCTCGCCCTCCT-MGB-NFQ   
TaqMan 
(AbD) 
15 F GTGACAGCCACCTTCCCTTATATC 
 R GTGGCACCCCTCACCAG 56 60 
 VIC VIC-CAGGACAGAAAGGAT-MGB-NFQ   
 FAM FAM-CAGGACAAAAAGGAT-MGB-NFQ   
TaqMan 
(AbD) 
16 F AGCCGCTCAGATCTTCTTCTCT 
 R TTGAACTTGTTGTAGCTAGCAAAAGC 75 60 
 VIC VIC-CAAAGCCCGGACCAA-MGB-NFQ   
 FAM FAM-CAAAGCCCAGACCAA-MGB-NFQ   
TaqMan 
(AbD) 
17 F CGGCCCCTTGGGTTTTC 
 R GAAGCTCGTCATGCAGTTCAC 68 60 
 VIC VIC-CCAGAGATGCCCTGGTGA-MGB-NFQ   
 FAM FAM-CAGAGATGCCATGGTGA-MGB-NFQ   
TaqMan 
(AbD) 
18 F GCAGAAGCGATAGCCAACATG 
 R CAAGCCCAGCGTGATTAACATC 78 60 
 VIC VIC-TTTCTTTGCCATCATCTT-MGB-NFQ   
 FAM VIC-TCTTTGCCGTCATCTT-MGB-NFQ   
TaqMan 
(AbD) 
19 F TCCCCACATATATAGCTTATCGGTTGA 
 R CAAAACAATTAGTAGTCTGAACACACACA 105 60 
 VIC VIC-CACGTACCTCTTTAAAT-MGB-NFQ   
 FAM FAM-ACGTACCTCGTTAAAT-MGB-NFQ   
TaqMan 
(AbD) 
20 F GCGTATTATTAAAAGTATTACCCCAGAAACAC 
 R CACAGCATTCAAGCGGATGTC 73 60 
 VIC VIC-CACAAGGAATTTCT-MGB-NFQ   
 FAM FAM-CACAAGAAATTTCT-MGB-NFQ   
TaqMan 
(AbD) 
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Table 4-3. Variant screening primers for the SLC6A4 locus. Labels are as follows: 
(F) Forward Primer, (R) Reverse Primer, TA (annealing temperature). *Sequencing 
reactions were carried out with universal primers (M13F(-21) 5′-
TGTAAAACGACGGCCAGT-3′ and M13R 5′- CAGGAAACAGCTATGAC-3′). 
 
Gene 
Conserved  
Non-coding 
Region 
Primer sequences (5´-3´) Product Size (bp) TA (°C) 
SLC6A4 F GTAGAGATGAGCCCAGGGTTCACAGT 
 
1 
R GCAATCACCGCACAGCAATAGTTT 
540 56 
 F* GGTCAAGAGAAAGCGGCACGAGCAGA 
 2 R* GCCCACTTCGAGCACTCCACGTTCCT 762 66 
 F* ACTGTGCTACGTGGTTGAAGGATATA 
 3 R* AAGAAAAGAGGAAAAACCCATGC 654 56 
 F* CATACGTGGGTGTGGAGCGAAAC 
 4 R* CATCACTGGGTTGCGTCTCTCCTT 730 59 
 F TTGGCTCTATGACCTGTAACT 
 5 R TTTCTGCCTGCAAGCTC 897 54 
 F GTCCAGTGTCATCTCAGCTAGGCA 
 6 R AGAGGGCAAGCAAGGTCGC 382 59 
 Exon Primer sequences (5´-3´) Product Size (bp) TA (°C) 
 F GGCTATCTAGAGATCAGACCATGTG 
 
1a 
R CTGGGGCGCATGCACCTCCT 
280 66 
 F CCCAGCATCAGTAACCTGCAC 
 1b R TCTGCACATGGCCTTTCTGCGT 207 61 
 F TTTCTCCTTCCTCTGTGTGTC 
 2 R CTGCTGAGTACCCATTGGATA 302 54 
 F CGGAGTTCTACAGAAGGTTGTT 
 2 R GGGTCACAGCCACTACTCGCA 308 61 
 F CTGTGATTCTCAGTCACAGATTGG 
 3 R GTCGCCAGCTGCCAGCCACTGATG 295 61 
 F GGGCTGCGGGGCTCTCCAGTG 
 4 R CAGAAAGGGGTGAGGAGCCCTTGG 420 66 
 F CCCGGGCACCCTCAAAGGAGC 
 5 R GTGCTGTCTGTCCAGGCTACT 315 67 
 F CTCCCTGGAACAGCATGGTGA 
 6 R TGACAGACAGGTACACATATTTCCC 212 59 
 F GCCTCTGCACTTAGCCACATGG 
 7 R GCAGTGGTATTAAGGCCTAAGCC 332 66 
 F CCCTGATCTTGGAACTGTCTC 
 8 R GATCTTTACAAAGATTCAAAGCAAAGC 248 61 
 F CTTTGTAGGACAGGTCTTGTCAAC 
 9 R CTCCTTTCCTCTTCATCCTCC 218 61 
 F CCTGTTTACTGTCCTGAAGGCCACA 
 10 R GCCAGGGCACTGTGTGAGATGG 303 67 
 F CTGGGGTACTCACGTTCGGTCCC 
 11 R CAGACCCATCATCGGGAGGTCAC 363 66 
 F GTCCTTTCTTAGTCTCTGCCTC 
 12 R GGAAGTCTTTCGCCAGGGCAAG 192 66 
 F TCGGAAACATCTCTATCTGAGTGG 
 13 R TTCTCCCAAAACAATTAGTAGTCTGAAC 293 61 
 F TGTCAGTGAGACTATTCCAACTCG 
 14 R GGAAACTCATTCACTTGG 309 61 
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Statistical Analyses  
Initial analysis of SNP genotype data involved quality control checks 
consisting of verification of internal controls and assessment of Mendelian 
inconsistencies, followed by final haplotype consistency analyses using 
Simwalk2 [117]. Conformity with anticipated Hardy-Weinberg equilibrium 
expectations was established. SNPs (excluding the variants occurring less than 
1%) were examined along with our previous marker set to determine intermarker 
LD using both the r2 and D´ measures calculated by the publicly available 
Haploview program [129]. Transmission disequilibrium (only for the common, 
>0.01, follow-up markers) in autism families was determined using the PDT 
statistic, a variant of the transmission disequilibrium test (TDT), developed for 
use with general pedigrees [119]. Common haplotypes were determined using 
Haploview [129], and analyzed using the FBAT analysis software package [130]. 
Results were considered significant at the nominal level for markers or 
haplotypes with P ≤ 0.05. 
In addition to TD being measured in all families, we performed analyses 
using only those families containing male-affected individuals. This approach was 
recently used by Stone et al. to examine the differences that sex of the autistic 
individuals would make in linkage analysis [79]. We excluded from these 
additional analyses any family containing a female-affected individual. 
Visualization Tools for Alignment (VISTA) analysis was performed via 
web-based submission (http://www.gsd.lbl.gov/vista/) of human and mouse 
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genomic sequence [121]. Regions showing evolutionarily conserved non-coding 
sequence were identified for variant screening purposes. 
 
Results 
 To examine in greater detail the serotonin transporter locus (SLC6A4), we 
chose additional markers and strategies to more closely examine a possible role 
for this gene in autism etiology. The details of our follow-up markers are 
highlighted in Table 4-1 and their relative positions across the transcriptional unit 
are illustrated in Figure 4-1. 
 
 
Figure 4-1. Schematic representation of SLC6A4 detailing follow-up marker 
locations. The 38kb transcriptional unit contains 15 total exons represented by 
the vertical boxes. Coding regions are indicated in black with the untranslated 
regions in gray. Markers are labeled and their positions indicated by arrows. 
 
 
 
 In addition to testing our hypothesis with respect to common variation at 
this locus, it is quite plausible that allelic heterogeneity may play a role. To test 
this hypothesis we choose to examine the 10 known rare non-synonymous 
changes to determine if they are enriched in our autism sample ([123] and 
dbSNP http://www.ncbi.nlm.nih.gov/SNP/). In addition we, along with our 
collaborators in the Blakely laboratory, performed variant screening across 
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exonic sequence and non-coding regions identified through VISTA as being 
evolutionarily conserved with mouse. The non-coding regions screened through 
re-sequencing are illustrated in Figure 4-2. 
 
 
 
Figure 4-2. Variant screening at SLC6A4 relative to sequence conservation. 
Output from VISTA analysis of the SLC6A4 transcriptional unit (indicated by gray 
arrow above the plot) is shown, with regions of non-coding sequence 
conservation (>75% identity) highlighted by pink shading and coding homology 
by blue shading. Regions of conservation that were screened for variants are 
indicated with a green bar above them. The length of the bar covers 
approximately the amount of sequence examined. 
 
 
 
 Genotypes at individual markers did not deviate from expectations of 
Hardy-Weinberg equilibrium (Data not shown). We also employed the publicly 
available Haploview program to map linkage disequilibrium across the locus, in 
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hopes of identifying the common haplotypes seen in our sample.  These common 
haplotypes in addition to our single markers were examined for association to 
disease. The single marker PDT results are presented in Table 4-4 for the 
common follow-up markers in both the overall dataset and the male only families 
dataset. Though the variant in intron 5 (hCV7473202) remains significant in the 
overall dataset of 384 families, the 5-HTTLPR variant is no longer significant.  
However, when we examine those families containing only male-affected 
individuals (235/384 or 61%), we observe that 5-HTTLPR is nominally significant 
and our intron 5 variant becomes even more significant. 
 
Table 4-4. Follow-up PDT analysis of the SLC6A4 locus 
Marker 
No.
Marker
PDT 
(P)
Allele
# of Alleles 
Transmitted
# of Alleles 
Not 
Transmitted
PDT 
(P)
Allele
# of Alleles 
Transmitted
# of Alleles 
Not 
Transmitted
1 hCV7473213 0.68 0.68
2 hCV11424041 1.00 0.78
484(s) 362 314
584(l) 398 446
4 hCV11424045 0.31 0.55
5 hCV7911197 0.28 0.25
6 hCV11424046 0.21 0.64
7 hCV1841705 0.93 0.91
8 hCV1841706 0.31 0.52
11 VNTR 0.65 0.72
A 93 124 A 47 76
G 1215 1184 G 711 682
Affected Male-Only Sample 
(235 families)
Overall Sample                   
(384 families)
hCV7473202
5-HTTLPR
14 0.010.03
3 0.14 0.03
 
  
 
 
Examination of linkage disequilibrium across all common markers studied, 
combining those in the previous report with our common (> 1%) follow-up 
markers, identifies three loosely defined haplotype blocks. The Haploview output 
is illustrated in Figure 4-3. Association analysis in both the overall dataset as well 
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as the male-affected only families, using FBAT, of all common haplotypes ( ≥ 
0.05) yielded no significant association (Table 4-5). 
 
 
 
Figure 4-3. LD analysis of SLC6A4 using Haploview. The black outline 
surrounds each of our self-defined haplotype blocks with intermarker D´ values 
labeled within the individual boxes. Intermarker linkage disequilibrium with D´ 
values of 1.0 are never shown, but indicated by the dark red boxes for a LOD 
score ≥ 2 and indicated by the blue boxes for a LOD score < 2. White shading 
indicates a D´ < 1 and a LOD < 2, while shades of pink/red indicate D´ < 1 and a 
LOD ≥ 2. 
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Table 4-5. FBAT haplotype analysis for SLC6A4. Gray denotes htSNPs. 
Markers numbers are labeled relative to Figure 4-3. 
 
Frequency 
# of 
Families
Observed 
Transmissions
Expected 
Transmissions
P
T - G - S 0.40 84 141 134 0.38
C - G - L 0.29 75 96 101 0.59
T - G - L 0.28 69 81 88 0.35
Frequency 
# of 
Families
Observed 
Transmissions
Expected 
Transmissions
P
A - T - T 0.47 93 178 168 0.26
A - C - T 0.46 94 141 145 0.71
T - C - A 0.07 28 26 33 0.20
Frequency 
# of 
Families
Observed 
Transmissions
Expected 
Transmissions
P
C - T - T - A - A - G - 12 - G - G - C - G 0.44 75 135 126 0.28
T - T - A - A - A - G - 10 - A - G - T - T 0.31 77 100 93 0.40
C - C - T - C - C - G - 12 - G - A - T - T 0.17 42 45 48 0.53
Frequency 
# of 
Families
Observed 
Transmissions
Expected 
Transmissions
P
T - G - S 0.40 52 90 80 0.14
T - G - L 0.32 50 53 64 0.10
C - G - L 0.25 45 46 49 0.61
Frequency 
# of 
Families
Observed 
Transmissions
Expected 
Transmissions
P
A - T - T 0.49 56 110 102 0.25
A - C - T 0.44 60 77 84 0.38
T - C - A 0.07 18 18 20 0.64
Frequency 
# of 
Families
Observed 
Transmissions
Expected 
Transmissions
P
C - T - T - A - A - G - 12 - G - G - C - G 0.45 52 90 80 0.16
T - T - A - A - A - G - 10 - A - G - T - T 0.29 43 50 48 0.74
C - C - T - C - C - G - 12 - G - A - T - T 0.17 31 30 33 0.60
7-8-9-10-11-12-13-14-15-16-17 Haplotype
1-2-3 Haplotype
4-5-6 Haplotype
Overall Sample (384 Families)
Affected Male-Only Sample (235 Families)
1-2-3 Haplotype
4-5-6 Haplotype
7-8-9-10-11-12-13-14-15-16-17 Haplotype
 
 
We examined all 384 families for the 10 rare non-synonymous variants. 
Only one of these rare variants was shown to have an allele frequency greater 
than 1% (GLY56ALA/rs6355/hCV11414113). Although this minor allele frequency 
did not differ significantly from a previous report by Glatt et al. [123], when tested 
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in a control panel of 100 unrelated Caucasian individuals obtained from the 
Coriell Cell Repository the minor allele frequency was 4% (8/200 chromosomes). 
This minor allele frequency is closer to that reported in dbSNP (0.02), but 
warrants further review and sequence confirmation. Rare alleles for three of the 
other non-synonymous variants were also detected: 1 heterozygous individual for 
the LEU362MET variant, 1 heterozygous individual for the LYS201ASN variant, 
and 3 heterozygous individuals for the LYS605ASN variant.  
 We re-sequenced six regions of conservation across the SLC6A4 locus to 
identify variants that may or may not be autism specific. Variant screening across 
these regions was initially conducted with a panel of our “most rigid” unrelated 
individuals and subsequently with our “most linked” unrelated individuals as 
described in the Materials and Methods section of this chapter. Results for the re-
sequencing efforts across the conserved regions are displayed in Table 4-6. 
Regions 1 and 2 did not show any variation in the samples we examined. With 
the exception of region 4, all other regions identified markers that have already 
been identified and listed in either dbSNP or the Celera database. In conserved 
region four we identified four heterozygous individuals for a single variant that to 
the best of our knowledge had not been previously identified. This A to G 
(common/rare) allele change is surrounded by the sequence 
GTGGATGTGAGGCAGTCTGACTGCCTT. Three of the markers (hCV7911197, 
hCV11424046, and hCV1841705) identified through screening were chosen to 
be genotyped on the entire sample and included in the association analysis 
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(Table 4-4 markers 5,6,and 7). Variants detected having relatively low frequency 
were excluded in the present study, since we hypothesized that a common 
variant in these conserved regions would be the source of our increased linkage. 
 
 
Table 4-6. Results of variant screening across the SLC6A4 locus. A panel of 
24 affected but unrelated individuals was chosen for re-sequencing purposes. 
The individuals came from the 24 families having the highest family-based 
multipoint heterogeneity lod score at the 50cM location on chromosome 17. 
 
 
 
Discussion 
 The genes involved in autism have been elusive, likely due to the complex 
phenotype harboring a complex genetic architecture. Using multiple strategies to 
tease apart this complex disorder may be the only way to gain insight into its 
underlying epidemiology. This follow-up study of the serotonin transporter locus 
addresses several lines of investigation. Previous evidence and suggestion of 
serotonin involvement, in particular relative to the serotonin transporter, is strong 
in research surrounding autism and other neuropsychiatric disorders. However, 
Gene
Conserved 
Non-coding 
Region
# of Unique Sequence 
Variations Detected
dbSNP rs#/ Celera hCV#
Minor Allele 
Frequency
SLC6A4 1 0 _ _
2 0 _ _
rs2020934/ hCV7911197 0.08
rs2020935/ hCV11424046 0.40
rs2020933/ hCV11424045 0.08
4 1 novel 0.08
5 1 rs8071667/ hCV28964487 0.09
rs2020940/ hCV11414117 0.04
rs25528/ hCV1841705 0.38
3 3
6 2
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the specific details of its involvement are not only unproven, but to date are very 
unclear. As mentioned previously, numerous studies having shown whole blood 
serotonin levels to be sexually dimorphic. Combining this with the average sex-
ratio of 4 affected males to 1 affected female in autism lends support for a 
biological mechanism involving the serotonergic pathway. However, without other 
strong evidence suggesting serotonin involvement in autism, such an argument 
would be necessarily weak given that any sexually dimorphic trait could be 
argued to play a role in autism susceptibility. 
In this follow-up study we set out to test several hypotheses.  We 
examined common alleles, rare coding alleles, and screened for novel variants 
across the serotonin transporter for involvement in autism. We did not find strong 
support for either a common allele, haplotype, or rare allele to increase autism 
susceptibility in our overall dataset of 384 autism families. However, we did find 
suggestive evidence for both the 5-HTTLPR variant and the intron 5 
(rs140700/hCV7473202) to be associated in families containing only male-
affected individuals. While other groups have detected association to the 5-
HTTLPR polymorphism (detailed in Chapter III), this is the first data to suggest 
this association to be specific to autism families containing only male-affected 
individuals. This work extends upon findings by other groups suggesting linkage 
and more specifically linkage at 17q near the serotonin transporter is increased 
when examining the subset of families containing only male-affected individuals. 
We speculate that our findings suggest a yet unknown role for SLC6A4 
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involvement in this phenomenon. Future directions will include examination of the 
variant screening of exonic sequence and further examination for male-specific 
increased risk for autism.  
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CHAPTER V 
 
GENETIC ANALYSIS OF THE 15q12 GABAA RECEPTOR SUBUNIT 
CLUSTER1 
 
 
 
Introduction  
 
Evidence for GABA and Glutamate Involvement in Autism 
There are a number of findings that support a role for the GABA (γ-
aminobutyric acid) neurotransmitter system in autism susceptibility. Two studies 
have shown decreased levels of GABAA receptors in autism.  Blatt and 
colleagues showed reduced binding of radiolabelled GABAA receptor ligands in 
autopsy brain specimens from individuals with autism [39]. Chugani and 
colleagues used PET imaging in children with autism and also showed reduced 
GABAA receptors [131]. The GABAA receptor agonist benzodiazepine is effective 
in treating seizure and anxiety disorders common in autism. Finally, elevated 
levels of circulating GABA and its essential precursor glutamate have been 
observed in children with autism [40-42]. 
 
15q11-q13 Autism Candidate Region 
A cluster of GABAA receptor subunit genes maps within the chromosome 
15q11.2-q13 autism candidate region (Figure 5-1). Interstitial duplications of this 
                                                
1 Adapted from Am J Med Genet B Neuropsychiatr Genet 2004 Nov 15, 131B:51-9. 
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region are associated with a significant risk of autism, and risk is greater for 
duplications of maternal compared to paternal origin [49, 132-136]. Maternal 
supernumerary pseudodicentric inverted duplicated marker chromosomes 15 (so-
called idic(15) markers) carry two additional copies of a larger region and give 
rise to a more severe autistic phenotype [137-141]. Duplication-mediated autism 
arguably stems from a dosage effect of genes in the duplicated intervals. 
Maternal or paternal deletions of the same region affected by interstitial 
duplications give rise to Angelman (AS [MIM 105830]) or Prader-Willi (PWS [MIM 
176270]) syndrome, respectively, because of the loss of expression of imprinted 
genes in the interval (reviewed in [142]; see Figure 5-1). This is noteworthy since 
symptoms of autism can be associated with both AS and PWS. In addition to 
regions of paternal-specific and maternal-specific gene expression, there is an 
apparently non-imprinted region containing a cluster of GABAA receptor subunit 
genes (GABRB3, GABRA5 and GABRG3). While the GABA genes will be the 
focus of this chapter, greater detail of the proximal 15q11-q13 region will follow in 
Chapter VII, which focuses on examination of the imprinting center and maternal 
expression domain. 
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Figure 5-1. Schematic map of the 15q11-q13 autism candidate region. (A) 
Autism duplication and PWS/AS deletion interval. The region of chromosome 15q 
subject to interstitial duplication in cases of autism or deletion in PWS or AS is 
shown. Imprinted paternal expression (PWS) and maternal expression (AS) 
domains are indicated above the map relative to specific genes. The autism 
candidate region includes the 15q imprinting center (IC), maternally-expressed 
genes and the cluster of GABAA receptor subunit genes. A scale in Mb for the 
interval is provided above the map. (B) The GABAA receptor subunit gene cluster. 
The 1-Mb interval containing GABRB3, GABRA5 and GABRG3 is expanded and 
shows relative position and transcriptional orientation (arrows) of each gene. 
Reference microsatellite markers previously shown to be linked or associated are 
also indicated. 
 
 
Accumulating genetic evidence also suggests the existence of genetic 
factor(s) in the GABA gene cluster region in idiopathic autism. Genomic linkage 
screens in autism have identified proximal 15q [27, 31, 109], but results are 
mixed as others have failed to detect significant linkage [21, 25, 28, 30]. Two 
recent reports, including one from our group, demonstrated that subsetting 
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autism families, based on variables from the Autism Diagnostic Interview-Revised 
(ADI-R), results in significantly increased evidence for linkage to the GABA 
region [53, 54]. Several reports have documented findings of allelic association at 
microsatellite [44-46, 143] and single nucleotide polymorphism (SNP) markers 
[144] in the GABA region. Two other groups, using microsatellite markers, did not 
identify association to autism in this region [51, 52]. Studies to date have involved 
analysis of only a small number of microsatellite or SNP markers and thus have 
not thoroughly surveyed this region for association. To test the hypothesis that 
common allele(s) in the GABA gene cluster confer risk for autism, we undertook 
a detailed analysis of linkage disequilibrium (LD) and allelic association across 
this 1-Mb region. 
 
Materials and Methods 
 
Families 
The sample for this study consisted of 123 multiplex families. Forty-eight 
multiplex families were recruited at the Tufts/New England Medical Center and 
75 affected sib-pair families were obtained from the Autism Genetics Resource 
Exchange (AGRE; http://agre.org). The vast majority of families (~98%) are of 
Caucasian ethnicity. All affected individuals were at least four years of age and 
were clinically assessed with the ADI or ADI-R and most with the Autism 
Diagnostic Observation Schedule (ADOS). At least one sib had to meet ADI 
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algorithm criteria for an autism diagnosis, while additional siblings may be on the 
broader autism spectrum. Families were excluded from the study if probands had 
a known medical or neurological condition suspected to be associated with their 
autistic phenotype (e.g. fragile X syndrome). The procedures for clinical 
evaluation of affected individuals for the AGRE families have been previously 
described [30].  
  
Molecular Analysis  
DNA was isolated from peripheral blood or lymphoblastoid cells using the 
PureGene kit according to the manufacturer’s recommendations (Gentra 
Systems, Minneapolis, MN). SNPs from the dbSNP and Celera SNP databases 
were selected based on their map position, minor allele frequency, and, in one 
case, a finding of allelic association by Menold et al. [144]. Marker and exon 
locations and intermarker distances are based on the public (UCSC; July 2003 
freeze; http://genome.cse.ucsc.edu/) and Celera 
(http://www.celeradiscoverysystem.com/index.cfm) assemblies and published 
gene structure information for GABRB3 and GABRA5 [145, 146]. Database 
reference numbers and other details for the markers studied are cited in Table 5-
1. Genetic (cM) distances are based on the deCODE genetic map [114]. 
Individual SNPs were genotyped by either fluorescent polarization template-
directed dye terminator incorporation assay (FP-TDI) or TaqMan™. FP-TDI PCR 
assays were developed and optimized to amplify an ~200 bp region flanking 
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SNPs. PCR primers and probes for assays are listed in Table 5-2. This 
information is proprietary for the majority of markers, for which Assays-On-
Demand™ were obtained from Applied Biosystems (Foster City, CA). 
For FP-TDI genotyping, PCR reaction volumes were 8 µl, employing 5 ng 
genomic DNA template, 0.2  M primers, 125  M dNTPs and Applied 
Biosystems AmpliTaq Gold DNA polymerase and buffer (Applied Biosystems). 
Cycling conditions included an initial denaturation at 95 °C for 10 min, followed by 
50 cycles of 94 °C for 15 s, optimal annealing temperature (TA°C) for 30 s, and 
72 °C for 15 s, and a final extension at 72 °C for 10 min. FP-TDI analysis was 
performed using materials supplied in commercially-available Acycloprime™ kits 
according to the manufacturer’s published protocols (Perkin-Elmer Lifesciences, 
Boston, MA) and as described elsewhere [112]. Samples were analyzed using a 
VICTOR2™ multi-label plate reader instrument (Perkin-Elmer Life Sciences). 
For TaqMan™ genotyping assays, reactions were performed in a 5 µl 
volume, employing 2.5ng genomic DNA template, according to manufacturer’s 
recommendations (Applied Biosystems). Cycling conditions included an initial 
denaturation at 95 °C for 10 min, followed by 50 cycles of 92 °C for 15 s, 60 °C 
for 1 min. Samples were analyzed using an ABI 7900HT™ Sequence Detection 
System. 
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Table 5-1. SNP markers spanning the GABAA receptor subunit cluster. Bold 
highlights microsatellite markers previously studied. 
 
Gene SNP 
No. Region 
dbSNP rs# 
/Celera hCV# Alleles 
Minor Allele 
Frequency 
Intermarker 
Distance (kb) 
Intergenic  Intergenic GABRB3   52.9 
Intergenic 1 Intergenic rs8025575/ hCV2911914 C/G 0.45 10.1 
GABRB3 2 Intron 8 rs2081648/ hCV2911917 T/C 0.15 12.5 
 3 Intron 7 
rs1432007/ 
hCV8866669 A/G 0.47 10.4 
 4 Intron 6 
rs1426217/ 
hCV2901088 G/A 0.38 46.3 
 5 Intron 3 
rs2873027/ 
hCV2901140 T/C 0.45 0.5 
 6 Intron 3 
rs4542636/ 
hCV2901143 T/C 0.45 20.3 
 7 Intron 3 
rs754185/ 
hCV2901163 T/C 0.34 14.7 
 8 Intron 3 
rs12912421/ 
hCV2901177 G/A 0.50 8.5 
 9 Intron 3 
rs11161328/ 
hCV2901182 A/G 0.28 7.6 
 10 Intron 3 
rs1346149/ 
hCV2061398 A/G 0.47 10.2 
 11 Intron 3 
rs878960/ 
hCV8865198 C/T 0.38 9.6 
 12 Intron 3 
rs1863464/ 
hCV2901200 G/A 0.18 12.8 
 13 Intron 3 
rs11631421/ 
hCV245488 T/C 0.44 5.9 
 14 Intron 3 
rs981778/ 
hCV2901236 A/G 0.43 31.8 
 15 Intron 3 
rs970408/ 
hCV2901263 C/T 0.10 8.0 
 16 Intron 3 
rs2059574/ 
hCV2901280 T/A 0.49 14.0 
  Intron 3 155CA-2   2.4 
 17 Intron 3 
rs3212337/ 
hCV218360 C/T 0.36 39.4 
Intergenic  Intergenic D15S511   1.9 
Intergenic 18 Intergenic rs4632100/ hCV30714164 A/G 0.18 15.7 
Intergenic 19 Intergenic rs4506865/ hCV30714186 A/G 0.10 47.7 
GABRA5 20 Intron 3 rs2075716/ hCV1843341 C/T 0.38 5.4 
 21 Intron 3 hCV474240 C/T 0.36 3.8 
 22 Intron 3 hCV11298361 G/A 0.41 8.3 
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 23 Intron 5 hCV252720 T/C 0.43 9.8 
 24 Intron 5 
rs9745027/ 
hCV27725 C/A 0.50 18.2 
 25 Intron 6 hCV42974 C/T 0.34 21.8 
 26 Exon 7 
rs140682/ 
hCV1028938 C/T 0.47 6.1 
 27 Exon 9 
rs140685/ 
hCV1028939 T/C 0.49 9.5 
Intergenic 28 Intergenic rs11263717/ hCV2078419 T/A 0.39 34.1 
GABRG3 29 Intron 2 rs1432129/ hCV8866584 C/A 0.47 18.7 
 30 Intron 2 hCV2078482 C/T 0.47 13.5 
 31 Intron 2 
rs6606855/ 
hCV2078497 A/G 0.45 8.8 
 32 Intron 3 
rs7172534/ 
hCV2078506 T/C 0.37 21.5 
 33 Intron 3 
rs4078843/ 
hCV2078548 G/A 0.31 45.3 
 34 Intron 3 
rs4555125/ 
hCV37817 A/G 0.49 30.8 
 35 Intron 3 
rs1029937/ 
hCV2665757 G/A 0.29 7.7 
 36 Intron 3 
rs208174/ 
hCV2665743 C/T 0.27 7.2 
 37 Intron3 
rs6606877/ 
hCV2665737 C/T 0.17 15.6 
 38 Intron 3 
rs2286946/ 
hCV2665715 A/G 0.48 5.2 
 39 Intron 3 rs741121/ hCV2665706 G/T 0.46 17.1 
 40 Intron 3 rs208129/ hCV2665692 A/T 0.42 1.6 
 41 Intron 3 rs208126/ hCV2665687 G/T 0.43 29.4 
 42 Intron 3 rs12907392/ hCV9408557 T/C 0.30 14.1 
 43 Intron 3 rs897173/ hCV9408511 A/G 0.25 16.8 
 44 Intron 3 rs897177/ hCV9408473 T/C 0.18 18.4 
 45 Intron 3 rs6606891/ hCV9408434 C/T 0.44 3.7 
 46 Intron 3 rs8043244/ hCV9408423 G/A 0.41 65.1 
 47 Exon 5 rs140674/ hCV18418 T/C 0.04 5.1 
 48 Intron 5 hCV435176 A/G 0.44 26.0 
 49 Intron 5 rs9672931/ hCV376685  G/A 0.27 7.5 
 50 Intron 5 hCV59714 A/G 0.27 26.0 
71 
 51 Intron 5 rs9635410/ hCV9399190 A/G 0.34 6.3 
 52 Intron 5 rs12440080/ hCV458188 G/A 0.45 23.0 
 53 Intron 5 rs11631444/ hCV473958 A/G 0.46 42.0 
 54 Intron 5 rs4550406/ hCV374658 C/T 0.28 36.1 
 55 Intron 6 rs11074283/ hCV34499 C/T 0.48 10.4 
 56 Intron 6 rs1871019/ hCV11670850 A/G 0.40 8.4 
 57 Intron 6 rs11631143/ hCV1846028 G/A 0.42 8.3 
  58 Exon 8 rs140679/ hCV1845989 T/C 0.43 62.9 
Intergenic 59 Intergenic rs1382056/ hCV8926104 G/A 0.48 _ 
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Table 5-2. PCR and genotyping primers for the GABA cluster SNPs. Labels 
are as follows: (F) Forward Primer, (R) Reverse Primer, (FP) FP-TDI extension 
primer, VIC and FAM are fluorescent labels for TaqMan™ allelic discrimination 
probes (SNPs indicated by bold text), AbD is an Assay-By-Design from ABI, AoD 
is an Assay-On-Demand from ABI. MGB stands for minor groove binder, and 
NFQ stands for non-fluorescent quencher. (*) SNPs 1, 4-8, 11-16, 21-46, 48-53, 
and 55-59 are AoDs. Sequence for primers and probes, for AoD assays, is 
proprietary information. 
 
 
SNP 
No. Primer sequences (5´-3´) 
Product 
size (bp) 
TA 
(°C) Assay 
* NA Unavailable < 200 60 TaqMan (AoD) 
2 F CATGAAAAGGGATTTGATAAATTGAGGTCAT 
 R CAACATCAGATAGATTTTAAACATATAAGCTTACCATTT 130 60 
 VIC VIC-ACTGTTTGAGATGCTG-MGB-NFQ   
 FAM FAM-AACTGTTTAAGATGCTG-MGB-NFQ   
TaqMan 
(AbD) 
3 F AGCCAGCCCATGCCTTTATC 
 R GATTCCACTTTTTCTTCATGACAGCAT 86 60 
 VIC VIC-AAAGCCACGGAGGCA-MGB-NFQ   
 FAM FAM-AAAGCCACAGAGGCA-MGB-NFQ   
TaqMan 
(AbD) 
9 F TGGTAAGCCACTGAGACAAGTAGG 
 R GTTTGTGCGTGTGCTTGGTAA 116 51 
 FP-R TAACAGTCTAAGGTCAGGGGGTTTCTACT   
FP 
10 F GCCATGGAGCAAAGACCCTA 
 R CTTGTGATGCACGTAGTTGTCTGA 107 53 
 FP-R CTTTCACAGTCACTGCTTTCACAGC   
FP 
17 F AAAGTCCTGTGAGCCCTTAATG 
 R GCTGGTGAGGTAGGTAATAGAGGT 194 53 
 FP-F GCTTTGTCCTGCAGTAAGAGTAAGAAAGT   
FP 
18 F GGGTGGAACGTGCAGACA 
 R CCCACACAGAGGCAGTCA 56 60 
 VIC VIC-CCACTCGGCACCGC-MGB-NFQ   
 FAM FAM-CCACTCAGCACCGC-MGB-NFQ   
TaqMan 
(AbD) 
19 F GCCATGTTAATTTAATGTCATTTTGGAGATTCT 
 R CATGTGATCTAACATAACAATAGATTTATCTGTTCCT 119 60 
 VIC VIC-CACCTGACAATTCT-MGB-NFQ   
 FAM FAM-ACACCTGATAATTCT-MGB-NFQ   
TaqMan 
(AbD) 
20 F CAGTTGCCCTCCACGGTTC 
 R ATCTTCAGGCACCTGTGGTTTATG 168 55 
 FP-F AGTTGCCTTGAAAGCCAGGCC   
FP 
47 F GAGCTAGACTGACACTTGGCTTTT 
 R GGCAGGAGTGTTCGTCCAT 95 60 
 VIC VIC-TGGCACTCGGCATT-MGB-NFQ   
 FAM FAM-CTGGCACTCAGCATT-MGB-NFQ   
TaqMan 
(AbD) 
54 F ATGCACTTATTACCCATTTGTATATCTTCCTT 
 R CTTTCACACGTCAACAATACAAAGACA 105 60 
 VIC VIC-AAATGGGCAAAGAAT-MGB-NFQ   
 FAM FAM-TTAAAAATGGACAAAGAAT-MGB-NFQ   
TaqMan 
(AbD) 
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Statistical Analyses 
Initial analysis of SNP genotype data involved quality control checks 
consisting of verification of internal controls and assessment of Mendelian 
inconsistencies, followed by final haplotype consistency analyses using 
Simwalk2 [117]. Conformity with anticipated Hardy-Weinberg equilibrium 
expectations was established, and SNPs were examined for intermarker LD 
using both the r2 and D´ measures calculated by the GOLD  (Graphical Overview 
of Linkage Disequilibrium) software package [118]. Similar to the definition 
described by Gabriel et al., SNP pairs were considered to be in strong LD if D´ 
values were >0.75 [147]. Neighboring SNPs were considered to be in a single LD 
block if all SNP pairs were in strong LD. Minimal block lengths were determined 
from intermarker spacing of SNPs defining the blocks. Transmission 
disequilibrium (TD) in autism families was determined using the pedigree 
disequilibrium test (PDT) statistic, developed for use with general pedigrees 
[119]. Common haplotypes (≥5%) were identified using TRANSMIT [120]; 
analysis of TD was performed using adjacent SNP pairs inclusive of loci 
significant in single marker analysis and haplotype tag SNPs for other multi-locus 
blocks. Results were considered significant at the nominal level for markers or 
haplotypes with P ≤ 0.05. 
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Results 
We selected and genotyped 59 SNP markers spanning the 1-Mb interval 
containing the GABRB3, GABRA5 and GABRG3 (Table 5-1 and Figure 5-2) 
genes. Markers were primarily selected based on minor allele frequency and 
intermarker spacing to provide dense representation of regional LD. The average 
minor allele frequency was 0.37; six markers had a minor allele frequency less 
than 0.2 and one less than 0.1. This last marker (rs140674) was chosen based 
on a published report of nominal association in GABRG3 [144]. The average 
intermarker spacing for the entire interval was 17.7 kb, while for individual genes 
it was 14.3, 10.3 and 18.7 kb, for GABRB3, GABRA5 and GABRG3, respectively. 
Genotyping for all SNPs was performed on DNA samples from 123 multiplex (48 
New England and 75 AGRE) families. Genotypes at individual markers did not 
deviate from expectations of HWE (data not shown). 
 
 
 
Figure 5-2. Schematic of markers located across the GABAA receptor 
cluster. SNP markers analyzed in this study are indicated by vertical hashes, 
above the scale in kb; proximity of SNPs 5/6, 21/22, 40/41 and 45/46 in relation 
to the scale is such that these markers are not distinguished by separate hashes. 
Associated markers are shifted up from other SNPs. Reference microsatellite 
markers previously shown to be linked and/or associated are also indicated. 
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With the goal of detecting and characterizing potential allelic effects on 
autism risk, we initially analyzed single marker genotypes for evidence of TD. 
Data were analyzed using the PDT, and resulting P-values are listed in Table 5-
3. Five of 19 markers, representing three distinct locations across the GABRB3 
gene, demonstrated significant association at the nominal level (P ≤ 0.05). The 
first location corresponds to SNP 1 (1df, χ2=5.25; P=0.02) and SNP 3 (1df, 
χ2=6.98; P=0.01), which are located towards the 3´ end of the gene. The second 
region has two sites showing significant allelic effects within intron 3. One 
involves adjacent SNPs 5 (1df, χ2=4.18; P=0.04) and 6 (1df, χ2=4.62; P=0.03). 
The final site corresponds to SNP 11 (1df, χ2=4.27; P=0.04). One marker within 
intron 5 of GABRA5 (SNP 23) also showed evidence for association (1df, 
χ2=4.62; P=0.03). An initial examination of haplotypes, specifically at markers 
showing evidence for association, involved analysis of adjacent SNP-pairs using 
TRANSMIT. Table 5-4 details these results, and includes single marker allelic 
transmission data for significant SNPs. Consistent with results from individual 
markers, several two-SNP haplotypes demonstrated significant transmission 
distortion. None of the 30 SNPs located across the ~570-kb GABRG3 gene 
showed evidence of association. 
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Table 5-3. Association analysis of single SNPs across the GABA cluster. 
 
 
Gene SNP No. Overall PDT (P)  Gene SNP No. 
Overall 
PDT (P) 
Intergenic 1 0.02     
GABRB3 2 0.37  GABRG3 29 0.18 
 3 0.01   30 0.21 
 4 0.21   31 0.25 
 5 0.04   32 0.61 
 6 0.03   33 0.89 
 7 0.82   34 0.18 
 8 0.94   35 0.94 
 9 0.82   36 0.60 
 10 0.07   37 0.60 
 11 0.04   38 0.66 
 12 0.80   39 0.85 
 13 0.21   40 0.66 
 14 0.28   41 0.16 
 15 0.74   42 0.51 
 16 0.61   43 0.06 
 17 0.78   44 0.94 
Intergenic 18 0.23   45 0.48 
Intergenic 19 0.67   46 0.25 
     47 0.71 
     48 1.00 
GABRA5 20 0.14   49 0.38 
 21 0.78   50 0.28 
 22 0.37   51 0.43 
 23 0.03   52 0.55 
 24 0.52   53 0.60 
 25 0.08   54 0.36 
 26 0.65   55 0.90 
 27 0.84   56 0.33 
Intergenic 28 0.89   57 0.79 
      58 0.60 
    Intergenic 59 0.75 
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Table 5-4. Pair-wise analysis of adjacent SNPs. 
Gene SNP No. 
Overall 
PDT 
(P) 
Allele T NT χ2 TRANSMIT (P) 
C 260 226  Intergenic 1 0.02 G 188 222 5.25  
GABRB3 2 0.37         
0.02 
 A 263 220 
 3 0.01 G 199 242 6.98 
0.02 
 4 0.21     
0.04 
 C 187 222 
 5 0.04 T 279 244 4.18 
0.13 
 C 182 218 
 6 0.03 T 272 236 4.62 
0.07 
 7 0.82      
0.13 
 10 0.07      
 C 265 296 
 11 0.04 T 191 160 4.27 
0.11 
 12 0.80      
0.04 
             
GABRA5 22 0.37          
 C 176 211 0.07 
 23 0.03 T 288 253 4.62  
 24 0.52      
0.01 
 
 
 
To characterize intermarker LD and haplotype structures across the entire 
1-Mb region, D′ and r2 measures were calculated from the genotype data using 
GOLD. D′ values for all intermarker combinations are represented in Figure 5-3, 
and 14 multi-SNP LD blocks (D′ > 0.75) are identified. Outside of these regions of 
relatively low haplotype diversity, LD between adjacent marker pairs is generally 
very low. While borders for individual blocks are not precisely defined, the multi-
SNP blocks shown are represented by 38 SNPs and comprise a minimum of 263 
kb of 1,040 kb, or 25%, of the entire interval. Average SNP coverage was higher 
78 
for GABRB3 (14.3 kb-1) and GABRA5 (10.3 kb-1), in comparison to GABRG3 
(18.7 kb-1) and intergenic regions (see Table 5-1). Examination of minimal block 
lengths in proportion to total genomic DNA for genes individually reveals that 
multi-SNP blocks represent 40%, 45% and 24% of the DNA encoding GABRB3, 
GABRA5 and GABRG3, respectively. Minimal block lengths ranged from 3.7 to 
46.8 kb, and the average block size was estimated to be 18.8 kb for this 
Caucasian sample; this block size is consistent with previous reports [147]. Two 
sets of overlapping blocks were identified. Blocks 1-2-3 and 4-5-6 overlap based 
on strong LD between SNP 2 and 4-5-6, despite weak LD between other SNPs in 
the two blocks. SNP 22 was also found to bridge two overlapping blocks, and 
these findings are similar to those reported elsewhere [148, 149]. 
For all multi-SNP blocks, common haplotypes (>5%) were identified using 
TRANSMIT (Table 5-5). This permitted identification of haplotype tags, or the 
subset of SNPs (htSNPs) that detect all common haplotypes for a given block. Of 
the 38 SNPs present within blocks, 7 were eliminated as redundant. At the 
current resolution, 82% of the SNPs in multi-locus LD blocks, or 88% of the total, 
were required to represent common haplotypes across this interval. Genotype 
data for the reduced set of SNPs was then analyzed using TRANSMIT to test for 
TD with autism; results of this analysis are presented in Table 5-5. Transmissions 
at two multi-locus blocks, both containing SNPs showing association individually, 
were found to deviate significantly from that expected under the null hypothesis. 
The SNP 1-2-3 block (2df, χ2=8.02; P=0.02), located at the 3′ end of GABRB3, 
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and the SNP 22-23-24 block (5df, χ2=15.5; P=0.01), located in GABRA5, both 
showed significant results. 
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Figure 5-3. Intermarker LD and haplotype blocks in the 15q12 GABAA 
receptor subunit gene region. D´ values corresponding to each pair-wise SNP 
combination are plotted, and LD/haplotype blocks (14) are revealed as regions of 
high LD (black squares) along the diagonal and are outlined with white borders.  
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Table 5-5. TRANSMIT haplotype analysis for LD blocks across GABA cluster. 
 
Observed Expected Global !2 P
C - C - A 0.17 93.8 87.8 1.24
C - T - A 0.37 205.2 189.4 4.23
G - T - T 0.45 201.0 222.8 8.01
G - C - C 0.44 200.0 218.4 4.57
A - T - T 0.36 195.0 182.9 2.30
G - T - T 0.19 105.0 98.2 1.45
A - A 0.21 104.1 106.4 0.10
G - A 0.48 240.9 235.7 0.51
A - G 0.30 151.9 152.3 0.01
G - T - A 0.62 318.0 308.8 1.53
A - C - G 0.16 77.0 79.5 0.18
G - C - G 0.22 103.0 110.6 1.47
C - A 0.41 209.9 200.8 1.45
C - G 0.24 115.5 122.1 1.06
T - G 0.35 171.6 173.0 0.04
G - C - A 0.05 28.4 25.2 0.93
A - T - A 0.39 199.9 194.1 0.52
G - T - A 0.06 27.2 30.5 0.67
G - C - C 0.37 163.6 184.9 6.93
G - T - C 0.11 67.8 56.0 4.89
C - C - A 0.36 171.2 179.8 1.36
C - C - T 0.12 60.8 58.7 0.18
C - T - T 0.06 30.4 28.2 0.39
T - T - T 0.44 221.5 222.1 0.01
A - C - G 0.44 209.8 219.8 1.77
C - C - A 0.08 39.6 39.4 0.00
C - T - A 0.47 244.5 234.7 1.82
G - C - C - A - G 0.35 173.5 172.4 0.02
G - C - T - A - G 0.17 78.0 81.2 0.42
G - C - C - G - T 0.22 117.5 111.1 0.93
A - T - C - G - T 0.25 124.0 128.7 0.50
G - C 0.28 136.9 133.3 0.23
G - T 0.29 156.7 151.0 0.64
T - T 0.42 198.4 208.6 1.73
T - A 0.33 171.9 164.2 1.00
C - G 0.57 270.9 278.1 1.10
T - G 0.07 36.2 37.5 0.12
T - A 0.54 276.0 274.2 0.08
T - G 0.46 224.0 225.8 0.08
A - A 0.48 244.0 237.5 0.69
A - G 0.21 104.0 103.8 0.01
G - G 0.31 150.0 156.6 0.88
G - A - C 0.38 180.0 188.3 1.17
A - G - T 0.62 314.0 305.7 1.17
Frequency !2Haplotypes
47-48
51-52
45-46
41-42
21-22
8-9
0.41
0.34
0.13
Transmissions
3.39
5.68
TRANSMIT
8.02 0.02
56-57-58
1-2-3
4-5-6
12-13-14
22-23-24
26-27-28
29-30-31
35-36-37-38-39
2.56
2.87
15.50
1.95
1.43
2.38
0.34
1.17 0.28
1.25 0.74
0.46
0.70
0.80 0.78
0.58
0.79
2.79 0.43
0.01
6.76
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Discussion 
Our results highlight the correlation between high local recombination 
rates, low LD and high haplotype diversity. The implication of this relationship is 
seen in the only modest reduction of genotyping using htSNPs and a requirement 
for dense SNP coverage for thorough representation of alleles in any association 
study. Application of this LD map to an autism dataset supports the existence of 
one or more risk alleles in the GABRB3-GABRA5 region. Association was 
identified for a number of SNPs and haplotypes in GABRB3, as well as one SNP 
and corresponding haplotypes in GABRA5. These results correlate well with 
linkage previously reported in this region for autism [31] and phenotypic subsets 
of autism [53, 54].  
We have described a first-generation LD map and corresponding 
haplotype structures for this 1-Mb autism candidate region. This is the first report 
to detail LD and provide dense analysis for allelic association to autism for the 
GABAA subunit gene cluster. The average haplotype block size (18.8 kb) is 
consistent with previous reports utilizing samples of European ancestry [147].  
Therefore, our data generally agree with the haplotype block structure proposed 
for the human genome, and add to the literature of detailed LD analyses across 
large physical regions [147-152]. The International “HapMap” Project is working 
to develop such a picture of LD for the entire genome [153]. One important 
reason driving this effort is the argument that identification of htSNPs significantly 
reduces the number of markers necessary to perform genome-wide or regional 
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association studies. The combined minimum block lengths described here 
represent <50% of the DNA encoding these genes, and after identification of 
htSNPs, 88% of markers are necessary to represent alleles across the region.  
This study reinforces the correlation between high local recombination, low 
LD and high haplotype diversity, noted previously by others [149, 154]. The sex-
equal genetic map estimates that the rate for this interval is 4 cM Mb-1, compared 
to a genome-wide average of 1.3 cM Mb-1. Thus, our findings are not entirely 
unexpected. Dense SNP coverage and genotyping a large fraction of markers 
become prerequisites for conducting a thorough disease association study for 
regions of low LD. A higher resolution of SNPs, particularly in GABRG3 and 
intergenic regions, will undoubtedly identify additional blocks, although a high 
proportion of SNPs will still be required to detect all common alleles across the 
region. While our study did not utilize a very dense SNP map (e.g. 5 kb-1), the 
average minor allele frequency (0.37) was high, and markers were analyzed in a 
number of families sufficient to permit effective establishment of haplotype phase 
and structure. Some genome-wide estimates of the ability to eliminate redundant 
SNPs using haplotype tags [147] do not reflect the complexity of analyzing such 
regions of great haplotype diversity and low LD.  
The findings of suggestive association in GABRB3 occur in multiple 
locations within the gene. Those which cluster towards the 3′ end of the gene lie 
~50 kb from the GABRB3 microsatellite marker shown to be linked [31, 54] and 
associated [45] by one group. It is unclear whether the GABRB3 microsatellite 
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marker, centromeric to our first SNP, lies within the same LD block containing 
SNPs 1-2-3. Two sites within the ~150-kb intron 3 showed association. SNPs 5 
and 6 are in a single block located at the centromeric end of this intron. The more 
telomeric site, corresponding to SNP 11, lies ~80 kb centromeric to microsatellite 
marker 155CA-2 (see Figure 5-2), found associated to autism by two groups [44, 
46]. Our own linkage studies in autism subsets have pointed to this region, and 
peak linkage occurs at the 5´ end of GABRB3 at D15S511 [53], ~40 kb from 
155CA-2.  
Comparison of our data to that in a single published report of association 
analysis of SNPs in this region in autism shows only two markers in GABRA5 
and two in GABRG3 common to both studies [144]. Neither of these markers 
demonstrated association in the current study, although the GABRG3 exon 5 
SNP showed nominal association in the Menold et al report. Unfortunately, a very 
low minor allele frequency (0.04 in our sample) for the GABRG3 exon 5 marker 
substantially hampers power to detect association, and this could explain the 
difference. Additionally, the Menold et al report described analysis of both 
multiplex (91) and trio (135) families, whereas this study involves only multiplex 
families. In contrast to this report, the Menold et al study failed to detect 
association in GABRB3 or GABRA5, although a much smaller number of markers 
(9) was examined for these genes.  
The observation of association at alleles at three distinct locations within 
GABRB3 as well as GABRA5, could be explained by the existence of multiple 
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autism risk alleles for these two genes. Such a scenario is consistent with the 
published data and a hypothesis that dup(15)-mediated autism is a contiguous 
gene duplication effect requiring the GABAA subunit genes in addition to the 
imprinted, maternally-expressed genes [155]. The relative strength of genetic 
effects, power to detect those effects, and potential phenotypic specificity of 
given genes or alleles bears consideration. Larger datasets will be required to 
provide power for detection of heterogeneous alleles and for analysis of 
phenotypic subsets. Increased evidence for linkage in families when data are co-
varied for “insistence on sameness” [54] or in which affected individuals have 
savant skills [53] suggests a possible phenotypic specificity or bias of allelic 
effects in this region. While confounding clinical, locus and allelic heterogeneity 
can explain difficulties in detecting significant association, the absence of strong 
association does not allow us to exclude the possibility that one or more of the 
associated alleles represents a false-positive result.  
While suggestive association was detected in GABRB3 and GABRA5, the 
current study involves multiple analyses on genotype data for a large number of 
SNP markers, and none of these data are corrected for multiple comparisons. 
Therefore, given a concern over potential type I error, these association results 
must be interpreted cautiously. We analyzed 59 SNPs, although not all tests 
were independent, since a number of these markers are in LD. If we assumed 35 
independent tests (one test per block and per SNP between blocks), then an 
adjusted significance threshold could be estimated to be 0.05/35=0.0014. Using 
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this criterion, none of these results are statistically significant. On the other hand, 
using this model, we would expect only 35x0.05=1.75 (i.e. ~2) significant 
(P≤0.05) results, and there is only a 10% chance of observing 4 or more 
independent nominally significant results in this dataset. We see six individually 
significant SNPs representing four sites not in LD. There is also a clustering of 
positive results in GABRB3 in proximity to markers previously shown to exhibit 
linkage and association. These considerations argue against type I error in this 
case. Ultimately, replication of these findings in independent samples will be key 
to determination of significance for these data. 
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CHAPTER VI 
 
A REPLICATION STUDY OF ALLELIC ASSOCIATION IN THE GABRB3 AND 
GABRA5 LOCI IN 943 AUTISM FAMILIES 
 
 
Introduction 
Evidence from Chapter V demonstrated a clustering of positive association 
results across the GABAA receptor subunit gene GABRB3 in a dataset of 123 
multiplex families [128]. Our current replication study examines 10 of these 
single-nucleotide polymorphism markers, which had previously shown nominally 
significant (P ≤ 0.05) association, in a total dataset of 943 families. Autistic 
families included in this study were identified and ascertained in the USA, 
Canada, Ireland, and Portugal.  
The background and logic for examining this region has been previously 
stated in great detail. It is our hypothesis that if the association we were detecting 
in our original study is central to autism, then we will be able to replicate our 
findings in a much larger study. Recall the previous association results fall in line 
with other positive linkage and association findings within this region of 15q11-
q13. The relative location of the follow-up markers across the GABAA receptor 
subunit cluster of genes is indicated in Figure 6-1. 
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Figure 6-1. Schematic map showing markers included in the GABA 
replication study. Vertical hashes above the scale in kb indicate SNP markers 
analyzed in this study; proximity of SNPs 5/6 in relation to the scale is such that 
separate hashes do not distinguish these markers. 
 
 
Materials and Methods 
 
Families 
The sample for this study consisted of 943 autism families. Two-hundred 
eighty-three (255 multiplex and 28 trio) families are part of the Autism Genetics 
Resource Exchange (AGRE; http://agre.org) (A number of which were obtained 
from the NIMH Center for Collaborative Genetic Studies on Mental Disorders 
(http://nimhgenetics.org/), 261 families (107 multiplex and 154 trio) were obtained 
through the Hospital for Sick Children, Toronto, Ontario, Canada and McMaster 
University, Hamilton, Canada; 85 trio families from the Trinity Centre for Health 
Sciences, St. James’ Hospital, Dublin, Ireland; 213 families (6 multiplex and 207 
trio) from the Hospital Pediatrico de Colmbra, Colmbra, Portugal; 98 families (70 
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multiplex and 28 trio) from Tufts/ New England Medical Center; 3 multiplex 
families from Vanderbilt University. The demographics of the entire sample are 
outlined in Table 6-1. The majority of families are of Caucasian ethnicity. IQ 
estimates were assessed using different measurement scales and have been 
omitted. Affected individuals were clinically assessed with the ADI or ADI-R and 
most with the Autism Diagnostic Observation Schedule (ADOS). At least one sib 
had to meet ADI algorithm criteria for an autism diagnosis, while additional 
siblings may be on the broader autism spectrum. Families were excluded from 
the study if probands had a known medical or neurological condition suspected to 
be associated with their autistic phenotype (e.g. fragile X syndrome). The 
procedures for clinical evaluation of affected individuals for the AGRE families 
have been previously described [30].  
 
 Table 6-1. Breakdown of families included in the GABA replication study. 
Statistics Overall AGRE Tufts Vanderbilt Canadian Irish Portuguese
Total Families 943 283 98 3 261 85 213
Multiplex 440 255 70 2 107 0 6
Trio 503 28 28 1 154 85 207
Affected individuals 1445 584 173 5 379 85 219
Male 1139 450 135 4 302 65 183
Female 306 134 38 1 77 20 36
Unaffected Relatives 2402 807 228 6 739 170 434
Ethnicity (%)
Caucasian 67% 57% 69% 100% 44% 100% 95%
Hispanic-Latino 2% 4% _ _ 3% _ _
African or African-American 2% 1% 3% _ 2% _ 3%
Asian 2% 1% 1% _ 6% _ _
Multi-ethnic <1% _ _ _ 1% _ _
Other 2% 8% _ _ _ _ _
Unknown 24% 27% 27% _ 44% _ 2%
Age at ADI (range) 2-47yrs 2-39yrs 2-47yrs 6-9yrs 2-40yrs 4-34yrs 2-15yrs  
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Molecular Analyses  
SNPs from the dbSNP and Celera SNP databases were previously 
selected based on their map position, minor allele frequency, and, in one case, a 
finding of allelic association [144]. This replication study focuses on ten of those 
markers demonstrating association in our original analysis. Database reference 
numbers and other details for the markers studied are cited in Table 6-2. Marker 
and exon locations and intermarker distances are based on the public (UCSC; 
July 2003 freeze; http://genome.cse.ucsc.edu/) and Celera 
(http://www.celeradiscoverysystem.com/index.cfm) assemblies and published 
gene structure information for GABRB3 and GABRA5 [145, 146]. Individual SNPs 
were genotyped using the TaqMan™ protocol (Applied Biosystems). Assays-By-
Design™ primers and probes are listed in Table 6-3. Information on markers for 
which Assays-On-Demand™ were obtained from Applied Biosystems (Foster 
City, CA) is proprietary. 
For TaqMan™ genotyping assays, reactions were performed in a 5 µl 
volume, employing 2.5ng genomic DNA template, according to manufacturer’s 
recommendations (Applied Biosystems). Cycling conditions included an initial 
denaturation at 95 °C for 10 min, followed by 50 cycles of 92 °C for 15 s, 60 °C 
for 1 min. Samples were analyzed using an ABI 7900HT™ Sequence Detection 
System. The genotyping of the Canadian samples was completed, by our 
collaborators at the Hospital for Sick Children, using the TaqMan™ protocol. 
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Table 6-2. SNP markers for the GABA follow-up study. Alleles are listed 
major/minor. Allele frequencies are based on the entire dataset of 943 families. 
Flanking microsatellite markers are highlighted in bold. Note:  allele frequencies 
across collection sites were similar for all markers. 
 
 
Gene SNP 
No. Region 
dbSNP rs# 
/Celera hCV# Alleles 
Minor Allele 
Frequency 
Intermarker 
Distance 
(kb) 
Intergenic  Intergenic GABRB3   52.9 
Intergenic 1 Intergenic rs8025575/ hCV2911914 G/C 0.47 10.1 
GABRB3 2 Intron 8 rs2081648/ hCV2911917 T/C 0.14 12.5 
 3 Intron 7 
rs1432007/ 
hCV8866669 A/G 0.48 10.4 
 4 Intron 6 
rs1426217/ 
hCV2901088 A/G 0.46 46.3 
 5 Intron 3 
rs2873027/ 
hCV2901140 C/T 0.46 0.5 
 6 Intron 3 
rs4542636/ 
hCV2901143 C/T 0.46 61.3 
 7 Intron 3 
rs878960/ 
hCV8865198 T/C 0.46 9.6 
 8 Intron 3 
rs1863464/ 
hCV2901200 G/A 0.20 70.3 
  Intron 3 155CA-2   39.1 
Intergenic  Intergenic D15S511   84.9 
GABRA5 9 Intron 6 hCV252720 T/C 0.42 9.8 
 10 Intron 6 
rs9745027/ 
hCV27725 C/A 0.48 _ 
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Table 6-3. PCR and genotyping primers for the GABA follow-up SNPs. 
Labels are as follows: (F) Forward Primer, (R) Reverse Primer, VIC and FAM are 
fluorescent labels for TaqMan allelic discrimination probes (the SNP is indicated 
by bold text), AbD is an Assay-By-Design from Applied Biosystems. MGB stands 
for minor groove binder, and NFQ stands for non-fluorescent quencher. 
 
 
SNP 
No. Primer sequences (5´-3´) 
Product 
size (bp) Assay 
1 F AGAAATGTAAAAAACTTGTCCAAACAATGGAA 
 R ACCTCCAAATTTCCTAACTGTTAAGCAA 
112 
 VIC VIC-CCTGTAAAGAATTCC-MGB-NFQ  
 FAM FAM-CCTGTAAACAATTCC-MGB-NFQ  
TaqMan 
(AbD) 
2 F CATGAAAAGGGATTTGATAAATTGAGGTCAT 
 R ACTCAACATCAGATAGATTTTAAACATATAAGCTTACC 133 
 VIC VIC-ACTGTTTGAGATGCTG-MGB-NFQ  
 FAM FAM-AACTGTTTAAGATGCTG-MGB-NFQ  
TaqMan 
(AbD) 
3 F AGCCAGCCCATGCCTTTATC 
 R GATTCCACTTTTTCTTCATGACAGCAT 86 
 VIC VIC-AAAGCCACAGAGGCA-MGB-NFQ  
 FAM FAM-AAAGCCACGGAGGCA-MGB-NFQ  
TaqMan 
(AbD) 
4 F ATCTGTTCTCCACATATCTTGCGAAA 
 R TGGGATATACAGTTTTTGCCAAATCTGA 101 
 VIC VIC-AAAGACAACTCTGAAGTGA-MGB-NFQ  
 FAM FAM-CAAAGACAACTCTAAAGTGA-MGB-NFQ  
TaqMan 
(AbD) 
5 F GGCTTGCCCACAAAATTACCA 
 R AACTAACTGCTTTGGCAAAACGAAA 68 
 VIC VIC-CCATCACGTAGATATT-MGB-NFQ  
 FAM FAM-CATCACGTGGATATT-MGB-NFQ  
TaqMan 
(AbD) 
6 F TTGGAATATAGAGGCTTAGGGACTGA 
 R CTGGTTTTGTTTCCCCTTCTTGTG 82 
 VIC VIC-ATCTGAAGACAAATCAATGT-MGB-NFQ  
 FAM FAM-ATCTGAAGACAAATCGATGT-MGB-NFQ  
TaqMan 
(AbD) 
7 F ACAAACAACCTGTTAGCCACTCTAA 
 R ATGCCATTCTTTCCTTTTCCACAAG 98 
 VIC VIC-CTCATGAGTGTATAAGAGTGT-MGB-NFQ  
 FAM FAM-ATGAGTGTATGAGAGTGT-MGB-NFQ  
TaqMan 
(AbD) 
8 F GCTGGCTCAGCGTTCCTA 
 R CCTCTCTTATGTTTCCTCTTGCTGTT 73 
 VIC VIC-CAGTCTCTAAACATTTC-MGB-NFQ  
 FAM FAM-CAGTCTCTAAACGTTTC-MGB-NFQ  
TaqMan 
(AbD) 
9 F TGGCTATGCAAACTACTGGTGAAAT 
 R GGACCCTGGCACTGAAGTG 80 
 VIC VIC-ATTCGTGCTTTGGTGATT-MGB-NFQ  
 FAM FAM-ATTCGTGCTTTAGTGATT-MGB-NFQ  
TaqMan 
(AbD) 
10 F TGGAAAGAGAGGTCCCTTCACT 
 R GCTGCTTTGGCTGGTTAAAATTCA 70 
 VIC VIC-CGCTCATGTATTCTCTATAAT-MGB-NFQ  
 FAM FAM-CTCATGTATTCGCTATAAT-MGB-NFQ  
TaqMan 
(AbD) 
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Statistical Analyses 
Initial analysis of SNP genotype data involved quality control checks 
consisting of verification of internal controls and assessment of Mendelian 
inconsistencies, followed by final haplotype consistency analyses using 
Simwalk2 [117]. Conformity with anticipated Hardy-Weinberg equilibrium 
expectations was established. Transmission disequilibrium (TD) in autism 
families was determined using the pedigree disequilibrium test (PDT) statistic, 
developed for use with general pedigrees [119]. Maternal and paternal specific 
transmissions were also assessed using the TSP test [156]. Common haplotypes 
(≥5%) were identified and analyzed using FBAT [130]; analysis of TD was 
performed using a sliding window approach of adjacent SNP pairs and haplotype 
tag SNPs for other multi-locus blocks. Results were considered significant at the 
nominal level for markers or haplotypes with P ≤ 0.05. 
 
 
Results 
 We find little evidence of significant association in our total replication 
dataset of 943 families. We examined for both single marker associations and 
multi-marker haplotype associations in the total dataset as well as a number of 
subsets. We individually tested for association within the Canadian, Irish, 
Portuguese, and our sample (AGRE, Tufts, Vanderbilt) subsets. Additional 
subsets included multiplex families only, trio families only, families with male-
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affected individuals only, and families containing female-affected individuals only 
(Table 6-1). 
Given the relevance of genomic imprinting across the 15q11-q13 region, 
we examined the overall dataset for evidence of parental-specific transmission to 
affected individuals using the TSP test. One marker was nominally significant in 
the overall dataset when transmitted from the father (hCV252720). This marker 
demonstrated greater significance, while another marker (hCV27725) became 
nominally significant when we examined the families containing only male-
affected individuals (Table 6-4). These two markers located within intron 6 of the 
GABRA5 gene are in strong linkage disequilibrium with one another (data 
previously shown). Recall from previous discussion the examination of the 
affected male only family subset may be a valid approach to investigate the 
sexually dimorphic findings in autism, and potentially the male to female ratio of 
affected individuals. The affected-female-containing families did not show any 
single marker associations. However, this is not surprising given the greatly 
decreased sample size and resulting loss in power. We also examined each 
sample based on the location of ascertainment and found no association (data 
not shown). The allelic transmission counts for the two significant makers 
(hCV252720 and hCV27725) in the overall dataset are found in Table 6-5. 
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Table 6-4. PDT and Tsp analysis of GABA follow-up markers. 
Multiplex Trio
Original 
Sample
Multiplex Trio
Original 
Sample
440 
Families
503 
Families
123 
Multiplex 
Families
265 
Families
406 
Families
75 
Multiplex 
Families
Gene
SNP 
No.
Celera hCV#/ 
dbSNP rs#
PDT 
(P)
Tsp   
Father     
(P)
Tsp    
Mother      
(P)
PDT         
(P)
PDT         
(P)
Tsp   
Father     
(P)
PDT 
(P)
Tsp   
Father     
(P)
Tsp    
Mother      
(P)
PDT         
(P)
PDT         
(P)
Tsp   
Father     
(P)
1
hCV2911914/ 
rs8025575
0.42 0.18 0.86 0.27 0.88 0.01 0.91 0.67 0.89 0.67 0.73 0.11
GABRB3 2
hCV2911917/ 
rs2081648
0.52 0.57 0.67 0.78 0.46 0.75 0.19 0.61 0.34 0.49 0.19 0.32
3
hCV8866669/ 
rs1432007
0.34 0.70 0.96 0.26 0.96 0.03 0.69 0.90 0.84 0.75 0.81 0.12
4
hCV2901088/ 
rs1426217
0.73 0.82 0.95 0.50 0.73 0.82 0.55 0.40 0.49 0.54 0.84 0.77
5
hCV2901140/ 
rs2873027
0.34 0.45 0.27 0.74 0.22 0.44 0.20 0.60 0.27 0.45 0.26 0.69
6
hCV2901143/ 
rs4542636
0.46 0.39 0.44 0.69 0.47 0.35 0.52 0.95 0.47 0.68 0.61 0.79
7
hCV8865198/ 
rs878960
0.26 0.31 0.62 0.13 0.83 0.41 0.21 0.14 0.90 0.18 0.77 0.08
8
hCV2901200/ 
rs1863464
0.86 0.63 0.73 0.74 0.88 0.59 0.34 0.14 0.93 0.54 0.46 0.09
GABRA5 9 hCV252720 0.50 0.05 0.46 0.47 0.91 0.13 0.43 0.02 0.22 0.29 0.89 0.19
10
hCV27725/    
rs9745027
0.33 0.16 0.87 0.45 0.54 0.83 0.23 0.04 0.90 0.22 0.71 0.57
Overall Sample Affected Male-Only Families
Total
943 Families
Total
677 Families
 
 
Table 6-5. Tsp allelic transmission data for GABA follow-up significant 
markers.  The number of fathers represents the number of heterozygous fathers 
used for each test. The number of transmissions (T) refers to the number of times 
a father, heterozygous for that marker, transmitted that particular allele to an 
affected child. The number of non-transmissions (NT) refers to the number of 
times a father, heterozygous for that marker, did not transmit that particular allele 
to an affected child. 
 
No. of 
Fathers
Allele T NT
No. of 
Fathers
Allele T NT
C 60 67 C 79 107
T 67 60 T 107 79
C 58 66 C 100 118
A 66 58 A 118 100
C 42 50 C 40 66
T 50 42 T 66 40
C 42 54 C 57 77
A 54 42 A 77 57
C 18 17 C 39 41
T 17 18 T 41 39
C 16 12 C 43 41
A 12 16 A 41 43
0.01 35
28 420.350.56
Overall Sample    
(943 Families)
Affected Male Only 
(677 Families)
Affected Female 
Containing             
(266 Families)
hCV252720
hCV27725/    
rs9745027
hCV252720
hCV27725/    
rs9745027
hCV252720
1.97
0.02
hCV27725/    
rs9745027
0.05
0.16
3.84
5.35
4.270.04
0.92
93
109
40
127
124
5392
96 67
Marker
Paternal Transmissions
Triads Sib-PairsTsp 
Father 
(P)
Father 
!2
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Discussion 
We were unable to replicate our previous findings of association in this 
larger dataset of families. There are multiple reasons for this lack of replication. 
First, we tested a very specific hypothesis; namely that a common variant at this 
locus is involved in autism risk. However, allelic heterogeneity may play an 
important role at this locus. The addition of more families, which may or may not 
share the involvement of this locus in their autism susceptibility, may cause the 
association to be non-significant. Secondly, our initial results could reflect false 
positive findings. Our findings do not rule out allelic heterogeneity within or 
across our sample populations. 
In an exploratory analysis, we do find evidence of association within the 
GABRA5 gene in the overall subset when we examine preferential transmission 
of alleles from the father. We detected a nominally significant over-transmission 
of the T allele for hCV252720 from fathers to affected individuals in our overall 
dataset of 943 families. This over-transmission is more significant when we 
examine the families only containing male-affected individuals. When we 
examine our original dataset of 123 families for this effect within the entire 
dataset and the male-only dataset we find no evidence of association with these 
two markers, however be do detect nominal significance with two other markers, 
but this significance is not found in the male-affected-only families. If the 
preferential transmission from fathers to male-affected individuals is indeed a real 
effect, we may have lacked sufficient power to detect this in our original study. 
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The subset of male only families in the original dataset was relatively small in 
comparison to the completed replication dataset (77 families and 677 families 
respectively). 
We have not corrected any of our results for multiple testing, so we can 
only speculate on their true significance. Any correction would cause these 
results to be non-significant. Future investigations into the apparent transmission 
biased within intron 6 of GABRA5 may warrant variant screening of this region for 
other putative variation, which may prove functional. 
Other approaches would include the examination of relevant phenotypic 
subsets. Recent reports, including one from our group, demonstrated that 
subsetting autism families based on variables from the Autism Diagnostic 
Interview-Revised (ADI-R) results in significantly increased evidence for linkage 
to the GABA region of chromosome 15 [53, 54]. By using more sophisticated 
methods for examining quantitative traits, we could test the hypothesis that the 
GABAA receptor subunit genes on chromosome 15 exert their effects within 
specific phenotypic traits across the broader autism phenotype. One such tool for 
association studies of quantitative traits is the QTDT program [157]. 
Our lack of replication may suggest an interaction effect across these loci. 
Examination of gene-gene interaction by way of allelic interaction studies 
between these genes, whose proteins are known to biological interact, may prove 
useful. Using methods such as the multifactor dimensionality reduction (MDR) 
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method, developed by Moore and colleagues, to examine allelic interaction will 
be essential to future studies within this region [72, 73]. 
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CHAPTER VII 
 
ASSOCIATION ANALYSIS ACROSS THE IMPRINTING CENTER AND 
MATERNAL EXPRESSION DOMAIN IN 15q11.2 
 
 
Introduction 
 An interval in proximal chromosome 15q, corresponding to 15q11-q13, 
has been targeted as a candidate region based on observations of duplications in 
a small percentage of autism cases (illustrated in Figure 7-1). These duplications 
are the most frequent chromosomal abnormality in autism, occurring in an 
estimated 1-3 percent of cases (reviewed in [155]) [49, 50]. Duplications of 
15q11-q13 are seen in two forms: (1) interstitial, tandem duplication of an 
approximately 5-Mb segment or (2)  supernumerary isodicentric, inverted, 
duplicated chromosomes 15 (so-called idic(15) marker chromosomes). Idic(15) 
marker chromosomes are almost always derived from  maternal chromosomes, 
possibly due to maternal meiotic nondisjunction events. In contrast, interstitial 
duplication of 15q11-q13 may arise on a maternal or paternally-derived 
chromosome.  
Proximal 15q duplications often present clinically with an autistic 
phenotype. Compared to interstitial dup(15), idic(15) duplications contain two 
additional copies of a larger interval, extending farther in a telomeric direction and 
including an additional 1-2 Mb of DNA. These cases typically present with a more 
severe phenotype, related to gene dosage and/or degree of chromosomal 
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imbalance. Interstitial dup(15) can occur on either parentally-derived 
chromosome, although studies suggest a greater correlation with dup(15) and 
autism when the duplication arises on a maternally-derived chromosome. One 
detailed study showed that seven of ten such maternal interstitial duplications 
were associated with an autism phenotype, while only a few cases of paternal 
dup(15) are seen in the context of an autism diagnosis. Thus there appears to be 
significant bias in parent-of-origin of a dup(15) with the risk of autism, or more 
broadly, the autism spectrum. This phenomenon should be understood in the 
context of two other genomic disorders involving chromosomal abnormalities of 
this region.  
 
 
Figure 7-1. Schematic of the 15q11-q13 region. 
 
Interstitial deletions of 15q11-q13 affecting the same 5-Mb interval 
involved with interstitial dup(15) are the major cause of the two other disorders: 
Prader-Willi Syndrome (PWS; OMIM# 176270) or Angelman Syndrome (AS; 
OMIM# 105830), depending on the parental origin of the sporadic deletion event. 
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Paternal deletions give rise to PWS, while maternal deletions give rise to AS; this 
reflects the corresponding loss of paternal-specific gene expression in PWS and 
maternal-specific gene expression in AS (reviewed in [142, 158]). Interstitial 
deletion in PWS and AS and duplication in cases of autism represents reciprocal 
meiotic products of unequal meiotic cross-over events mediated by large 
sequence duplicates, or so-called duplicons, located at either end of the deletion 
interval [159, 160]. In addition to deletion, occurring in 65-70% of PWS and AS 
cases, maternal uniparental disomy (UPD) accounts for ~20-25% of PWS cases 
and paternal UPD for ~2-3% of AS cases.  
Underscoring the epigenetic and specifically genomic imprinting 
phenomena occurring in this region,  imprinting mutations occur in ~5-7% of both 
disorders, typically involving microdeletions (e.g. 100 kb or less), and point to a 
region extending from the 5' end of the paternally-expressed gene SNRPN (small 
nuclear ribonucleoprotein polypeptide N) as harboring the 15q11-q13 imprinting 
center (IC; [161, 162]); this empirically-determined functional locus has an 
apparent bipartite structure and is required for normal control of imprinted gene 
expression in the region [163]. Specifically, the IC is required to facilitate the 
switch (if necessary) during gametogenesis in defining the appropriate maternal 
or paternal identity of the inherited chromosome (reviewed in [155]). Small 
deletions or other unidentified mutations in this region result in a failure of the 
imprinting switch process, subsequently leading to inappropriate expression 
patterns of imprinted loci. A recent study in 58 autism families by Jiang and 
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colleagues described excess paternal compared with maternal allele sharing, 
which appeared maximized closer to the IC [22]. 
A number of paternally-expressed transcripts are located within the 
proximal third of the PWS/AS deletion interval [142, 158]. While evidence points 
towards involvement of a gene termed Necdin (gene symbol: NDN; [164]) as 
being a significant contributor to the PWS phenotype [165, 166], there remains a 
lack of certainty as to which gene(s) contribute to the human condition.  
Identification of maternal, de novo, loss-of-function mutations in the E6-AP 
ubiquitin-protein ligase gene (UBE3A) [167, 168], identified this locus as being 
responsible for the AS phenotype. UBE3A is located telomeric from the IC and 
SNRPN, is adjacent to another maternally-expressed gene termed ATP10A 
(previously ATP10C) that encodes a putative aminophospholipid translocase 
possibly involved in CNS signaling [169], and is thus located within a domain of 
maternally-expressed genes; we have termed this the maternal expression 
domain (MED; [47]).  
Clinically, PWS and AS are quite distinct, but of relevance is the presence 
of features in common with autism in both disorders. PWS is characterized by 
infantile hypotonia, failure to thrive, and feeding difficulties. By two years of age, 
PWS patients develop hyperphagia and subsequent obesity, the most obvious 
aspect of the phenotype. People with PWS display mild to moderate mental 
retardation and physical findings that include decreased stature, small hands and 
feet, almond-shaped eyes, and hypogonadism [170]. Behavioral abnormalities 
are common, and include aggression, self-abuse, preoccupation with ordering 
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and arranging, resistance to change in daily routines, and food foraging. With the 
exception of food-related behaviors, these other behavioral features are things 
frequently seen in autism. AS is more severe, with profound mental retardation, 
absent speech, epilepsy, ataxic gait, hand-flapping, and inappropriate laughter. 
Motor stereotypes (such as hand-flapping), seizures or actual epilepsy, severely 
compromised language skills, and poor coordination are also features found 
within the autism population [6]. Therefore, with both of these very different 
disorders, there is phenotypic overlap or commonality with autism. An 
outstanding question, therefore, is whether these overlapping commonalities 
reflect genetic variants or deficiencies present in the idiopathic autism population. 
The bias of maternal dup(15) in association with autism, has been 
interpreted by some as a significant indicator of maternal UBE3A (and ATP10A) 
over-expression (two copies in the case of maternal interstitial duplications) as 
being the sole or primary factor causing (or conferring substantial risk for) autism. 
If this were the case one would predict that maternal UPD PWS cases would be 
“more autistic”. While one published report attempts to make this argument [171], 
the data in support of this premise are mostly anecdotal and not compelling. Thus 
in the absence of information clearly documenting that maternal UPD, and 
documenting that two expressed copies of UBE3A and ATP10A are necessary 
and sufficient to result in autism or a higher rate of autistic traits, we propose that 
dup(15)-autism is the result of a contiguous gene duplication defect within 15q11-
q13 rather than a simple gene-dosage effect involving the maternally expressed 
genes.  
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The argument proposing a contiguous gene duplication effect in genetic 
risk in dup(15) autism cases, points to the cluster of GABAA receptor subunit 
genes (examination of these genes is described in Chapters V and VI), for which 
better genetic evidence exists suggesting a role in idiopathic autism. However, it 
in no way excludes the hypothesis that epigenetic dysfunction, which would be 
very difficult to detect by traditional analytical methods, plays a role in conferring 
risk for autism. In fact, a recent report documents reduced UBE3A and GABRB3 
expression in MECP2-deficient brain tissue [172]. This supports hypothetical 
involvement of MeCP2, the methyl-DNA-binding protein deficient in Rett 
Syndrome (another Pervasive Developmental Disorder), in facilitating paternal 
silencing of UBE3A by acting in trans at the differentially-methylated 15q IC or 
elsewhere in the region. It also raises the specter that epigenetic gene silencing 
in 15q11-q12 extends beyond UBE3A and ATP10A. Paternal silencing of UBE3A 
in the brain is speculated to involve a paternal antisense transcript (ATS), 
promoting from the SNRPN promoter and transcribed through the MED [173]. 
The antisense orientation relative to UBE3A and ATP10A (and possibly GABRB3 
as well) is thought to promote silencing via RNA interference mechanisms.  
The purpose of this study is to focus on the MED and corresponding 
imprinting center to test the hypotheses that a common allele or set of alleles in 
this region might (1) be involved in causing abnormal epigenetic effects or 
imprinting regulation or (2) affect one of the maternally-expressed genes directly.  
To test these hypotheses, we examined SNPs and haplotypes across the region 
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for evidence of transmission disequilibrium generally, or in a parental-specific 
manner in autism families.   
 
Materials and Methods 
 
Families 
The sample for this study consisted of 384 autism families (327 multiplex 
and 57 trio families). Two-hundred eighty-three families were obtained from the 
Autism Genetics Resource Exchange (AGRE; http://agre.org), 98 multiplex and 
trios from Tufts/ New England Medical Center, and 3 multiplex families from 
Vanderbilt University. The majority of families are Caucasian. All affected 
individuals were at least four years of age and were clinically assessed with the 
ADI or ADI-R and most with the Autism Diagnostic Observation Schedule 
(ADOS). At least one sib had to meet ADI algorithm criteria for an autism 
diagnosis, while additional siblings may be on the broader autism spectrum. 
Families were excluded from the study if probands had a known medical or 
neurological condition suspected to be associated with their autistic phenotype 
(e.g. fragile X syndrome). The procedures for clinical evaluation of affected 
individuals for the AGRE families have been previously described [30].  
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Molecular Analyses  
DNA from Tufts and Vanderbilt samples was isolated from peripheral 
blood or lymphoblastoid cells using the PureGene kit according to the 
manufacturer’s recommendations (Gentra Systems, Minneapolis, MN). A number 
of our samples were or obtained from the NIMH Center for Collaborative Genetic 
Studies on Mental Disorders (http://nimhgenetics.org/), involving a contract 
repository at Rutgers University. SNPs from the dbSNP and Celera SNP 
databases were selected based on their map position, and minor allele 
frequency, and potential for having a functional effect. Visualization Tools for 
Alignment (VISTA) analysis was performed via web-based submission 
(http://www.gsd.lbl.gov/vista/) of human and mouse genomic sequence [121]. 
Regions showing evolutionarily conserved non-coding sequence were identified 
as an additional means of identifying regions wherein variants were selected for 
examination. The reasoning is that conserved regions are more likely to harbor 
functionally significant (e.g. regulatory) sequences. Therefore, such regions are 
specifically targeted to provide the ability to represent potential unknown 
functional (but non-coding) variation. Marker and exon locations and intermarker 
distances are based on the public (Ensembl; Dec 2004 release 27.35a.1; 
http://www.ensembl.org) and Celera 
(http://www.celeradiscoverysystem.com/index.cfm) assemblies. Database 
reference numbers and other details for the markers studied are cited in Table 7-
1. All SNPs were genotyped using the TaqMan™ protocol (Applied Biosystems, 
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Foster City, CA). PCR primers and probes for assays are listed in Table 7-2. This 
information is proprietary for the majority of markers, for which Assays-On-
Demand™ were obtained from Applied Biosystems (Foster City, CA). 
For TaqMan™ genotyping assays, reactions were performed in a 5 µl 
volume, employing 2.5ng genomic DNA template, according to manufacturer’s 
recommendations (Applied Biosystems). Cycling conditions included an initial 
denaturation at 95 °C for 10 min, followed by 50 cycles of 92 °C for 15 s, 60 °C 
for 1 min. Samples were analyzed using an ABI 7900HT Sequence Detection 
System. 
 
Table 7-1. SNP markers spanning the Imprinting Center (IC) and Maternal 
Expression Domain (MED) region on 15q11-q13. Alleles are listed 
major/minor. 
 
 
Gene SNP 
No. Region 
dbSNP rs# 
/Celera hCV# Alleles 
Minor Allele 
Frequency 
Intermarker 
Distance 
(kb) 
Intergenic 1 Intergenic rs12902137/ hCV1796103 T/C 0.27 5.7 
Intergenic 2 Intergenic rs12905620/ hCV9710866 T/C 0.24 49.9 
Intergenic 3 Intergenic rs975907/ hCV8378225 A/G 0.41 20.6 
Intergenic 4 Intergenic rs1463292/ hCV8378415 A/G 0.42 32.9 
Intergenic 5 Intergenic rs3913224/ hCV7516185 T/C 0.18 30.6 
Intergenic 6 Intergenic rs11161139/ hCV1244494 C/T 0.38 7.8 
SNRPN 7 Promoter hCV1244509 T/G 0.19 21 
 8 Intron 2 rs736008/ hCV2979338 T/C 0.44 16.6 
 9 Intron 2 rs5001649/ hCV2979365 T/C 0.29 17.7 
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 10 Intron 2 rs2047433/ hCV2979396 G/T 0.39 10.9 
 11 Intron 3 rs11634496/ hCV2979419 C/A 0.30 8.1 
 12 Intron 3 rs8037745/ hCV1223678 A/G 0.39 7.6 
 13 Intron 3 rs4906695/ hCV1223674 G/C 0.17 10.4 
 14 Intron 4 rs2736708/ hCV16287658 A/G 0.21 34.4 
 15 Intron 4 rs220030/ hCV3214754 T/C 0.36 0.5 
 16 Intron 4 rs220029/ hCV3214752 G/A 0.08 9.9 
 17 Intron 5 rs220034/ hCV1025117 G/A 0.09 5.9 
 18 Intron 6 rs2554428/ hCV2066559 C/T 0.34 3.4 
 19 Exon 7  (5’ UTR) 
rs705/ 
hCV2066555 T/C 0.46 101.5 
Intergenic 20 Intergenic rs4906699/ hCV2066488 T/C 0.43 3.6 
Intergenic 21 Intergenic rs11161166/ hCV2066485 T/A 0.45 7.5 
Intergenic 22 Intergenic rs1549478/ hCV2066478 C/T 0.44 20.1 
Intergenic 23 Intergenic rs7162559/ hCV152343 G/A 0.34 127 
Intergenic 24 Intergenic rs2714758/ hCV132223 A/G 0.06 44.4 
Intergenic 25 Intergenic rs1977036/ hCV422420 C/T 0.13 4.8 
Intergenic 26 Intergenic hCV422410 T/C 0.10 47.2 
Intergenic 27 Intergenic rs4906951/ hCV2625778 T/C 0.28 4.8 
UBE3A 28 Intron 11 hCV11487073 G/A 0.12 19.9 
 29 Intron 9 rs12907375/ hCV2558359 A/G 0.26 5.8 
 30 Intron 6 rs10162823/ hCV2558365 G/A 0.14 11.8 
 31 Intron 5 rs4906708/ hCV11487149 C/T 0.26 21.2 
 32 Intron 4 rs2340625/ hCV2558398 C/G 0.22 32.1 
 33 Intron 1 rs7496951/ hCV2558422 G/C 0.27 8.6 
  Intron 1 D15S122   2.5 
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 34 Intron 1 hCV2558441 G/A 0.13 2.8 
 35 Promoter rs2526025/ hCV2558443 C/A 0.18 25.7 
Intergenic 36 Intergenic rs969860/ hCV8766820 C/G 0.13 36.4 
Intergenic 37 Intergenic rs4906719/ hCV28014321 G/T 0.47 0.5 
Intergenic  Intergenic D15S210   42.3 
Intergenic 38 Intergenic rs2189713/ hCV2564743 T/C 0.41 54.6 
Intergenic 39 Intergenic rs2925280/ hCV15943093 T/C 0.42 10.5 
Intergenic 40 Intergenic rs2930599/ hCV26647614 G/A 0.32 26.1 
Intergenic 41 Intergenic rs1385388/ hCV431962 T/C 0.30 39.6 
Intergenic 42 Intergenic rs7181116/ hCV454609 T/C 0.33 3.9 
ATP10A 43 Exon 22 rs1047700/ hCV1157519 T/C 0.18 1.6 
 44 Exon 19 rs2076745/ hCV15863547 T/C 0.01 3.1 
 45 Intron 17 rs8041681/ hCV1157511 A/G 0.31 7.8 
 46 Intron 15 rs2066705/ hCV12080790 T/C 0.36 16.5 
 47 Exon 12 rs2066704/ hCV12080806 C/T 0.08 8.6 
 48 Exon 10 rs2066703/ hCV12080811 G/A 0.06 2 
 49 Intron 8 rs2014053/ hCV320540 T/C 0.47 19.4 
 50 Intron 3 rs4906629/ hCV394756 G/A 0.19 4.8 
 51 Intron 3 rs12901627/ hCV394762 C/T 0.38 21.6 
 52 Intron 3 rs11161217/ hCV125931 A/C 0.45 7.4 
 53 Intron 3 rs7165728/ hCV24876 T/C 0.22 7 
 54 Intron 3 rs2044311/ hCV12064096 A/T 0.25 0.9 
 55 Intron 3 rs8038726/ hCV232863 G/A 0.20 2.6 
 56 Intron 2 rs11632263/ hCV11300397 C/T 0.49 2.9 
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 57 Intron 2 rs11636393/ hCV399638 C/T 0.39 6.3 
 58 Intron 2 rs12439329/ hCV11300400 A/T 0.49 10.4 
 59 Intron 2 rs872537/ hCV8864618 A/T 0.42 0.4 
 60 Intron 2 rs1867511/ hCV9400334 A/G 0.22 9.1 
 61 Intron 2 rs1345098/ hCV8864621 T/G 0.45 0.4 
 62 Intron 2 rs1345099/ hCV9400402 A/G 0.49 10.6 
 63 Intron 2 rs11161232/ hCV423475 C/T 0.24 7.6 
 64 Intron 2 rs11630555/ hCV504244 T/C 0.44 11.3 
 65 Intron 2 rs11633552/ hCV60097 C/G 0.17 11.4 
 66 Intron 2 hCV402689 T/C 0.18 10.6 
 67 Intron 1 rs2076749/ hCV15863526 A/T 0.26 1.3 
 68 Promoter rs1444621/ hCV8864860 C/T 0.07 29.6 
Intergenic 69 Intergenic rs4906642/ hCV1591365 A/T 0.37 42 
Intergenic  Intergenic D15S1513   34 
Intergenic 70 Intergenic rs1397855/ hCV8866740 C/T 0.10 2.3 
Intergenic 71 Intergenic rs1511493/ hCV8866723 G/A 0.45 2.1 
Intergenic  Intergenic D15S540   77.4 
Intergenic 72 Intergenic rs1403590/ hCV8865982 T/C 0.43 80.1 
Intergenic 73 Intergenic rs693798/ hCV578309 G/A 0.08 23.4 
Intergenic 74 Intergenic rs2030601/ hCV11669761 C/T 0.45 79.6 
Intergenic 75 Intergenic rs1435831/ hCV8864717 C/T 0.39 57.6 
Intergenic 76 Intergenic rs4906872/ hCV240706 A/C 0.37 52.5 
Intergenic 77 Intergenic rs3922665/ hCV26111547 T/C 0.47 63.4 
Intergenic 78 Intergenic rs4906673/ hCV2911753 A/G 0.38 81 
Intergenic  Intergenic GABRB3   _ 
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Table 7-2. PCR and genotyping primers for the IC-MED region SNPs. Labels 
are as follows: (F) Forward Primer, (R) Reverse Primer, VIC and FAM are 
fluorescent labels for TaqMan allelic discrimination probes (SNPs indicated by 
bold text), AbD is an Assay-By-Design from ABI, AoD is an Assay-On-Demand 
from ABI. Sequence for primers and probes for AoD assays are proprietary 
information. MGB stands for minor groove binder, and NFQ stands for non-
fluorescent quencher. 
 
SNP 
No. Primer sequences (5´-3´) 
Product 
size (bp) Assay 
* NA Unavailable < 200 TaqMan (AoD) 
1 F CCTCTCCAGAACTCAGGTTGTG 
 R GATGCACCACCTGTGTTTTGTC 109 
 VIC VIC-ATGTGTACTGACGGAGAA-MGB-NFQ  
 FAM FAM-ATGTGTACTGACAGAGAA-MGB-NFQ  
TaqMan 
(AbD) 
2 F CATCCTGGCACCATTAACCATCA 
 R CAAATGCTAGTCTATGTAGTTTGCATGAA 82 
 VIC VIC-TTACTGCATACAGAGAGC-MGB-NFQ  
 FAM FAM-TTTTACTGCATATAGAGAGC-MGB-NFQ  
TaqMan 
(AbD) 
3 F GTGTATGCATAGCACCTGTAGGA 
 R CCTTTTAGATCCATCTTAAATCTTTGATTCACTG 85 
 VIC VIC-CCAGTGGACGACCTT-MGB-NFQ  
 FAM FAM-CCAGTGGATGACCTT-MGB-NFQ  
TaqMan 
(AbD) 
4 F GCTCGCAATACAAAGGAAAAATGTGT 
 R ACTGTGTATAGGTCAATTATGATCTTCCCT 106 
 VIC VIC-TCGATAATTAAACTCCATTTGTA-MGB-NFQ  
 FAM FAM-CGATAATTAAACTCCGTTTGTA-MGB-NFQ  
TaqMan 
(AbD) 
5 F CAACTTCAAGCTTTCCTGGTAATATTTAGTC 
 R TGAGATTAAAAAAAGAAAACTGCAAACAAATGTT 114 
 VIC VIC-CCAAAACAAACAAACAA-MGB-NFQ  
 FAM FAM-CAAAACAAGCAAACAA-MGB-NFQ  
TaqMan 
(AbD) 
6 F CGTGATGTCACAGGCACAGA 
 R TCCATTCCATGAGAGAGTTATGTTTGG 72 
 VIC VIC-CTCAGCACGGTGTCC-MGB-NFQ  
 FAM FAM-CTCAGCACAGTGTCC-MGB-NFQ  
TaqMan 
(AbD) 
7 F GGCCAACTTCATTCAAATGTCTTCTC 
 R CCAGCCATTTTCTACAGAGACATG 90 
 VIC VIC-CTTCCCGTTTTCTC-MGB-NFQ  
 FAM FAM-CCTTCCCTTTTTCTC-MGB-NFQ  
TaqMan 
(AbD) 
8 F TCCTGCGAAAGATACAAAGTCAGAAA 
 R GCTGGTAAGGTGAAATTAAGGCATGA 103 
 VIC VIC-AAAACGACATTTCGGCACC-MGB-NFQ  
 FAM FAM-AAAACGACATTTTGGCACC-MGB-NFQ  
TaqMan 
(AbD) 
9 F CTTAATAACTAAATGAATTGCCCTGCTTTGT 
 R CCCCTGAAATGAGGAGACATGAATC 81 
 VIC VIC-TTCAGGAATGATTAGGCAAA-MGB-NFQ  
 FAM FAM-TTCAGGAATGATTAAGCAAA-MGB-NFQ  
TaqMan 
(AbD) 
  
10 F TGTGAAATTCCAACTTCTGGACAGT 
 R CCTGCTTACTTGGCTGCAAAG 80 
 VIC VIC-TCTGATTTTCCTGGCTTC-MGB-NFQ  
 FAM FAM-TTCTGATTTTACTGGCTTC-MGB-NFQ  
TaqMan 
(AbD) 
11 NA Unavailable < 200 TaqMan (AoD) 
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12 F CATTTCCGTTGCATTTTTGTGAACA 
 R CCTCAAGTACAGGAAGAAAGCTGAA 107 
 VIC VIC-TGTTGCATGTAGTAGATG-MGB-NFQ  
 FAM FAM-TTGCATGTGGTAGATG-MGB-NFQ  
TaqMan 
(AbD) 
13 F GTATTTATTTTTATCCTGTATCACCAAGCGTTT 
 R GAAATTTAGAAGACGATGATGAGAGGGTAA 82 
 VIC VIC-CCGAGTATCGTAATCAG-MGB-NFQ  
 FAM FAM-CCGAGTATCCTAATCAG-MGB-NFQ  
TaqMan 
(AbD) 
14 F CCAGTGGCTGAATCTACTTTCTCT 
 R CAAGTGGAAGGTAAGGAGGAAGAG 79 
 VIC VIC-CTGGAGATATATAAAATT-MGB-NFQ  
 FAM FAM-TGGAGATACATAAAATT-MGB-NFQ  
TaqMan 
(AbD) 
15 F ATTGATTGTGGTTATGGCGCATTT 
 R CTCACCCTCAGGTCTTCCTATGT 77 
 VIC VIC-CCAGCTTTTTTGTACCGC-MGB-NFQ  
 FAM FAM-CAGCTTTTTCGTACCGC-MGB-NFQ  
TaqMan 
(AbD) 
16 F AGCGGCCACTTTTATTCATCAGATA 
 R ACAAAGGACTTTAGGGCCCAAATT 86 
 VIC VIC-TTGGAGTACTGAATAAA-MGB-NFQ  
 FAM FAM-CTTGGAGTACTAAATAAA-MGB-NFQ  
TaqMan 
(AbD) 
17 F TGTGCGTTTTCATTTTGAGAGTAATTGG 
 R CCTGAGAATCCTAAACACATGGACAA 94 
 VIC VIC-CAGGATTGGTTAACACT-MGB-NFQ  
 FAM FAM-CAGGATTGATTAACACT-MGB-NFQ  
TaqMan 
(AbD) 
18 F CTCTATGGAGACCCTCTATAATTTTAAATTTTAACAGA 
 R CTAGGGTTGGCCAAGGCA 96 
 VIC VIC-CATAGCAAATGAGACACAC-MGB-NFQ  
 FAM FAM-ATAGCAAATGAAACACAC-MGB-NFQ  
TaqMan 
(AbD) 
19 F GCCCAGCTTGCATTGTTTCTAG 
 R TCCACAGTTAAAACTTGATGCTTCTGA 93 
 VIC VIC-TGACGCGGGTTCT-MGB-NFQ  
 FAM FAM-TGACGCAGGTTCT-MGB-NFQ  
TaqMan 
(AbD) 
20 F TGGTGGATACCTCAGGATGGT 
 R CTCATACCTGCAAACATGGAACATT 71 
 VIC VIC-CCTTTGGAAAACCA-MGB-NFQ  
 FAM FAM-CCTTTGAAAAACCA-MGB-NFQ  
TaqMan 
(AbD) 
21 F AGTTTGAGAACAGTGGAGTTCCAATC 
 R CTCACAATGCATGGAACACAACAT 66 
 VIC VIC-ACCTGGCATAGCTTT-MGB-NFQ  
 FAM FAM-ACCTGGCTTAGCTTT-MGB-NFQ  
TaqMan 
(AbD) 
22 F CATAGCCTCTTTGCCGCATTTC 
 R GCCTGATCATGCAATACACAAATCC 71 
 VIC VIC-AACATATGGGATGTGACATG-MGB-NFQ  
 FAM FAM-TAACATATGGGATATGACATG-MGB-NFQ  
TaqMan 
(AbD) 
23 F GCATTAGATGATAGATTAAATTAGATGCTTCATTAAACATT 
 R AGAATCTCTCTTAAAATATACAAAGACTCAATGAAGG 147 
 VIC VIC-CCAACAATATCCATCTAAAA-MGB-NFQ  
 FAM FAM-CAACAATATCCACCTAAAA-MGB-NFQ  
TaqMan 
(AbD) 
24 F AGCTCTGACCCTTCCTGACT 
 R TGCATCTAGCAGGACCTGGATAT 74 
 VIC VIC-CTGAGCTGTGATGACC-MGB-NFQ  
 FAM FAM-TGAGCTGTGGTGACC-MGB-NFQ  
TaqMan 
(AbD) 
25 F CAGTGGCATCCTGTCTTATGAGT 
 R ACAATTAAAGCAAGTCTTGGGTCACT 71 
 VIC VIC-CACACTAAAGTGCACACTG-MGB-NFQ  
 FAM FAM-CACACTAAAGTACACACTG-MGB-NFQ  
TaqMan 
(AbD) 
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26 F CACAGACTTCACCTTAGGGTTTTACA 
 R AAGCACTGTACACAATCAACAACAAAT 90 
 VIC VIC-CACCAGGCCCCTCC-MGB-NFQ  
 FAM FAM-CACCAGACCCCTCC-MBG-NFQ  
TaqMan 
(AbD) 
27 F CAGGACAGTGGAGTAAAGAAAACAGA 
 R ATGACTGCCTAGTTCCCTCCT 78 
 VIC VIC-AAATTTTAAGCCTCGTGAGAGT-MGB-NFQ  
 FAM FAM-AAATTTTAAGCCTCATGAGAGT-MGB-NFQ  
TaqMan 
(AbD) 
28 F AAGTGAAGATGCTGGGTAGGAATG 
 R CCTTTCCAATTTGGCCTTGTGTTAC 64 
 VIC VIC-CAGCGAGAAAAGTGT-MGB-NFQ  
 FAM FAM-AGCGAGGAAAGTGT-MGB-NFQ  
TaqMan 
(AbD) 
29 F AACAGACACATTTAAACCATGTATCCATCT 
 R TTGGGACTTCCTGGTTTGCTTAA 97 
 VIC VIC-TTTAAGAGAGTACAATATATTTG-MGB-NFQ  
 FAM FAM-AGAGAGTACAATGTATTTG-MGB-NFQ  
TaqMan 
(AbD) 
30 F ATTTCAATTAAGAAAAATACACTGAATACTAAAGCAGTTT 
 R GGGTTCTAGTCCATTAAAAGGTGGTAA 97 
 VIC VIC-TCTCTCACAATAAGACTTA-MGB-NFQ  
 FAM FAM-CTCTCACAGTAAGACTTA-MGB-NFQ  
TaqMan 
(AbD) 
31 F AGGTTAATTTTAGAGGCACACAGACAA 
 R GTGGGAGTCATTAAAAATTCTACATGTTGT 100 
 VIC VIC-TTGGCGCAATGGA-MGB-NFQ  
 FAM FAM-ATATTTGGCACAATGGA-MGB-NFQ  
TaqMan 
(AbD) 
32 F CTGTCTTCTCTGATTCCAGGTGTTA 
 R GAGGATGCTTGGGAATAGCTAAGAA 74 
 VIC VIC-CTGCCTAGAACACTATGA-MGB-NFQ  
 FAM FAM-CTGCCTAGAACAGTATGA-MGB-NFQ  
TaqMan 
(AbD) 
33 NA Unavailable < 200 TaqMan (AoD) 
34 F GTATTTCTTAAACTTTAGGTCGTCTCCCA 
 R GGATCATTTTACTGCCTGCAATATTGAG 85 
 VIC VIC-CAGCAAATTATTATAGATTTT-MGB-NFQ  
 FAM FAM-CAAATTATTACAGATTTT-MGB-NFQ  
TaqMan 
(AbD) 
35 F GCCTCACAACTATAACCAACCATTG 
 R GGCTTAATACTATCATTATCATCAGTTGTCCT 95 
 VIC VIC-AAGCTAGAAGAATTTAAG-MGB-NFQ  
 FAM FAM-AAGCTAGAAGACTTTAAG-MGB-NFQ  
TaqMan 
(AbD) 
36 F TTGTGCCCCAGGTTCAGTAC 
 R CTGAAGTGGGTTAGAAGATGGGAAT 73 
 VIC VIC-TCACCACAACATGGC-MGB-NFQ  
 FAM FAM-CACCAGAACATGGC-MGB-NFQ  
TaqMan 
(AbD) 
37 F AGCTCTAAATTGTGGTGCATACTGA 
 R GCCTTACAGCTGACGAAATGC 73 
 VIC VIC-CTCAGAGAAATAAAATAAGTG-MGB-NFQ  
 FAM FAM-CTCAGAGAAATAAAATCAGTG-MGB-NFQ  
TaqMan 
(AbD) 
38 F GTCAGGTACCTACACTGGCTTTAC 
 R GCTCTGTGTTGATTTTGCAAGGAAT 88 
 VIC VIC-TGTACTATATCACATACCCC-MGB-NFQ  
 FAM FAM-CTATATCGCATACCCC-MGB-NFQ  
TaqMan 
(AbD) 
39 F GCCTAGAGTACTTATTGCAACACCAA 
 R CTACGTTGATGCCTTCTAAGGTTACT 95 
 VIC VIC-AAAGGGAATCAAAGTCCAT-MGB-NFQ  
 FAM FAM-AAGGGAATCAAGGTCCAT-MGB-NFQ  
TaqMan 
(AbD) 
     
113 
40 F TTCCAAAACATAGTTATCTGTTGGCTGTA 
 R ACATTAGGAAAATCTGTGAACAGTTGAAGA 98 
 VIC VIC-CATTCCTTCATTTGGAAAT-MGB-NFQ  
 FAM FAM-TTCCTTCGTTTGGAAAT-MGB-NFQ  
TaqMan 
(AbD) 
41 F CTCTCTGCCCCTCTTTGTTCTG 
 R AGCCCAAAGGAGCAAAGCA 86 
 VIC VIC-CCTGAAGGGCCAGCCT-MGB-NFQ  
 FAM FAM-CCTGAAGGACCAGCCT-MGB-NFQ  
TaqMan 
(AbD) 
42 F CTCAGGGCCCGTGTAACAG 
 R CACTCAGAAGGGAAGCCATCTC 65 
 VIC VIC-CCACACCACTGAGAGG-MGB-NFQ  
 FAM FAM-CCACACCATTGAGAGG-MGB-NFQ  
TaqMan 
(AbD) 
43 F CGCCTTGAAGATGCTCCTATAAGTA 
 R ACTCAGGCCGATCAGGACTT 64 
 VIC VIC-TGGTCTGGCCCCTG-MGB-NFQ  
 FAM FAM-TGGTCTGGCCCTTG-MGB-NFQ  
TaqMan 
(AbD) 
44 F CCGGATCCAGCTGGTAAGAAAA 
 R CGACGCCGCCTTCCA 91 
 VIC VIC-TTTGCTTTTCCATTCCTTA-MGB-NFQ  
 FAM FAM-TTGCTTTTCCGTTCCTTA-MGB-NFQ  
TaqMan 
(AbD) 
45 F GCAAAGCCAATGACCTCATCAAC 
 R GGTCCCCGTGGACAATCA 56 
 VIC VIC-ATCGCTGCAGTGACC-MGB-NFQ  
 FAM FAM-CGCTGCGGTGACC-MGB-NFQ  
TaqMan 
(AbD) 
46 F GCACAGGCAAGAAGAATTGTTTGAT 
 R CGCTTTCACAGGACTGAGTTCA 102 
 VIC VIC-CAAGAAAATCTAGCACATTG-MGB-NFQ  
 FAM FAM-CAAGAAAATCTAACACATTG-MGB-NFQ  
TaqMan 
(AbD) 
47 F GAGGTAATTCTGAGTTTTGCTCCGA 
 R CCAGTTCTTACCCATGTTTCTGCTT 95 
 VIC VIC-CAACCTAGTTGACACCAGAG-MGB-NFQ  
 FAM FAM-ACCTAGTTGACGCCAGAG-MGB-NFQ  
TaqMan 
(AbD) 
48 F ACCTTCTCCAGCAGCTTTGG 
 R CTGCCAGCCTCCCTTTCTC 64 
 VIC VIC-AGAAGGATATCATGCCCGAC-MGB-NFQ  
 FAM FAM-AAGGATATCACGCCCGAC-MGB-NFQ  
TaqMan 
(AbD) 
49 F TCCTGTCTGGATGAAATGCTATGG 
 R CTGAGTCCAAACCCTAGCTGTAG 88 
 VIC VIC-CACTCCCAGACTGCACA-MGB-NFQ  
 FAM FAM-ACTCCCAGATTGCACA-MGB-NFQ  
TaqMan 
(AbD) 
50 F CCATCAGTCAGACTTGTCAACCT 
 R CCAGAGCAGAAGGGTGGAT 77 
 VIC VIC-CATGGACAAAAGTAG-MGB-NFQ  
 FAM FAM-CATGGACAAAGGTAG-MGB-NFQ  
TaqMan 
(AbD) 
51 F CTGGAGAAAAGGTGCTCTCTCT 
 R TGCCTTTAGGGTCCCTTTTATTACAAA 85 
 VIC VIC-CCCTCTTACGCTGTGCA-MGB-NFQ  
 FAM FAM-CCCTCTTACACTGTGCA-MGB-NFQ  
TaqMan 
(AbD) 
52 F CTCACCTTAATTCTTCCAGCTCTGT 
 R AAAGGGTTTGCGTCTCTGTGA 85 
 VIC VIC-ATCATGAATACAATACCTCTGTCT-MGB-NFQ  
 FAM FAM-ATGAATACAATACCGCTGTCT-MGB-NFQ  
TaqMan 
(AbD) 
53 F TCCACATCCCAGTAGGCAATAGT 
 R AGGAATCGACCTTTAAGGAAAGCAA 67 
 VIC VIC-CTCGACTTCAGGAAAC-MGB-NFQ  
 FAM FAM-CGACTTCAGAAAAC-MGB-NFQ  
TaqMan 
(AbD) 
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54 F CGCCCCACTCCCTACAG 
 R TCGGCACCAGCCCATC 84 
 VIC VIC-CTGTCTGTGGACCTC-MGB-NFQ  
 FAM FAM-CTGTCTGAGGACCTC-MGB-NFQ  
TaqMan 
(AbD) 
55 NA Unavailable < 200 TaqMan (AoD) 
56 F CCTAGATGCTGAAGAGAGGAGTGT 
 R GGTTTGGTGGATCTTGAATTAGAGGAT 83 
 VIC VIC-CCCTGCCATTTTA-MGB-NFQ  
 FAM FAM-CCCCTGTCATTTTA-MGB-NFQ  
TaqMan 
(AbD) 
57 F CACATCCATGAAGGCAGACAGT 
 R GCTACAGCTGGGCATGAAATG 65 
 VIC VIC-CTTGAGTGATGCACAAGA-MGB-NFQ  
 FAM FAM-TTGAGTGATGCGCAAGA-MGB-NFQ  
TaqMan 
(AbD) 
58 F AATTCAGATCTTAGAGCACGAAGCA 
 R AGTCTCCTGGAGGTGAATTAACACT 73 
 VIC VIC-CCAGGCACCTCCAG-MGB-NFQ  
 FAM FAM-ACCAGGCTCCTCCAG-MGB-NFQ  
TaqMan 
(AbD) 
59 F GTTTCCTCCAGGTGCTCTTATGG 
 R CCGGATTTGCCAGGAATTATCTCA 70 
 VIC VIC-TCACAAAGACTCAGCCCT-MGB-NFQ  
 FAM FAM-CACAAAGACACAGCCCT-MGB-NFQ  
TaqMan 
(AbD) 
60 F TGGGTGCTGGGACATTTTCTC 
 R CGAGTTGTCCTAGCCATTCAGT 64 
 VIC VIC-TCCTGCTTCTCAGGTACA-MGB-NFQ  
 FAM FAM-CTGCTTCTCGGGTACA-MGB-NFQ  
TaqMan 
(AbD) 
61 F TTTCTTTTTTCATTCAAAGCGAGGGAA 
 R AAATGCAAGTGTTCTTGGAAAAGGTT 83 
 VIC VIC-AATAACAAGGACTCCCTAAAT-MGB-NFQ  
 FAM FAM-AAGGACGCCCTAAAT-MGB-NFQ  
TaqMan 
(AbD) 
62 F TTTGAAAGTGATTACAAACCTCTACTTCTCA 
 R CATGCATTTCTTACTTATTTGATGCAGAAGA 96 
 VIC VIC-CAGTGCAAGATTTA-MGB-NFQ  
 FAM FAM-CAGTGCAGGATTTA-MGB-NFQ  
TaqMan 
(AbD) 
63 F ACTTTCAGAAATTAACTATTCAAAGAAGCAACATT 
 R CACTGTGTGCTTTCCAAGCC 119 
 VIC VIC-CAAACCCCAGTTTCTGT-MGB-NFQ  
 FAM FAM-AAACCCCAATTTCTGT-MGB-NFQ  
TaqMan 
(AbD) 
64 F CTGCATTGTCCCATGAGGTCAT 
 R GCACGTTTACTAAAGCCACTTGT 86 
 VIC VIC-CTTTTGAAACGGGTTTAA-MGB-NFQ  
 FAM FAM-TTCTTTTGAAACAGGTTTAA-MGB-NFQ  
TaqMan 
(AbD) 
65 F TGGGCCACCTGTTGCT 
 R CCAGGAGACCCAGACCCA 62 
 VIC VIC-CTTTTGCCCATCCACC-MGB-NFQ  
 FAM FAM-CTTTTCCCCATCCACC-MGB-NFQ  
TaqMan 
(AbD) 
66 F ACCAGCAGGAGTCTAACAGTCA 
 R GGCTTCCCCACGTTTTGG 61 
 VIC VIC-CCCCTTCTCAACCTT-MGB-NFQ  
 FAM FAM-CCCCTTTTCAACCTT-MGB-NFQ  
TaqMan 
(AbD) 
67 F TTTCTGTTCTTTCTTCATGGAAAGGAGAA 
 R GAGGGAAACAGACACTCAAATACCT 89 
 VIC VIC-CAAATTCTGTCTTTGCTATAG-MGB-NFQ  
 FAM FAM-AAATTCTGTCTTAGCTATAG-MGB-NFQ  
TaqMan 
(AbD) 
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68 F GATTTCCAGGAAGGCCTAGCT 
 R GATTCCCCAGATCACACAGCTT 67 
 VIC VIC-AGACCTTTCCAGAGGTGA-MGB-NFQ  
 FAM FAM-ACCTTTCCGGAGGTGA-MGB-NFQ  
TaqMan 
(AbD) 
69 F CAGCTGAAGAAAACAGAAAGATGAAACT 
 R GATCATTTCAATTTGAATTCCCAGTGCTT 95 
 VIC VIC-CAAAGAAAAGTTGCATGTTAA-MGB-NFQ  
 FAM FAM-CAAAGAAAAGTTGCTTGTTAA-MGB-NFQ  
TaqMan 
(AbD) 
70 F TCCCCTAAGTACTTCCAGTAGATGTAAC 
 R AGCTCAATAAATCTATCCCTGTGCATT 103 
 VIC VIC-ACTGCTGGACTGTATG-MGB-NFQ  
 FAM FAM-CTGCTGGGCTGTATG-MGB-NFQ  
TaqMan 
(AbD) 
71 F AGGAGCCATGCATTAAGTTGCT 
 R GAACCTGAAAGACCCTCTGTGAAA 137 
 VIC VIC-CAAGCACTCAGCTGTG-MGB-NFQ  
 FAM FAM-AAGCACTCGGCTGTG-MGB-NFQ  
TaqMan 
(AbD) 
72 F TGGGCTGCACTTGCCAAT 
 R GCCGCTCTGCTTCTTAGCTAT 56 
 VIC VIC-TTGCCAGGTGTTGCT-MGB-NFQ  
 FAM FAM-TTTTGCCAGATGTTGCT-MGB-NFQ  
TaqMan 
(AbD) 
73 F GGTGGGAGGGTGATAGACAGAA 
 R CCAATGCATTCTAATCCCCTACCA 69 
 VIC VIC-ACACCATGCTATCCCGT-MGB-NFQ  
 FAM FAM-CACCATGCTGTCCCGT-MGB-NFQ  
TaqMan 
(AbD) 
74 F CCAAAATGAGTCCCAGGAAGCT 
 R CTGCCCCACCACAGAATAGG 75 
 VIC VIC-CTGACCCTCACGCCCA-MGB-NFQ  
 FAM FAM-CTCTGACCCTTACGCCCA-MGB-NFQ  
TaqMan 
(AbD) 
75 F TCAGCCCCATTTCTCTACCAGA 
 R AGGACGAAAGCAGCTGGTATTT 95 
 VIC VIC-CTAATTCAAGTAATGACATCCTAT-MGB-NFQ  
 FAM FAM-TTCAAGTAATGACGTCCTAT-MGB-NFQ  
TaqMan 
(AbD) 
76 F CTGCCTGTGTTCTAAGCAACTCT 
 R AGAGACAACAGAATTAGCAGAGCATAAA 85 
 VIC VIC-CTGCCAATAGATGCC-MGB-NFQ  
 FAM FAM-CTGCCAATCGATGCC-MGB-NFQ  
TaqMan 
(AbD) 
77 F GATGGGTTCAGTGGCTAAAGGAA 
 R CCTGAGGCATTGAGTTTTCAGTACA 81 
 VIC VIC-AGCTCATTTCAGCCCCAT-MGB-NFQ  
 FAM FAM-CTCATTTCGGCCCCAT-MGB-NFQ  
TaqMan 
(AbD) 
78 F GCAGCACCATGGGTAATATGAAATG 
 R TGCATCCCAACCCAAGGAAAA 89 
 VIC VIC-TTTATTCTAGGGTCATCTGTCAC-MGB-NFQ  
 FAM FAM-TCTAGGGTCACCTGTCAC-MGB-NFQ  
TaqMan 
(AbD) 
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Statistical Analyses 
Initial analysis of SNP genotype data involved quality control checks 
consisting of verification of internal controls and assessment of Mendelian 
inconsistencies, followed by final haplotype consistency analyses using 
Simwalk2 [117]. Conformity with anticipated Hardy-Weinberg equilibrium 
expectations was established. Transmission disequilibrium (TD) in autism 
families was determined using the pedigree disequilibrium test (PDT) statistic, 
developed for use with general pedigrees [119]. Maternal and paternal specific 
transmissions were also assessed using the TSP test [156]. Common haplotypes 
(≥5%) were determined using Haploview [129], and analyzed using the FBAT 
analysis software package [130]. TD for haplotypes was performed using 
haplotype tag SNPs for multi-marker blocks. Results were considered significant 
at the nominal level for markers or haplotypes with P ≤ 0.05. 
 
 
Results 
We examined 78 single nucleotide polymorphisms across the IC and MED 
domains of 15q11.2-q12 (Figure 7-2). No nominally significant (P ≤ 0.05) single 
marker association results were found in the total dataset of 384 families. 
However, we would have expected to find 78x0.05=3.9 (i.e. ~4) significant (P ≤ 
0.05) results. Extending from work previously done in the lab [47, 143], we 
examined the entire dataset for maternal and paternal transmissions using the 
TSP test; this statistic also allows for simultaneous analysis of both multiplex and 
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singleton families, while allowing for separate analyses of paternal- and 
maternal-specific transmissions. Three markers (4,12, and 16) located in and 
around SNRPN demonstrated nominal (P ≤ 0.05) evidence for TD when 
maternally-inherited. Two additional markers (45 and 76) showed nominal TD 
when paternally-transmitted. Though these results are well within expectations 
given the testing of all 78 markers for parental transmissions, they warrant follow-
up study. 
 
 
 
Figure 7-2. Schematic map detailing SNPs genotyped across the 
Imprinting Center (IC) and Maternal Expression Domain (MED). The autism 
candidate region includes the 15q imprinting center (IC), maternally-expressed 
genes (UBE3A and ATP10A) and the cluster of GABAA receptor subunit genes. 
The 2-Mb interval containing SNRPN, UBE3A, and ATP10A is expanded and 
shows relative position and transcriptional orientation (arrows) of each gene. 
Microsatellite markers used in our genome-wide linkage screen are indicated as 
references. Vertical hashes above the scale in kb indicate SNP markers analyzed 
in this study. The proximity of a large number of SNPs in relation to the scale is 
such that separate hashes do not distinguish these markers. 
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Intermarker LD was examined using the Haploview program [129]. 
Examination of LD across all markers included in the present study identifies 12 
loosely defined haplotype blocks, compared with 58 blocks detected using data 
(markers with minor allele frequency > 0.05) from the latest HapMap release 
(#14, 2004-12-10) and the default algorithm of Gabriel et al. within the Haploview 
program [147]. Haploview output for such a large region would be impractical to 
show, but markers defining the 12 blocks described are indicated in Table 7-3. 
Association analysis in the overall dataset, using FBAT, of all common 
haplotypes yielded no significant association (data not shown). 
In addition to examination of the entire dataset (384 families), we also 
examined those families only containing male-affected individuals (235 families) 
separately from those families containing female-affected individuals (149 
families). These analyses were performed in the context that other groups have 
recently presented findings with regard to sex-specific differences on other 
chromosomes as described in Chapters III and IV [78, 79]. All single marker 
results for the described datasets are presented in Table 7-3. 
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Table 7-3. Single marker analysis across the IC-MED region. Blocks of markers in 
high LD are highlighted in green. 
Gene # Marker PDT
Tsp 
Father
Tsp 
Mother
PDT
Tsp 
Father
Tsp 
Mother
PDT
Tsp 
Father
Tsp 
Mother
1 hCV1796103 0.892 0.280 0.388 0.754 0.726 0.178 0.599 0.239 0.758
2 hCV9710866 0.312 0.941 0.481 0.889 0.666 0.745 0.143 0.612 0.502
3 hCV8378225 0.868 0.586 0.331 0.906 0.527 0.677 0.727 0.908 0.335
4 hCV8378415 0.468 0.689 0.047 0.502 0.853 0.493 0.733 0.441 0.017
5 hCV7516185 0.241 0.131 0.458 0.687 0.311 0.579 0.183 0.248 0.623
6 hCV1244494 0.485 0.730 0.499 0.824 0.491 0.469 0.159 0.189 0.691
7 hCV1244509 0.753 0.587 1.000 0.235 0.104 0.274 0.066 0.248 0.159
8 hCV2979338 0.609 0.564 0.663 0.881 0.518 0.490 0.308 0.898 0.895
9 hCV2979365 0.679 0.358 0.463 0.908 0.351 0.373 0.592 0.777 0.898
10 hCV2979396 0.215 0.160 0.203 0.550 0.322 0.596 0.227 0.317 0.152
11 hCV2979419 0.182 0.055 0.932 0.068 0.122 0.838 0.823 0.257 0.876
12 hCV1223678 0.140 0.551 0.007 0.126 0.683 0.020 0.636 0.663 0.228
13 hCV1223674 0.137 0.325 0.835 0.092 0.392 0.903 0.732 0.599 0.366
14 hCV16287658 0.368 0.586 1.000 0.408 0.375 0.855 0.692 0.800 0.647
15 hCV3214754 0.537 0.217 0.944 0.102 0.356 0.112 0.346 0.413 0.250
16 hCV3214752 0.111 0.917 0.030 0.119 0.803 0.016 0.553 0.847 0.083
17 hCV1025117 0.205 0.751 0.152 0.112 0.522 0.046 1.000 0.706 0.096
18 hCV2066559 0.517 0.165 0.885 0.096 0.404 0.265 0.360 0.251 0.083
19 hCV2066555 0.965 0.592 0.655 0.349 0.919 0.428 0.272 0.352 0.092
20 hCV2066488 0.659 0.357 0.588 0.668 0.919 0.726 0.856 0.198 0.201
21 hCV2066485 0.849 0.107 0.241 0.679 0.371 0.541 0.461 0.159 0.015
22 hCV2066478 0.789 0.057 0.195 0.758 0.278 0.932 0.455 0.100 0.035
23 hCV152343 0.608 0.641 0.837 0.953 0.827 0.413 0.419 0.377 0.211
24 hCV132223 0.143 0.273 0.406 0.325 0.450 0.732 0.262 0.157 0.411
25 hCV422420 0.302 0.535 0.384 0.380 0.182 0.198 0.574 0.578 1.000
26 hCV422410 0.500 0.558 0.113 0.932 0.138 0.192 0.222 0.157 0.297
27 hCV2625778 0.799 0.601 0.665 0.636 0.588 0.336 0.394 0.837 0.081
28 hCV11487073 0.590 0.522 0.149 0.694 0.249 0.133 0.713 0.564 0.535
29 hCV2558359 0.763 0.704 0.394 0.817 0.503 0.157 0.846 0.803 0.921
30 hCV2558365 1.000 0.361 0.337 0.941 0.204 0.286 0.932 0.866 0.718
31 hCV11487149 0.571 0.877 0.477 0.560 0.626 0.157 0.844 0.701 0.765
32 hCV2558398 0.435 0.805 1.000 0.679 0.811 0.486 0.490 0.909 0.345
33 hCV2558422 0.421 0.502 0.549 0.179 0.376 0.208 0.783 1.000 0.777
34 hCV2558441 0.817 0.404 0.324 0.941 0.128 0.286 0.782 0.465 0.701
35 hCV2558443 0.464 0.193 0.802 0.242 0.196 0.726 0.810 0.662 0.406
36 hCV8766820 0.907 0.600 0.435 0.820 0.172 0.286 0.647 0.239 1.000
37 hCV28014321 0.811 0.840 0.823 1.000 0.799 0.629 0.712 0.508 0.814
38 hCV2564743 0.664 0.331 0.099 0.571 0.353 0.071 1.000 0.706 0.739
39 hCV15943093 0.136 0.210 0.127 0.088 0.085 0.138 0.880 0.895 0.639
40 hCV26647614 0.965 0.538 0.732 0.391 0.404 0.566 0.260 0.869 0.134
41 hCV431962 0.061 0.054 0.627 0.063 0.047 0.347 0.527 0.622 0.633
42 hCV454609 0.725 0.592 0.086 0.628 0.922 0.465 0.939 0.332 0.051
43 hCV1157519 0.645 0.401 0.514 0.947 0.751 0.467 0.525 0.336 0.884
44 hCV15863547 0.317 1.000 0.317 0.317 NA 0.317 1.000 1.000 1.000
45 hCV1157511 0.122 0.018 0.651 0.275 0.022 0.673 0.272 0.387 0.335
46 hCV12080790 0.200 0.086 1.000 0.490 0.072 0.331 0.251 0.617 0.340
47 hCV12080806 0.256 0.225 0.706 0.419 0.456 0.873 0.414 0.297 0.683
48 hCV12080811 0.435 0.592 0.362 0.482 0.691 0.480 0.710 0.715 0.564
49 hCV320540 0.760 0.883 0.596 0.924 0.441 0.697 0.701 0.497 0.706
50 hCV394756 0.524 0.454 0.398 0.182 0.193 0.914 0.455 0.456 0.181
51 hCV394762 0.769 1.000 0.586 0.404 0.289 0.448 0.610 0.225 0.096
52 hCV125931 1.000 0.360 0.941 0.306 0.063 0.615 0.206 0.285 0.583
53 hCV24876 0.748 0.688 0.883 0.703 0.608 0.753 0.386 0.197 0.917
54 hCV12064096 0.227 0.190 0.313 0.081 0.180 0.099 0.801 0.674 0.662
55 hCV232863 0.705 0.793 0.605 0.949 0.371 0.666 0.524 0.484 0.761
56 hCV11300397 0.704 0.812 0.758 0.215 0.490 0.574 0.270 0.181 0.138
57 hCV399638 0.835 0.728 0.603 0.367 0.819 0.782 0.494 0.423 0.211
58 hCV11300400 0.808 0.203 0.524 0.824 0.292 0.635 0.907 0.475 0.112
59 hCV8864618 0.571 0.157 0.492 0.174 0.117 0.531 0.442 0.793 0.751
60 hCV9400334 0.811 0.505 1.000 0.332 0.221 0.588 0.389 0.564 0.486
61 hCV8864621 0.328 0.663 0.741 1.000 0.928 0.798 0.124 0.541 0.835
62 hCV9400402 0.254 0.766 0.776 0.726 0.719 0.535 0.022 0.285 0.722
63 hCV423475 0.111 0.814 0.153 0.426 0.583 0.437 0.133 0.371 0.239
64 hCV504244 0.155 0.560 0.937 0.834 1.000 0.553 0.047 0.317 0.362
65 hCV60097 0.348 0.730 0.300 0.635 0.399 0.502 0.042 0.710 0.014
66 hCV402689 0.869 0.728 0.662 0.845 0.916 0.536 0.540 0.647 0.869
67 hCV15863526 0.758 0.780 0.861 0.700 0.157 0.233 1.000 0.063 0.086
68 hCV8864860 0.411 0.272 0.806 0.345 0.078 0.884 0.895 0.706 0.819
69 hCV1591365 0.635 0.056 0.429 0.351 0.239 1.000 0.748 0.103 0.251
70 hCV8866740 0.656 0.270 0.917 0.869 0.267 0.541 0.366 0.715 0.433
71 hCV8866723 0.496 0.470 0.611 0.237 0.178 0.584 0.701 0.612 0.904
72 hCV8865982 0.232 0.354 0.820 0.726 0.915 0.340 0.042 0.174 0.378
73 hCV578309 0.934 1.000 0.889 0.831 0.739 0.532 0.696 0.695 0.450
74 hCV11669761 0.061 0.484 0.265 0.069 0.531 0.028 0.465 0.752 0.346
75 hCV8864717 0.265 0.377 0.421 0.910 0.259 0.833 0.074 1.000 0.237
76 hCV240706 0.560 0.021 0.161 0.307 0.003 0.608 0.715 0.748 0.063
77 hCV26111547 0.695 0.440 0.723 0.346 0.200 0.931 0.565 0.710 0.623
78 hCV2911753 0.509 0.411 0.566 0.435 0.353 0.825 0.035 0.007 0.336
Affected Female 
Containing Families (149)
ATP10A
SNRPN
UBE3A
All Families (384)
Affected Male Only 
Families (235)
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Table 7-4. Tsp allelic transmission data for significant IC-MED markers.  The 
number of fathers/mothers represents the number of heterozygous 
fathers/mothers used for each test. The number of transmissions (T) refers to the 
number of times a parent, heterozygous for that marker, transmitted that 
particular allele to an affected child. The number of non-transmissions (NT) refers 
to the number of times a parent, heterozygous for that marker, did not transmit 
that particular allele to an affected child. 
 
 
 
 
Marker
Tsp 
Father 
(P)
Father 
!2
Allele
No. of 
Fathers
T NT
No. of 
Fathers
T NT
Tsp 
Mother 
(P)
Mother 
!2
Allele
No. of 
Mothers
T NT
No. of 
Mothers
T NT
A 12 17 63 87
G 17 12 87 63
A 9 9 89 55
G 9 9 55 89
G 0 1 36 18
A 1 0 18 36
T 12 11 74 54
C 11 12 54 74
A 15 10 56 90
G 10 15 90 56
A 7 15 68 90
C 15 7 90 68
A 6 5 60 36
G 5 6 36 60
G 0 1 22 8
A 1 0 8 22
G 2 2 22 10
A 2 2 10 22
T 7 7 50 32
C 7 7 32 50
A 8 9 35 57
G 9 8 57 35
T 10 15 28 46
C 15 10 46 28
A 5 10 32 54
C 10 5 54 32
A 4 9 21 37
G 9 4 37 21
A 7 2 48 28
T 2 7 28 48
T 5 2 46 28
C 2 5 28 46
T 7 4 28 16
C 4 7 16 28
C 4 2 32 16
G 2 4 16 32
A 4 6 40 18
G 6 4 18 40
hCV60097
hCV2911753
6
5.95
4.46
3.81
6.00
13
9
7
11
0.014
0.007
5.73
0.015
10 297.41
0.017
0.035
0.051
hCV8378415
hCV2066485
hCV2066478
hCV454609
4617
15 430.003 8.78
4 16
25 37
64
7922
3.71
5.29
18 72
1 27
7.32
4.74
hCV1223678
hCV3214752
0.007
0.030
hCV240706
0.020 5.44hCV1223678
0.021
hCV1157511 0.018
hCV431962 0.054
0.016 5.83
0.046 4.00
Triads
0.047 3.95 29
Triads Sib-pair
3.95 14 41
73255.64
23
0.022 5.24
4.860.028
0.047
Overall Sample    
(384 Families)
Affected Male Only 
(235 Families)
Affected Female 
Containing             
(149 Families)
hCV8378415
hCV3214752
hCV1025117
hCV431962
hCV1157511
hCV11669761
hCV240706
11 48
151
24
Sib-pair
29
38
37
22
75
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Discussion 
There is compelling evidence for the involvement of 15q11-q13 in risk for 
autism spectrum disorders. The evidence is direct and quite clear for the small 
percentage of cases exhibiting interstitial or idic(15) duplications. When taken as 
a whole, genetic studies within families affected by idiopathic autism seem to 
point towards the cluster of GABAA receptor subunit genes, and in particular 
GABRB3 and GABRA5. The picture is quite complicated, however. Maternal bias 
of genetic risk for duplication to be associated with autism suggests involvement 
of maternally-expressed genes. We acknowledge the maternal bias, but given 
the risk for autism in the case of paternal duplication and the absence of 
compelling data suggesting the paternal UPD PWS represents a class of PWS 
patients with more autistic behaviors, we conclude that dup(15) autism is (at least 
to some degree) a contiguous gene duplication effect.  
We must now consider this background in the context of a recent report 
implicating epigenetic effects involving not just UBE3A, but also GABRB3, in Rett 
syndrome, AS and autism [172]. The fact that GABRB3 has a common 
transcriptional orientation with UBE3A and ATP10A, makes the hypothesis of 
possible RNA interference-based epigenetic gene silencing effect for GABRB3 at 
least plausible. Equally plausible, however, is the presence of, probably 
heterogeneous, variants in GABRB3 and/or GABRA5 that result in partial or 
complete loss-of-function alleles of one of these genes.  
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This analysis of the IC/MED region does not allow for a definitive 
conclusion on these points, however. While a number of markers do show 
nominal evidence for an effect, interpretation is hindered by the absence of a 
very strong main allelic effect at any one of these markers. While many sectors 
within this very large stretch of DNA were sufficiently covered relative to LD 
patterns, this is not universally true for all regions (data not shown) given the high 
recombination rate across this stretch of DNA. Therefore, we cannot conclude 
that a “negative” result in the absence of thorough coverage of all LD intervals, 
excludes the possibility that a significant effect was not missed.  
To some degree, this survey was exploratory. We can hypothesize effects 
on either maternal or paternal alleles or both, there could be gender effects in 
terms of potential risk, and possibly even both parent-of-origin and sex-specific 
genetic effects. Any attempt to query for all of these scenarios necessarily 
represents a hypothesis-generating exercise. The number of tests performed 
reduces any given result to non-significance, if corrected for multiple testing; this 
is certainly true for the conservative application of a Bonferroni correction, but 
also true if one were to consider all markers in one block of LD to represent one 
independent test.  We also have no a priori understanding of the size of any 
given genetic effect. These results would be consistent with potential allelic 
heterogeneity or any given putative TD affecting a relatively small number of 
families individually. 
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Future directions will include insuring complete coverage based on LD, for 
regions not completely represented; this is particularly true for the IC and regions 
of sequence homology. Given studies in PWS and AS cases with imprinting 
mutations that have led to well defined intervals within the imprinting center that 
are critical for the maternal-to-paternal or paternal-to-maternal imprint switch, it 
may be desirable to re-sequence or screen these short regions for evidence of 
sequence alteration more common to autism cases than in a control group. 
Similarly, regions of significant sequence homology in non-coding regions within 
the MED may be screened. Both of these situations would address the possibility 
that multiple different sequence variants (arising independently) can exert a 
functional effect on imprinting control or on UBE3A, ATP10A, or even GABRB3. 
Using larger datasets, such as with the Autism Genome Project, or smaller 
samples available through the NIMH repository, we may want to test for excess 
paternal (or maternal) allele-sharing across this region, to follow-up on a previous 
report [22]. 
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CHAPTER VIII 
 
A SECOND GENERATION GENOME-WIDE LINKAGE ANALYSIS TO 
IDENTIFY LOCI WITH AUTISM SUSCEPTIBILITY GENES1 
 
 
 
Introduction 
Several groups, including ours, have undertaken genome-wide screens of 
multiplex autism families for susceptibility loci [21, 25, 27-32, 109, 174, 175].  
Comparing the results from all studies identifies a few genomic regions in 
common across multiple studies. Chromosomes 7q and 2q have received the 
greatest attention [28, 29, 48, 110, 111, 174, 176-178], and observations of 
chromosomal abnormalities in isolated autistic probands reinforce the plausibility 
of these regions for involvement in idiopathic autism. Genetic studies of autism 
are substantially complicated by both clinical and locus heterogeneity, and it is 
possible that epistatic or epigenetic mechanisms may play important roles in 
genetic etiology [8, 22]. Analytical strategies that address the latter concerns are 
limited, and most studies to date have focused on analysis of main effects using 
a global autism diagnosis to define affection status. Moving forward, more 
sophisticated approaches are being proposed in which trait-based subsets of the 
broader autism phenotype are used in genetic analyses. Similarly, given the 
interdependence of genes and their protein products within biological systems, 
                                                
1 Adapted from BMC Med Genet 2005 Jan 12, 6:1 
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analytical approaches that address potential interaction between susceptibility 
loci will also be critical to characterizing gene-phenotype relationships in autism. 
We report a second generation 10-cM microsatellite-based genomic 
screen of multiplex autism families. The dataset for this screen includes 71 
families recruited by the Tufts/New England Medical Center, a well-characterized 
set of 85 families from the Autism Genetics Resource Exchange (AGRE) and 2 
families from Vanderbilt University. Several sites of suggestive linkage are 
identified, although none meet criteria for genome-wide significance. The loci with 
greatest support for linkage were 17q11.2 and 19p13; the latter site 
demonstrated significantly increased allele-sharing when the Ordered-Subset 
Analysis (OSA) algorithm was employed using a quantitative trait-based autism 
phenotypic subset related to specific developmental milestones as a covariate to 
rank families.  
 
Materials and Methods 
 
 
Families 
The demographics for the 158 family dataset comprising the studies in this 
report are shown in Table 8-1. Families were recruited through three sites: (a) 71 
families were recruited through the Tufts/NEMC site, (b) 2 families were recruited 
from the Vanderbilt University site, and (c) the remainder of families (85) were 
chosen from the AGRE repository based on criteria identical to those used for our 
own recruitment. Multiplex families (mostly affected sibling-pairs) had one 
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affected individual who met full criteria for autistic disorder based on Autism 
Diagnostic Interview-Revised (ADI-R; [3, 4, 179]) algorithm scores, while the 
second individual either met criteria or in some cases was under the cut-off by 
only one or two points. Exclusion criteria to enrich for idiopathic autism include 
dysmomrphology, abnormal chromosomal karyotype, diagnosis of fragile X 
syndrome, and other genetic disorders of known etiology. Individuals were 
assessed by the respective groups using the ADI-R at a developmental age >18 
months; Tufts/NEMC and Vanderbilt groups included individuals between the 
ages of 4 and 22; in cases in which ADI-R interviews were performed initially at 
<4 years, they were repeated when the probands reached 4 years of age. All 
individuals were additionally assessed using the Autism Diagnostic Observation 
Schedule [3, 180] and the Vineland Adaptive Behavior Scales – Interview Edition 
[181, 182].  
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Table 8-1. Genomic screen sample demographics. *ADI-Rs performed <4 yrs 
were repeated at 4 yrs for Tufts/NEMC families. **IQ estimates are based on the 
Vineland Daily Living standard scores. ***IQ estimates are based on the overall 
Vineland Adaptive Behavior standard scores. 
 
Families in 
Linkage Screen 158 Ethnicity  
I.Q. estimate 
distributions  
Tufts/NEMC 71 Caucasian (242) 73.0% Tufts/NEMC** (148)  
AGRE 85 Tufts/NEMC (130) 87.8% <30 13 
Vanderbilt 2 AGRE (108) 59.7% 30-49 21 
Affected 
Individuals 333 Vanderbilt (4) 100.0% 50-69 37 
Males 257 Hispanic-Latino (14) 4.2% 70+ 17 
Females 76 AGRE (14) 7.7% Unknown 60 
Tufts/NEMC Total 148 African-American (8) 2.4% AGRE*** (181)  
Males 117 Tufts/NEMC (6) 4.1% <30 17 
Females 31 AGRE (2) 1.1% 30-49 27 
AGRE Total 181 Asian (8) 2.4% 50-69 15 
Males 137 Tufts/NEMC (2) 1.4% 70+ 13 
Females 44 AGRE (6) 3.3% Unknown 109 
Vanderbilt Total 4 Multi-ethnic (14) 4.2% Vanderbilt*** (4)  
Males 3 AGRE (14) 7.7% <30 1 
Females 1 Other (2) 0.6% 30-49 1 
Age at ADI (range) 2-46.7 Tufts/NEMC (2) 1.4% 50-69 0 
Tufts/NEMC* 2-46.7 Unknown (45) 13.5% 70+ 2 
AGRE 2-38.0 Tufts/NEMC (8) 5.4% Unknown 0 
Vanderbilt 6.2-9.2 AGRE (37) 20.4%   
 
 
 
Genotype Data and Statistical Analyses  
DNA from Tufts and Vanderbilt samples was obtained from peripheral 
blood or immortalized lymphoblastoid cell lines using the PureGene Kit (Gentra 
Systems). While a minority of families from the Tufts/NEMC cohort had been 
genotyped previously [109], both new and previously genotyped families were 
genotyped by deCODE (Reykjavik, Iceland) using their 500 marker (~8 cM 
intermarker spacing) panel and corresponding genetic map [114]. Genotype data 
were obtained from the AGRE website (http://agre.org) for families whose 
samples were included in this study.  Clinical procedures and genotyping for the 
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AGRE sample has been described previously [30, 183]. Because we utilized 
existing genotype data, AGRE samples had a distinct but overlapping panel of 
markers compared to the Tufts or Vanderbilt families. All AGRE genetic markers 
were carefully placed on the deCODE map, with order and spacing (both genetic 
and physical) properly insured through exhaustive comparisons between 
genotyped markers, available genetic maps, and physical DNA sequence 
assemblies in both public and Celera databases.  
Genotype data for each chromosome underwent thorough error detection 
and genotype confirmation. Initially, data were tested for Mendelian 
inconsistencies using PEDCHECK [184] and RELPAIR 
(http://www.sph.umich.edu/statgen/boehnke/relpair.html), followed by application 
of SIMWALK2 (v2.89) [185] to construct haplotypes in all genotyped family 
members to detect genotyping errors reflected by unlikely double recombinants. 
In the event that error checking indicated that a genotype was highly improbable, 
the genotype data for that marker were excluded for the entire family. 
Allele frequencies were estimated using genotype data from all unrelated 
individuals in the combined dataset, consisting of more than 300 chromosomes. 
These allele frequencies were compared with available data from other 
Caucasian populations, and no significant differences were observed (data not 
shown). The LAPIS program of the PEDIGENE system [186] was used to output 
appropriate analysis files for the different programs. 
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Linkage was analyzed using both model-dependent and model-
independent methods. For autosomes, two-point and multipoint heterogeneity 
LOD (HLOD) scores were calculated under both dominant and recessive models 
using Allegro [187]. Disease allele frequency was estimated to be 0.01 and 0.1 
for dominant and recessive models, respectively. The phenocopy rate was 
0.0005, and the penetrance value was set at 0.5 for the analysis. The reduced 
penetrance value was set at 50% given the likelihood of oligogenic inheritance 
and the possibility of heterogeneity, such that not all individuals having the allele 
would present with disease. These parameters, while minimizing our power 
somewhat, have a smaller impact on the lod scores when there is either linkage 
or no linkage and were therefore selected to be robust [116]. Phenotypic status 
was only considered for affected individuals, and other family members were 
designated as having an unknown phenotypic status. Nonparametric analysis 
involved calculating allele-sharing LOD* values using affected relative pair data 
based on an exponential model that uses the Spairs scoring function as 
recommended by McPeek [188].  NPL scores and corresponding P-values were 
also calculated by Allegro. Data from the X chromosome were analyzed using 
ASPEX v2.5 (http://aspex.sourceforge.net/) and FASTLINK [189] v4 to calculate 
two-point and multipoint MLOD scores. Peak parametric (HLOD) or 
nonparametric LOD* scores ≥1.5 were considered as “suggestive” evidence for 
linkage and listed in Table 8-2, along with corresponding peak marker, deCODE 
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cM location, and chromosomal band position. The LOD ≥ 1.5 cutoff was chosen 
to provide a small and focused group of regions for initial follow-up. 
The nonparametric genome-wide significance threshold [190, 191] for 
linkage at the P=0.05 level was determined by conducting simulations using 
Merlin [192] with the current dataset. The Simulate option in Merlin was used to 
produce 1000 random datasets that preserve the properties of the original data 
for marker informativeness, spacing and missing data patterns. An empirical 
significance threshold was determined by using the 95th percentile of the resulting 
distribution.  
OSA [193] identifies genetically more homogeneous subsets of the overall 
data by ordering families according to covariate trait values in ascending or 
descending order. OSA takes the first family and calculates an allele-sharing 
LOD* score. In an iterative process, OSA successively adds families, re-
calculating LOD* scores with each addition, and it identifies the division in the 
dataset at which maximum linkage is obtained on the chromosome being 
analyzed. Permutation testing using randomized data is used to determine the 
empirical significance of the observed results.   This approach has been applied 
with success to identify or increase evidence in support of linkage to complex 
disease susceptibility loci [54, 194, 195].  
To explore potential genetic interaction or other genetic correlations 
between sites of main effect (i.e. suggestive linkage), OSA was applied using 
family-specific LOD scores as the covariate trait. Families were ranked in 
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descending or ascending order, according to the family-specific LOD score at 
peak linkage for sites demonstrating LOD scores ≥1.5. Nonparametric allele-
sharing analysis was then performed for the other six chromosomes (see Table 
8-2) showing LOD scores ≥1.5. For instances of empirically significant increases 
in evidence for linkage, we explored the nature of the genetic correlation to ask 
whether it reflected clinical correlations in the respective subsets. We employed 
previously published clusters of correlated variables, identified by principal 
components analyses of ADI/ADI-R items, to represent putative phenotypic 
subsets in autism [76, 196]. The ADI-based factor subsets correspond to “(1) 
language, (2) social intent, (3) developmental milestones, (4) rigid-compulsive 
behaviors, (5) savant skills, and (6) sensory aversion”, as determined by Folstein 
and colleagues [76]; and (7) “insistence on sameness” as described by Cuccaro 
and colleagues [196]. The description of these factors reveals significant inter-
sibling correlation in the case of affected sib-pair families for all of these factors 
with the exception of “social intent” [76]. We thus compared the seven ADI-based 
factor score means (both the mean of family means and the mean of affected 
individuals) using a t-test for the families above and below the OSA-determined 
split in the dataset resulting in maximal linkage. Subsequent analysis involved 
specific examination of the “developmental milestones” cluster. The milestones 
factor indexes on the following ADI items: “(1) To walk unaided; (2) to sit unaided 
on flat surface; (3) age of first single words; (4) age of first phrase; (5-6) 
acquisition of bladder control: daytime, night; (7) acquisition of bowel control.” 
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Analysis of the “developmental milestones” factor as a potential 
phenotypic subset related to the autism linkage correlations was performed by 
applying the OSA algorithm. We used “developmental milestones” family means, 
normalized via SAS v9.1.2 and Box-Cox transformation procedures, as an 
ascending ranking covariate. LOD* scores were calculated according to the OSA 
algorithm, and the resulting increase in linkage achieved with the OSA-
determined family subset was analyzed through permutation testing. 
 
Results 
Seven chromosomes revealed one or more regions of linkage with a 
model-dependent or model-independent LOD score ≥1.5 (Figure 8-1). No locus 
reached the empirically derived genome-wide significance level of 2.92.  These 
suggestive loci include 3p25, 6q23, 12p12, 16p12-p13, 17q11, 17q21 and 19p13 
(Table 8-2). Data provide the most compelling support for 17q11.2 and 19p13 as 
harboring autism susceptibility loci.  
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Figure 8-1. Genome-wide nonparametric linkage analysis in 158 multiplex 
families for autism loci. Individual plots show allele-sharing LOD* scores 
calculated for autosomes using Allegro and MLOD scores for the X chromosome 
calculated using ASPEX. 
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Table 8-2. Linkage data for loci with LOD scores > 1.5. Superscript (D) 
represents a score calculated assuming a dominant model of inheritance and 
superscript (R) represents a score calculated assuming a recessive model of 
inheritance. 
 
Chromosome deCODE cM Marker HLOD LOD* 
3p25.3 25 D3S3691 1.76R 2.22 
6q23.2 131 D6S1656 1.61R 0.62 
7q35 152 D7S2195 1.65R 1.14 
12p12.1 45 D12S1591 1.50R 1.43 
16p13.2 15 ATA41E04 1.64D 1.38 
16p13.12 33 D16S3062 1.87D 1.60 
16p12.3 43 D16S490 1.80D 1.49 
17q11.2 53 D17S1294 2.85D 2.13 
17q21.2 69 D17S1299 1.90D 1.60 
19p13.11 40 D19S930 2.55R 1.92 
19p13.11 56 D19S113 2.20R 1.39 
 
 
For 17q11.2, peak linkage was observed at 53 cM on the deCODE genetic 
map, corresponding to marker D17S1294 (Table 8-2), at which we see a 
multipoint HLOD of 2.85. Nonparametric multipoint analysis revealed an allele-
sharing LOD* score of 2.13 and an NPL score of 2.84 (P=0.0024). A second 
telomeric linkage peak can be distinguished on 17 at ~69 cM, corresponding to 
17q21.2. Marker D17S1299 at this site yielded a HLOD of 1.9 and nonparametric 
results were a LOD* of 1.66 and an NPL score of 2.26 (P=0.012). The more 
proximal peak at ~53 cM lies in close proximity (~150 kb) to the serotonin 
transporter (SLC6A4) locus, long considered to be an attractive functional 
candidate gene for autism and other neuropsychiatric conditions. Figure 8-2 
shows multipoint LOD score plots for both dominant and recessive parametric 
(HLOD) and nonparametric allele-sharing LOD* values for chromosomes 17 and 
19.  
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Figure 8-2. Multipoint linkage analysis under all models for chromosomes 
17 (A) and 19 (B). Multipoint parametric HLOD plots for both dominant (blue) and 
recessive (red) models, and nonparametric allele-sharing LOD* values (black) 
are displayed across the respective chromosomes. OSA analysis using 
ascending “developmental milestones” factor scores to order families is shown 
for chromosome 19, for which a 92-family optimal subset was identified and used 
to calculate allele-sharing LOD* scores (dashed black line). 
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The second most significant result was observed on 19p13, where peak 
linkage was detected at marker D19S930, mapping to ~40 cM and yielded a 
multipoint HLOD of 2.55 (Table 8-2 and Figure 8-2). Nonparametric analyses at 
this locus showed a LOD* of 1.92 and a corresponding NPL of 2.77 (P=0.003). 
As with chromosome 17, the multipoint analyses show a second more telomeric 
peak, corresponding to marker D19S113. The recessive HLOD at this site was 
2.20, with model-independent LOD* and NPL values of 1.39 and 2.10 (P=0.018), 
respectively. 
To address the possibility of gene-gene interaction, we applied the OSA 
approach with family-specific LOD scores as the ranking trait. Families, almost all 
of which have affected sib-pairs, were ranked in both ascending and descending 
order using family-specific LOD scores. The three most significant correlations 
are presented in Figure 8-3.  Using chromosome 19 lod scores (High to Low) as 
the covariate, the results on chromosome 17q, while non-significant (P=0.1), 
showed an increase in linkage at the more distal peak on 17q21.1 from a LOD* of 
1.7 to 3.6 and identified an optimal subset of 52 families. Applying the same 
covariate, a significant increase was seen on chromosome 6q, with a smaller, 
completely overlapping, 30-family optimal subset. This subset resulted in an 
increase in LOD* values from 1.0 to 3.6 at ~164 cM (P=0.004). Another 
significant finding involves the 7q region, possibly representing the most 
replicated site of linkage in autism [28, 48, 111, 174, 176-178]. Given a 
substantial focus on this region over several years, we lessened our criteria to 
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examine any other chromosome demonstrating a LOD score >1. Application of 
OSA using chromosome 7q linkage data, again ranking families based on LOD 
scores in a descending manner, lead to a significant increase in linkage on 5p at 
~41 cM from a LOD* of 1.1 to 3.3 in a 41-family subset. Thus, in these three 
cases, notwithstanding the non-significance of the 19p13/17q21 result, there is a 
positive correlation of linkage in varying but overlapping subsets of the data 
between these respective pair-wise locus combinations within the same set of 
families. There were no significant correlations found using ranked LOD scores 
from low to high as a covariate in any of our OSA analyses. 
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Figure 8-3. OSA using family-specific LOD scores as the ranking covariate. 
Families were ordered based on descending LOD scores at peak linkage for 19p13 and 
allele-sharing LOD scores calculated in the optimal subset for (A) chromosome 17 or (B) 
chromosome 6. Families were also ranked based on descending LOD scores at peak 
linkage on chromosome 7q (C), and LOD scores calculated for chromosome 5. Solid 
lines reflect multipoint LOD scores corresponding to the entire dataset for the 
chromosome being analyzed, while dashed lines represent analysis of the optimal 
subset (above the dataset division in all cases) identified from OSA; these were 52 
families for chromosome 17, 30 for chromosome 6 and 41 families for chromosome 7. 
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To further explore the basis of the observed results, we tested the 
hypothesis that underlying phenotypic correlates might explain genetic 
correlations.  We tested for differences in the mean values for the seven factor 
traits in the optimal subsets compared to the means of the remaining families 
using a t-test. This comparison for all seven available factors revealed a 
nominally significant difference in the chromosome 19 subsets identified through 
OSA analysis, of both chromosomes 17 and 6, for the “developmental 
milestones” factor [76]. The families in the optimal OSA subset have lower scores 
and therefore are more rapidly achieving developmental milestones. A similar 
procedure for the chromosome 7-based subsets revealed no obvious differences 
in any of the factors (data not shown). 
To directly test the hypothesis that chromosome 19 linkage was related to 
reduced affection for the “developmental milestones” factor, we performed an 
OSA analysis in which families were ranked in ascending order based on mean 
values for the milestones factor score. Figure 8-2 shows the results from this 
analysis, which generated increased evidence for linkage to 19p13 with peak 
LOD* scores increasing from 1.9 to 3.4. Permutation testing revealed this 
increase to be empirically significant (P=0.04), thus further supporting this region 
as harboring a genetic risk factor. 
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Discussion 
We have presented evidence in support of autism susceptibility loci on 
chromosomes 17q and 19p. Our results suggest that the 19p locus is related to a 
phenotypic profile involving a more rapid achievement of particular 
“developmental milestones”. Features indexed in this ADI-based factor are: (1) 
ability to walk unaided; (2) ability to sit unaided on a flat surface; (3) age of first 
single words; (4) age of first phrase; (5-6) acquisition of bladder control: daytime 
and night; and (7) acquisition of bowel control. Analyses leading to this 
conclusion also showed positive genetic correlations between optimal OSA-
defined subsets contributing to linkage at 19p13 and increases in linkage at loci 
on 17q21 and 6q23. A similar positive genetic correlation was shown for 
chromosomes 7q and 5p. However this observation lacks evidence of an 
underlying phenotypic relationship based on the clusters of clinical variables, or 
autism subsets, tested in the current study. While the increase in linkage at 
17q21 was not empirically significant, the differences in “milestone” score means 
between the optimal chromosome 19 subsets seen for both chromosomes 17(52 
families) and 6q (30 families) were significant. These exploratory data led to the 
significant finding of increased linkage in the single direct test of our hypothesis 
concerning the phenotypic correlation related to chromosome 19 linkage. 
Despite the significance of the final results on 19, we remain cautious in 
the interpretation of the overall results. As with a number of other genomic 
screens in autism, no single main effect locus achieved genome-wide 
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significance. Support for a number of these loci, particularly at 17q11.2 and 
19p13 comes from similar suggestive linkage in other genomic screens for 
autism. Although not all screens detect these loci (not an uncommon finding in 
linkage studies for complex genetic disorders), the evidence is strong regarding 
an effect at 19p, within 10 cM of our peak: (1) The Duke/South Carolina 
Collaborative Autism Team reported a maximum multipoint lod score (MMLS) of 
1.21 and a MLOD=1.38 [31]; (2) PARISS (Paris Autism Research International 
Research Study) reported an MMLS=1.37 [27]; (3) The International Molecular 
Genetic Study of Autism Consortium (IMGSAC) reported an MLS of 1.16 [25]; (4) 
The Mt. Sinai group reported an NPL of 1.56 which increased to 2.31 when only 
families with obsessive-compulsive behaviors were considered for this region 
[175]. While a portion of our sample overlaps with those of other studies, we   
Similarly, several groups have reported evidence for linkage at 17q11. The 
recently published AGRE follow-up genomic screen identified an MLS of 2.83 
near SLC6A4 [32]. A genome scan for attention deficit/hyperactivity disorder 
(ADHD) identified an MLS of 2.98 near this locus [197]. An IMGSAC follow-up 
screen for autism [48] reported a maximum multipoint LOD score of 2.34, with 
sex-specific analysis suggesting an excess sharing of paternal alleles at 
HTTINT2 in the SLC6A4 gene on chromosome 17q11.2. Our own more 
preliminary analysis of linkage in this region, using a highly overlapping dataset 
to that in the current study, revealed very similar results [198]. Given our 
inclusion of some AGRE families, it is not completely unexpected that 17q11.2 
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linkage is similar to that seen the larger AGRE 2nd-stage screen [32], however 
AGRE families only represented about half of the overall dataset. Families 
recruited from the Tufts/NEMC site clearly contribute to this linkage based on the 
LOD score-based family subset compositions. In fact, if you examine the 
multipoint HLOD scores under a dominant model of inheritance for the AGRE 
only families versus the Tufts/NEMC families, the HLOD score at marker 
D17S1294 is 1.25 for the AGRE families versus 1.84 for the Tufts/NEMC.  
The 17q21 locus is worth further consideration. Our data support the 
premise that the adjacent linkage peaks represent distinct loci and are not an 
artifact of primary linkage at 17q11.2. The evidence for linkage at 17q21, while 
weaker than that at 17q11.2 only 16 cM centromeric, specifically showed an, 
albeit non-significant, interlocus correlation with 19p13 linkage. Linkage at 
17q11.2 in this subset of families actually decreases slightly. Of particular interest 
is the fact that the distal region harbors the integrin β3 (ITGB3) locus, which was 
identified recently from a genome-wide quantitative trait locus (QTL) association 
screen for platelet serotonin levels [199]. We see nominal evidence of linkage to 
autism at this site, and ~20-25% of individuals with autism have elevated levels 
of circulating serotonin.  
The other “suggestive” (LOD ≥ 1.5) loci reported here have also been 
detected in other genome-wide scans for autism loci. A broad region of 7q has 
been detected in most screens [28, 48, 111, 174, 176, 178]. The 16p region has 
been identified by IMGSAC, and others [25, 30, 48, 175]. Chromosomal 
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abnormalities have also been reported for this region in cases of autism 
(reviewed in [9]). Linkage at 3p was reported by at least two groups [28, 31]. 
Linkage has also been reported at our 6q locus by at least one other group [27]. 
Thus, while not significant, the replication of these linkage observations provides 
support for the likelihood that many of these loci represent true sites of main 
effect in autism.  
The application of OSA to detect putative interlocus correlations between 
the 19p13 and 17q21, 19p13 and 6q23, and between 7q35 and 5p are limited to 
some degree in significance by their highly exploratory and hypothesis-
generating nature. Given the number of comparisons between loci, and the 
number of comparisons between optimal subset pairs (on 19p or 7q) for the traits 
means, the potential for type I error is increased. Therefore our interpretation 
must be made with appropriate caveats. Nevertheless, the multiple exploratory 
comparisons generated a hypothesis: that linkage to 19p13 was related to a 
more rapid achievement for specific milestones. We were able to test this 
hypothesis with a single analysis revealing an empirically significant increase for 
linkage at this site. A combination of our results related to autism linkage and 
Ordered-Subset Analysis for ascending milestone scores, taken in the context of 
replicated observations of suggestive linkage by other groups, strengthens 
support for the presence of an autism gene at this site. In the end, ultimate 
interpretation will rely upon replication of these phenomena with independent 
samples to confirm these observations.  
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Finally, our results highlight the utility of using trait-based subsets of 
autism to identify putative susceptibility loci for this complex disorder. We and 
others have hypothesized a likely increased specificity of individual risk genes 
and corresponding alleles for traits or subphenotypes comprising the broader 
autism spectrum. Therefore methods such as (1) the Ordered-Subset Analysis 
that has power to identify more homogeneous samples from the overall 
population of families, or (2) QTL linkage and association analyses have the 
ability to provide greater sensitivity in the discovery of disease genes in the 
context of locus and clinical heterogeneity. Additionally, OSA or other forms of 
conditional linkage analyses have the ability to uncover potential interactions 
between loci. This is an important concept since the inherent interdependence of 
proteins in common pathways or networks acting during development and normal 
neuronal function could be easily imagined to act genetically in concert with one 
another. 
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CHAPTER IX 
 
REFINED LINKAGE ANALYSIS AND ASSOCIATION STUDIES IN 17q AND 
19p 
 
 
 
Introduction 
 The genome-wide linkage screen using the broader autism phenotype 
provided several potential regions for follow-up study. Our two most prominent 
regions, 17q and 19p, have been identified by several groups as described in 
Chapter VIII. To narrow our regions of interest at these two loci, we chose to 
incorporate the use of SNPs across a LOD-based confidence interval of 
approximately 1.0 for chromosome 17 and 1.5 for chromosome 19. Although 
linkage at a given locus is more traditionally performed using microsatellite 
markers, rapid evolution of SNP genotyping technologies and availability of many 
SNP markers with a minor allele frequency (MAF) near 0.5 makes SNP-based 
follow-up a reasonable and cost-effective alternative. In fact, a recent report 
documents that a relatively dense SNP follow-up panel can provide greater 
information content than that afforded by microsatellites [200]. We hypothesize 
that follow-up genotyping will narrow our regions of interest, and thereby limit the 
size of physical intervals and corresponding list of potential candidate genes. 
This biologically unbiased strategy will permit us to establish a potential list of 
positional candidates and/or provide a narrowed region for LD-based mapping of 
common allele-based disease risk in autism.  
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Materials and Methods 
 
Families 
The largest sample for this study consisted of 384 autism families (327 
multiplex and 57 trio families). Two-hundred eighty-three families were obtained 
from the Autism Genetics Resource Exchange (AGRE; http://agre.org), 98 
multiplex and trios from Tufts/ New England Medical Center, and 3 multiplex 
families from Vanderbilt University. A number of the AGRE samples were 
obtained from the NIMH Center for Collaborative Genetic Studies on Mental 
Disorders (http://nimhgenetics.org/). Initial samples for the linkage follow-up 
analysis were smaller and completed prior to the acquisition of additional 
families. A significant majority of “known” families are of Caucasian ethnicity; 
however, a number of AGRE samples do not have ethnicity information 
(“unknown”). All affected individuals were at least four years of age and were 
clinically assessed with the ADI or ADI-R and most with the Autism Diagnostic 
Observation Schedule (ADOS). At least one sib had to meet ADI algorithm 
criteria for an autism diagnosis, while additional siblings may be on the broader 
autism spectrum. Families were excluded from the study if probands had a 
known medical or neurological condition suspected to be associated with their 
autistic phenotype (e.g. fragile X syndrome). The procedures for clinical 
evaluation of affected individuals for the AGRE families have been previously 
described [30].  
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Molecular Analyses  
SNPs from the dbSNP and Celera SNP databases were selected for 
linkage follow-up based on their map position, minor allele frequency, and 
potential for functional effects within constraints of their position and allele 
frequency. SNPs across the CRSP7 gene region were chosen based on the 
above criteria with the exception of constraining selection on intermarker distance 
and allele frequency in the general population. Marker and exon locations and 
intermarker distances are based on the Celera 
(http://www.celeradiscoverysystem.com/index.cfm) assembly. Database 
reference numbers and other details for the markers studied are cited in Tables 
9-1, 9-2, and 9-3. Genetic (cM) distances indicated in Table 9-1 and Table 9-2 
are based on the deCODE genetic map [114]. Individual SNPs were genotyped 
using the TaqMan™ system developed by Applied Biosystems (Foster City, CA). 
PCR primers and probes for assays performed across the chromosome 19 genes 
are listed in Table 9-4. This information is proprietary for all the markers chosen 
for linkage follow-up, for which Assays-On-Demand™ were obtained from 
Applied Biosystems (Foster City, CA). 
For TaqMan™ genotyping assays, reactions were performed in a 5 µl 
volume, employing 2.5 ng genomic DNA template, according to manufacturer’s 
recommendations (Applied Biosystems). Cycling conditions included an initial 
denaturation at 95 °C for 10 min, followed by 50 cycles of 92 °C for 15 s, 60 °C 
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for 1 min. Samples were analyzed using an ABI 7900HT Sequence Detection 
System. 
 
Table 9-1. SNP markers for chromosome 17 linkage follow-up. Alleles are 
listed major/minor. Microsatellite markers spanning the follow-up region are 
highlighted in bold.  
 
Gene SNP No. Region Marker Alleles 
Minor 
Allele 
Frequency 
Approx.  
cM 
Location 
Intermarker 
Distance 
(kb) 
   D17S900   41 35 
HS3ST3B1 1 Intron 1 hCV2587060 C/T 0.43 41 31 
 
   D17S921   41 225 
   D17S839   43 649 
PMP22 2 Exon 5 3’ UTR 
rs13422/ 
hCV774376 G/T 0.47 44 1074 
TRPV2 3 Intron 6 rs7222754/ hCV12125529 C/T 0.38 45 1146 
   D17S1857   46 1060 
Intergenic 4 Intergenic rs9915758/ hCV2036889 G/A 0.44 47 86 
   D17S2196   47 521 
NP_055949 5 Exon 4 rs3744137/ hCV1385623 C/A 0.49 47 997 
MYO15A 6 Exon 16 rs2280777/ hCV2601396 T/C 0.46 48 1703 
PRPSAP2 7 Intron 4 rs2305064/ hCV1129714 A/G 0.46 49 752 
C17orf35 8 Intron 1 rs4450456/ hCV7444583 C/T 0.44 50 342 
   D17S1871   50 1158 
Intergenic 9 Intergenic rs7215373/ hCV25636564 C/T 0.50 51 585 
   D17S1824   52 776 
MYO18A 10 Exon 16 rs8076604/ hCV1555487 G/A 0.47 52 485 
NP_689558 11 Intron 1 rs3110492/ hCV2923617 G/A 0.43 53 460 
   D17S1294   53 380 
CPD 12 Intron 8 rs9913237/ hCV2980234 C/G 0.47 53 1104 
RAB11FIP4 13 Intron 3 rs2017548/ hCV2181821 G/A 0.46 54 130 
156 
   D17S1800   54 883 
MYO1D 14 Intron 21 rs1018866/ hCV2536985 T/G 0.39 55 461 
   D17S798   56 120 
ACCN1 15 Intron 3 rs7217619/ hCV2033368 C/T 0.45 56 727 
   D17S1850   56 64 
 16 Intron 1 rs915484/ hCV1820633 A/C 0.38 57 358 
   D17S1293   60 728 
CCT6B 17 Intron 1 rs1482103/ hCV7447761 G/A 0.42 63 1475 
TRIP3 18 Intron 4 rs7222903/ hCV1163237 G/T 0.46 64 529 
   D17S1867   65 528 
AP1GBP1 19 Intron 14 rs3110621/ hCV2554333 T/C 0.39 66 960 
LASP1 20 Intron 1 rs1873050/ hCV11935244 C/T 0.46 67 1111 
PSMD3 21 Intron 2 rs2305482/ hCV15977478 C/A 0.43 68 652 
SMARCE1 22 Intron 7 rs1474454/ hCV7571606 C/T 0.46 69 203 
   D17S1299   70 1149 
DNAJC7 23 Intron 2 rs12948970/ hCV11613990 T/A 0.49 71 763 
Q8N4A7 24 Intron 1 rs1078523/ hCV2160077 A/G 0.48 72 1287 
G6PC3 25 Exon 1 5’ UTR 
rs228758/ 
hCV557390 C/T 0.50 73 873 
Intergenic 26 Intergenic rs4793165/ hCV7915790 A/G 0.41 74 847 
Intergenic 27 Intergenic hCV2544808 A/G 0.47 74 891 
GOSR2 28 Intron 6 rs758391/ hCV2275279 G/A 0.40 75 980 
SP2 29 Exon 3 rs2228251/ hCV95252 T/C 0.46 76 1002 
NP_075567 30 Intron 4 rs12453374/ hCV1242900 C/G 0.50 76 581 
        
NGFR 31 Intron 1 rs575791/ hCV2305277 G/A 0.47 77 218 
NP_110429 32 Intron 7 rs2017835/ hCV7476484 A/G 0.48 77 1339 
SPAG9 33 Intron 3 rs2041319/ hCV11936873 T/A 0.45 78 714 
CA10 34 Intron 4 rs1989800/ hCV2536374 T/A 0.38 79 451 
   D17S788   79 1232 
157 
Intergenic 35 Intergenic rs1502501/ hCV8732620 G/T 0.47 80 378 
NP_115948 36 Exon 1 rs3803824/ hCV7957804 C/T 0.38 81 1295 
Intergenic 37 Intergenic rs244356/ hCV2576424 T/G 0.42 83 1204 
NP_694960 38 Intron 2 
rs966793/ 
hCV2665614 T/C 0.39 84 786 
AKAP1 39 Intron 2 rs2241073/ hCV349718 G/T 0.46 85 289 
   D17S957   87 _ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
158 
Table 9-2. SNP markers for chromosome 19 linkage follow-up. Alleles are 
listed major/minor. Microsatellite markers spanning the follow-up region are 
highlighted in bold. 
 
Approx. 
cM
Location
D19S221 32 59
rs1054487/
hCV3004808
CACNA1A 2 Intron 27
rs2074880/ 
hCV346304
A/C 0.38 33 231
3 Intron 1
rs7250452/ 
hCV2883344
A/G 0.42 34 240
D19S840 34 454
LPHN1 4 Intron 2
rs40282/ 
hCV8728798
T/C 0.42 35 407
D19S179 37 383
rs2285980/
hCV2569724
D19S714 37 24
rs1290617/
hCV7496758
TPM4 7 Intron 1
rs2278006/ 
hCV16006818
A/T 0.46 38 173
D19S917 39 142
rs1870071/
hCV11459169
rs8110418/
hCV3057319
rs12461484/
hCV11699366
rs901792/
hCV1975557
rs812847/
hCV7494847
D19S930 40 132
rs4447554/
hCV11699091
D19S593 41 46
rs891205/
hCV7493310
Exon 18 rs404733/
3¢ UTR hCV795434
rs2074797/
hCV2585304
rs1122821/
hCV11462980
rs2239369/
hCV2537047
rs386976/
hCV2305565
rs2012013/
hCV7497240
rs2915929/
hCV8163344
D19S419 49 533
rs347787/
hCV3057412
rs997669/
hCV2885582
D19S433 51 _
0.46 50 1478
CCNE1 23 Intron 4 T/C 0.37 51 108
Intergenic 22 Intergenic G/A
0.46 46 1149
Q96IR2 21 Intron 3 A/C 0.41 48 2467
Intergenic 20 Intergenic C/T
0.47 44 819
Intergenic 19 Intergenic T/C 0.47 45 1360
MEF2B 18 Intron 4 T/A
0.46 43 40
HOMER3 17 Intron 1 A/G 0.41 44 241
COPE 16 Exon 8 T/C
0.36 41 816
IL12RB1 15 A/T 0.46 42 844
NR2F6 14 Intron 1 A/C
0.5 40 113
CPAMD8 13 Intron 13 T/A 0.49 40 208
Intergenic 12 Intergenic A/G
0.43 39 48
MGC3169 11 Intron 4 T/C 0.21 39 64
CRSP7 10 Promoter G/C
0.28 39 179
SLC35E1 9 Promoter A/G 0.11 39 60
EPS15L1 8 Intron 17 T/C
0.46 37 647
Intergenic 6 Intergenic T/G 0.38 37 442
SLC1A6 5 Intron 2 C/G
Alleles
Minor Allele 
Frequency
Intermarker 
Distance 
(kb)
MAN2B1 1 Exon 8 G/A 0.4 32 601
Gene SNP No. Region Marker
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Table 9-3. SNP markers across the CRSP7 and SLC35E1 region of 
chromosome 19p13. Alleles are listed major/minor. 
 
Gene SNP No. Region 
dbSNP rs# 
/Celera hCV# Alleles 
Minor Allele 
Frequency 
Intermarker 
Distance (bp) 
EPS15L1 1 Intron 2 rs2305781/ hCV16191652 G/A 0.13 75,910 
CHERP 2 Exon 17 rs17029/ hCV2885433 C/T 0.27 14,193 
 3 Intron 5 rs8101084/ hCV29287905 G/A 0.12 19,156 
SLC35E1 4 Intron 6 rs12461181/ hCV3057302 T/C 0.07 3,658 
 5 Intron 5 rs731617/ hCV3057305 C/T 0.34 17,776 
 6 Promoter rs8110418/ hCV3057319 A/G 0.10 33,210 
CRSP7 7 Intron 1 rs751788/ hCV795308 G/C 0.01 13,351 
 8 Intron 1 rs3786602/ hCV3057145 A/G 0.33 1,524 
 9 Intron 1 rs11668934/ hCV3057143 G/A 0.05 1,665 
 10 Intron 1 rs10408776/ hCV3057144 C/T 0.14 2,707 
 11 Intron 1 rs3786604/ hCV27482120 A/G 0.16 4,023 
 12 Promoter rs3760673/ hCV31765862 T/C 0.33 1,138 
 13 Promoter pcr3SNP1 G/A 0.11 296 
 14 Promoter rs7351094/ hCV29287914 G/T 0.11 197 
 15 Promoter rs10425272/ hCV30483070 A/G 0.10 481 
 16 Promoter pcr2SNP1 T/C 0.05 983 
 17 Promoter rs12461484/ hCV11699366 G/C 0.43 12,973 
Intergenic 18 Intergenic rs4808051/ hCV27896147 C/T 0.07 1,526 
MGC2747 19 Exon 4 rs10402/ hCV11459109 T/C 0.05 201 
 20 Exon 3 rs706762/ hCV8931897 G/A 0.08 32,950 
MGC3169 21 Exon 3 rs730120/ hCV970369 G/A 0.05 584 
 22 Intron 4 rs901792/ hCV1975557 T/C 0.20 _ 
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Table 9-4. PCR and genotyping primers for the SNPs spanning the 19p13 
region. Labels are as follows: (F) Forward Primer, (R) Reverse Primer, (FP) FP-
TDI extension primer, VIC and FAM are fluorescent labels for TaqMan allelic 
discrimination probes (Bold highlights SNP), AbD is an Assay-By-Design from 
ABI, AoD is an Assay-On-Demand from ABI. MGB stands for minor groove 
binder, and NFQ stands for non-fluorescent quencher. 
 
SNP 
No. Primer sequences (5´-3´) 
Product 
size (bp) Assay 
1 F GCTGACAGTGAACAGAAAAGGACAA 
 R GCATGCCTGAGCTGAAAGC 
78 
 VIC VIC-CAGAATAGAAGCCTGGCTG-MGB-NFQ  
 FAM FAM-CAGAATAGAAGCCCGGCTG-MGB-NFQ  
TaqMan 
(AbD) 
2 NA Unavailable < 200 TaqMan (AoD) 
3 F GTGTGCGTGCAAATCAGTGA 
 R CAGCCACGGCCTCCTT 63 
 VIC VIC-CTGTGTCTGTTTCCTG-MGB-NFQ  
 FAM FAM-CTGTGTCTGTCTCCTG-MGB-NFQ  
TaqMan 
(AbD) 
4 NA Unavailable < 200 TaqMan (AoD) 
5 F CGCCAAGATCATAAACCAGTCAGT 
 R TCCCGGGCGCTCAAG 66 
 VIC VIC-ATGTCAGAGCTTTGC-MGB-NFQ  
 FAM FAM-TATGTCAAAGCTTTGC-MGB-NFQ  
TaqMan 
(AbD) 
6 NA Unavailable < 200 TaqMan (AoD) 
7 F GCTGTCTGGTGTGGTAGTGATC 
 R CCCTTCTTCCTTCACTCAAAACTGA 71 
 VIC VIC-CAAGGGATAGAGCATC-MGB-NFQ  
 FAM FAM-CAAGGGATACAGCATC-MGB-NFQ  
TaqMan 
(AbD) 
8 F GGTGGCCACATCCTCGTT 
 R AGGAGAGCCGTTAGCTACCAT 65 
 VIC VIC-CCAGGGTGATGTAGTAGT-MGB-NFQ  
 FAM FAM-CAGGGTGATGTGGTAGT-MGB-NFQ  
TaqMan 
(AbD) 
9 F CATCAGAAACCTTCTGGAAGCTTCA 
 R GGAGTAGGTTCTGTCCTCGAATTTT 87 
 VIC VIC-CATAACAACAGGTGTGCTT-MGB-NFQ  
 FAM FAM-CATAACAACAGATGTGCTT-MGB-NFQ  
TaqMan 
(AbD) 
10 F CCCATGCTTGGAGCACCTT 
 R TCCACACCCTGCTCTAAGAGT 58 
 VIC VIC-AAAGCGGCTGTTTTG-MGB-NFQ  
 FAM FAM-AAAAGCAGCTGTTTTG-MGB-NFQ  
TaqMan 
(AbD) 
11 F CCTGCTGCTATAGGAATTCAAATGC 
 R CCTTGACAAAGGAATTCTTAGGAGGAA 90 
 VIC VIC-CTCTCACTTTTAGCCCC-MGB-NFQ  
 FAM FAM-CTCACTTTCAGCCCC-MGB-NFQ  
TaqMan 
(AbD) 
12 F GAGGCCGCCGAGCTT 
 R AGCTCTGTTGGAAATGCTCTTGT 56 
 VIC VIC-CCTTTCCATCCCGTCTC-MGB-NFQ  
 FAM FAM-CTTTCCACCCCGTCTC-MGB-NFQ  
TaqMan 
(AbD) 
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13 F CCAAGTCATGTCAGTGCTTCTTAGT 
 R CTGGGTGACAGAGCAAGACT 100 
 VIC VIC-TCCAGATGTTTGTTTATTT-MGB-NFQ  
 FAM FAM-TCCAGATGTTTATTTATTT-MGB-NFQ  
TaqMan 
(AbD) 
  
14 F ACACCCTTTTACGTACATTAAATGTGGAA 
 R GAGCTATTTCTGGAATGAATGAAATACTTCATAAAAT 118 
 VIC VIC-CCGTGTGTGTGTTGTGTA-MGB-NFQ  
 FAM FAM-CCGTGTGTGTTTTGTGTA-MGB-NFQ  
TaqMan 
(AbD) 
15 F CGAACCATCACAGCAAGAGGAATTA 
 R CAACTTTCTGCATTGAGACATCCTT 90 
 VIC VIC-CATCTTCGCATAACTGACA-MGB-NFQ  
 FAM FAM-TCTTCGCATAGCTGACA-MGB-NFQ  
TaqMan 
(AbD) 
16 F CCCATGGCAAGAGCAAGTCAT 
 R CAGAGCGAGACTCCATCACAAATAT 97 
 VIC VIC-TCCTCTCCCTTTTTTCTAT-MGB-NFQ  
 FAM FAM-CCTCTCCCTTTCTTCTAT-MGB-NFQ  
TaqMan 
(AbD) 
17 F AGACCTCAATTTTTTAATCCCATCTTCAAGT 
 R CACCCCCCAACCAGGTT 94 
 VIC VIC-ACTGGAACCTTTGTGTATC-MGB-NFQ  
 FAM FAM-ACTGGAACCTTTCTGTATC-MGB-NFQ  
TaqMan 
(AbD) 
18 F GTCTGAATAAGGCAGGAAGGTTTCT 
 R GAACAGGCACGCCAAGATC 81 
 VIC VIC-CAGGCCAAATGAAT-MGB-NFQ  
 FAM FAM-CAGGCCAGATGAAT-MGB-NFQ  
TaqMan 
(AbD) 
19 NA Unavailable < 200 TaqMan (AoD) 
20 F CGTGGTGGGTGGAAAAGTGT 
 R ACGTGGCTGGGAAACCAT 52 
 VIC VIC-CGCCGAGGTGTGC-MGB-NFQ  
 FAM FAM-TCGCCAAGGTGTGC-MGB-NFQ  
TaqMan 
(AbD) 
21 F GAGCAGATCAGCCAGGATGTAG 
 R GCTGTGCGCCATGCT 52 
 VIC VIC-CTCCCGAAGCAATG-MGB-NFQ  
 FAM FAM-CTCCCAAAGCAATG-MGB-NFQ  
TaqMan 
(AbD) 
22 F ACAATGAAAAATCATCCCAGTGGAGAA 
 R GGAGCAATGGCTTTCCTAGCT 
79 
 VIC VIC-CCACTGGACCAAAAG-MGB-NFQ  
 FAM FAM-CCACTGAACCAAAAG-MGB-NFQ  
TaqMan 
(AbD) 
 
 
Variant screening was performed on exonic sequence and non-coding 
putative promoter regions across the CRSP7 and SLC35E1 loci. Our laboratory 
screened these regions through direct sequencing. PCR products for re-
sequenced samples were submitted to the Vanderbilt Shared Sequencing 
Resource Facility after initial PCR reactions were performed in the lab. PCR 
reaction volumes were 8 µl, employing 10 ng genomic DNA template, 0.2 µM 
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primers, 125 µM dNTPs and AmpliTaq Gold DNA polymerase and buffer (Applied 
Biosystems). Cycling conditions included an initial denaturation at 95 °C for 10 
min, followed by 50 cycles of 94 °C for 30 s, optimal annealing temperature 
(TA°C) for 30 s, and 72 °C for 1 min, and a final extension at 72 °C for 10 min. 
Post-PCR reaction cleanup was performed using Exo-Sap-It (USB) and then sent 
to the core for sequencing using the Big-Dye terminator system. Larger regions 
were amplified from both directions to get complete sequence information for the 
region of interest. Some sequencing reactions were carried out with universal 
primers (M13F (-21) 5′-TGTAAAACGACGGCCAGT-3′ and M13R 5′- 
CAGGAAACAGCTATGAC-3′). Sequencing primers for all sequenced intervals 
are shown in Table 9-5. 
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Table 9-5. Sequencing primers for variant screening across the CRSP7 and 
SLC35E1 loci. Labels are as follows: (F) Forward Primer, (R) Reverse Primer, 
(TA) Annealing temperature. *Note that some sequencing reactions were carried 
out with universal primers (M13F(-21) 5′-TGTAAAACGACGGCCAGT-3´ and 
M13R 5´- CAGGAAACAGCTATGAC-3´) added to the 5´ end of the listed primer.  
 
Gene Region  Primer sequences (5´-3´) Product Size (bp) 
TA 
(°C) 
CRSP7 F* CGCTGGCAGAAATTTTTAAAACCCTT 
 
Snp1 
R* CCACAGGGTCAGAGGGTATGAGCTT 
708 64 
 F* GGAAAAGGCAAGGAAGTTAGTGTC 
 
PCR1 
R* CCTTTCTGTATCCCCATCCCTAC 
942 59 
 F* TCATCAAATACACGGTAGCG 
 
PCR2 
R* ACTTGACCTCCTGACACTAACTTC 
913 59 
 F* TTTTGCATGGGTCAGGTTATT 
 
PCR3 
R* TGTGTGTTGTGTATCCTGGTGTAT 
930 59 
 F* AGACCCTTCTACCCGCCTCT 
 
PCR4 
R* CTTAAAATAACCTGACCCATGCAA 
772 59 
Gene Exon  Primer sequences (5´-3´) Product Size (bp) 
TA 
(°C) 
CRSP7 F CGGCGGGTACTTACGTTGCTC 
 
1 
R CTCCCAACCTCCTCAGCGTG 
423 59.3 
 F CATCAAGGCCACTGTAAGGA 
 2 R CATCAGATGGCAGAGTAGAGG 802 52.0 
 F* ATTTTGTTGAGGTGGGGGTAGT 
 3 R* GTCATGTGCCAGAAGCTTCTC 895 57.5 
 F AGCTTCTGGCACATGACA 
 3 R GTCAGGACACACAGGGTA 655 60.2 
 F CACTGGGCTTTCCGCACTG 
 3 R TTCACTGTCAGGGCCACTTCC 962 57.5 
SLC35E1 F GCTTCCTCCTGCCACGGCTGTT 
 1 R CGACCAATGGGAAACGGCGTAG 764 62.6 
 F AACGGGGAGGAAAATTGGATCTGA 
 2 R TTTGGTAGGGGAGGGACACGC 575 57.3 
 F CCGGCCAGAAAAACAAACTATT 
 3 R TTTCAAAGTGTTAGGTGGTATCCC 445 62.8 
 F TGAGGCATTACAGAGGACTGACTG 
 4 R TCCAGGTCTTGCGAGATTCAC 283 53.3 
 F CAGTGGCAAAGCTCTGACATACAA 
 5 R AGTGCTGTCTTTACCTTCCGGTCT 395 56.3 
 F GCGACACCATGCCCGGCTAAT 
 6 R CGCAGCCAGCCAGTTGATTGACTT 1512 64.0 
 F ACTTCCCATGTTATTCCGTTCAAT 
 7 R GCGCAGTCTCAGCTCACTACAA 1112 56.8 
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Statistical Analyses  
Initial analysis of SNP genotype data involved quality control checks 
consisting of verification of internal controls and assessment of Mendelian 
inconsistencies, followed by final haplotype consistency analyses using 
Simwalk2 [117]. Conformity with anticipated Hardy-Weinberg equilibrium 
expectations was established.  
Linkage was analyzed using both model-dependent and model-
independent methods. Multipoint heterogeneity LOD (HLOD) scores were 
calculated under both dominant and recessive models using Allegro [187]. 
Disease allele frequency was estimated to be 0.01 and 0.1 for dominant and 
recessive models, respectively. The phenocopy rate was 0.0005, and the 
penetrance value was set at 0.5 for the analysis. These simple models were 
chosen somewhat arbitrarily, simply making the disease allele frequency 10-fold 
greater under a recessive model than under the dominant model. The reduced 
penetrance value was set at 50% given the likelihood of oligogenic inheritance 
and the possibility of heterogeneity, such that not all individuals having the allele 
would present with disease. These parameters, while minimizing our power 
somewhat, have a smaller impact on the lod scores when there is either linkage 
or no linkage and were therefore selected to be robust [116]. Phenotypic status 
was only considered for affected individuals, and other family members were 
designated as having an unknown phenotypic status. Nonparametric analysis 
involved calculating allele-sharing LOD* values using affected relative pair data 
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based on an exponential model that uses the Spairs scoring function as 
recommended by McPeek [188].   
Transmission disequilibrium (TD) in autism families was determined using 
the pedigree disequilibrium test (PDT) statistic, developed for use with general 
pedigrees [119]. Maternal and paternal specific transmissions were also 
assessed using the TSP test [156]. Common haplotypes (≥5%) were determined 
using Haploview [129], and analyzed using the FBAT analysis software package 
[130]. TD for haplotypes was performed using haplotype tag SNPs for multi-
marker blocks. Results were considered significant at the nominal level for 
markers or haplotypes with P ≤ 0.05. Common haplotypes were determined 
using Haploview, and analyzed using the FBAT analysis software package [130]. 
Results were considered significant at the nominal level for markers or 
haplotypes with P ≤ 0.05. 
In addition to TD being measured in all families, based on the well-known 
male bias in people affected by autism and observations of sex-specific biases in 
genetic risk by Stone et al., we performed analyses using only those families 
containing male-affected individuals [79]. Thereby excluding from these 
additional analyses any family containing a female-affected individual. 
Visualization Tools for Alignment (VISTA) analysis was performed via 
web-based submission (http://www.gsd.lbl.gov/vista/) of human and mouse 
genomic sequence [121]. Regions showing evolutionarily conserved non-coding 
sequence were identified for future variant screening purposes. 
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Results 
 To move forward with a more detailed examination of apparent genetic 
risk being detected in 19p and 17q, we attempted to define a narrowed interval of 
linkage for both regions, by increasing information content through genotyping 
SNP markers in an ~1-cM grid across linked intervals. Markers were chosen to 
cover LOD-based confidence intervals. The chromosome 17 follow-up involved 
39 markers, spanning approximately 46 cM. For chromosome 19p, 23 markers 
were genotyped across approximately 19 cM. Markers were spaced at 
approximately 1-cM intervals and chosen specifically to lie within genes in the 
two intervals. An identical 158-family dataset, examined in the initial genome-
wide linkage scan and detailed in Chapter VIII, was used for our linkage follow-up 
analysis. Figure 9-1 shows the multipoint parametric HLOD plots for both 
chromosome 17 (under a dominant model) and chromosome 19 (under a 
recessive model). Plots reflecting data from only the SNP follow-up panel are 
shown, as well as a plot for combined data in which the SNP genotype 
information was integrated with the existing microsatellite data. Although the 
information content across the follow-up regions did not significantly increase 
with the addition of our follow-up markers, our results did help to prioritize the 
region of greatest interest below our original broader peaks. The plots for 
chromosome 17 demonstrate a narrowing of the interval, for the centromeric 
(more prominent) peak, to roughly 6 cM (50-56 cM on the deCODE map) from 
the original ~20 cM region (40-60 cM). The peak corresponding to the narrowed 
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interval remains centered directly under SLC6A4. The plot containing combined 
data for chromosome 19 not only substantially narrows the region of interest from 
the 18 cM  (32-50 cM) to a 2 cM region (~39-41 cM), but also increases our peak 
LOD score from 2.6 to 3.1. 
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Figure 9-1. Follow-up multipoint linkage analysis for chromosomes 17 (A) 
and 19 (B). Multipoint parametric HLOD plots for chromosome 17 (Dominant 
model) and chromosome 19 (Recessive model) are shown. Linkage analysis 
showing our original “Microsatellites only” (green), our follow-up “SNPs only” 
(yellow), and the “Combined” set of microsatellite and SNP markers (black).  
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 While recognizing a substantial improbability of detecting meaningful 
association using markers spaced at 1 cM intervals, we nevertheless took 
advantage of availability to this data by testing available families for evidence of 
allelic association. Given that follow-up markers were chosen not based on map 
position and high minor allele frequency alone, but also based on their location 
within genes; thus we hoped to bias towards the ability to detect, by virtue of 
strong LD, the potential for functional effects. Family-based TD analysis was 
performed using PDT, and we tested in a more exploratory fashion for maternal- 
or paternal-specific TD effects using the Tsp statistic. Results of these analyses 
are shown in Table 9-6. While the data for chromosome 17 are generally 
negative, we identified several markers on 19p that demonstrated nominal 
evidence for association to autism. Although there is a cluster of significant 
values, linkage follow-up marker 10 (hCV11699366) yielded the most significant 
finding.  
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Table 9-6. PDT analysis of follow-up SNPs across 17q and 19p.  
 
 
 
The nominally significant TD values were clustering around a group of 
genes at approximately 40 cM. Continuing with the unbiased approach to detect 
common disease-associated risk alleles, additional markers were selected and 
genotyped across the ~300-kb region wherein association was detected. 
Particular focus was placed around marker hCV11699366, demonstrating 
Chromosome
Marker 
No.
Overall 
PDT (P)
Tsp 
Father 
(P)
Tsp 
Mother 
(P)
Chromosome
Marker 
No.
dbSNP rs#/ 
Celera hCV#
Overall 
PDT 
(P)
Tsp 
Father 
(P)
Tsp 
Mother 
(P)
17 1 0.21 0.29 0.16 19 1 0.16 0.92 0.33
2 0.13 0.37 0.65 2 0.32 0.77 0.02
3 0.33 0.31 0.52 3 0.60 1.00 0.50
4 0.95 0.29 0.81 4 0.67 0.23 0.12
5 0.68 0.26 0.40 5 0.72 0.27 0.83
6 0.58 0.38 0.77 6 0.36 0.64 0.23
7 0.24 0.29 0.09 7 0.95 0.64 0.53
8 0.62 0.41 0.31 8 0.04 0.23 0.03
9 0.66 0.86 0.91
10 0.46 0.50 0.53
11 0.30 0.34 0.23
12 0.69 0.54 1.00
13 0.08 0.11 0.57 11 0.38 0.12 0.51
14 0.81 0.73 0.20 12 0.15 0.55 0.85
15 0.13 0.03 0.48 13 0.20 0.49 0.36
16 0.86 0.75 0.81 14 0.74 0.92 0.19
17 0.95 0.60 0.67 15 0.49 0.30 0.25
18 0.32 0.61 0.37 16 0.58 0.71 0.36
19 0.25 0.43 0.04 17 0.23 0.84 0.54
20 0.65 1.00 0.83 18 0.05 0.30 0.55
21 0.13 0.20 0.44 19 0.39 0.59 0.70
22 0.86 0.62 0.91 20 0.49 0.09 0.06
23 0.60 1.00 0.77 21 0.86 1.00 0.29
24 0.09 0.31 0.46 22 0.08 0.92 0.05
25 0.76 0.68 0.59 23 0.65 0.74 0.76
26 0.82 0.61 0.92
27 0.96 0.83 0.48
28 0.13 0.17 0.09
29 0.77 0.92 0.92
30 0.80 1.00 0.80
31 0.50 0.78 0.30
32 0.25 0.85 0.25
33 0.72 0.21 0.74
34 0.31 0.56 0.80
35 0.15 0.90 0.35
36 0.95 0.92 0.63
37 0.07 0.18 0.82
38 0.23 0.61 0.82
39 0.39 0.23 0.84
0.04
10
rs12461484/ 
hCV11699366
0.01 0.10 0.09
9
rs8110418/ 
hCV3057319
0.01 0.25
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relatively significant TD (P = 0.0012, rounded to 2 decimal places in Table 9-6). 
Analysis of additional markers in the 158-family dataset surrounding 
hCV11699366, located in the promoter of CRSP7, revealed five SNPs (including 
hCV11699366) that showed nominally significant evidence for TD. Moreover, 
examination of haplotype blocks using both HapMap data, as well as our own 
genotype data, revealed that all five of these markers were located within a single 
haplotype block containing three genes: CRSP7, SLC35E1, and CHERP.  
Specific markers, significant associations, corresponding genes, intermarker LD 
relationships based on D´ values are all shown in Figure 9-2. HapMap LD data, 
based on 30 CEPH trios, are compared to that generated from our much larger 
dataset; the resulting increased information is reflected in the difference between 
the Haploview LD plot using HapMap data (Figure 9-2, lower half) and Haploview 
output generated from our own data (Figure 9-2, upper half). 
172 
 
Figure 9-2. Schematic and analysis of the 19p13 region. Markers surrounding 
hCV11699366 are illustrated. Markers demonstrating significant association have 
accompanying p values. Relative intermarker spacing is also shown. LD blocks are 
numbered right to left. The black outline surrounds each of our self-defined haplotype 
blocks with intermarker D´ values labeled within the individual boxes. Intermarker linkage 
disequilibrium with D´ values of 1.0 are never shown, but indicated by the dark red boxes 
for a LOD score ≥ 2 and indicated by the blue boxes for a LOD score < 2. White shading 
indicates a D´ < 1 and a LOD < 2, while shades of pink/red indicate D´ < 1 and a LOD ≥ 
2. 
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Given that hCV1169936 was located in the promoter of CRSP7, we 
evaluated the possibility of this marker correlating with one or more transcription 
factor binding sites. Sequence corresponding to either allele was tested using the 
web-based CONSITE program [201], and haplotypes for the significant SNP-
containing block (block #3) were detailed using Haploview (Figure 9-3). While 
significant caveats accompany any such in silico prediction, we found that the 
over-transmitted allele [C] at hCV1169936, corresponds to a non-consensus 
residue in the consensus binding site sequence for a basic helix-loop-helix factor 
Spz1. 
 
 
Figure 9-3. CONSITE output of the 19p13 region LD block #3. 
 
Given the likelihood of identifying this number of markers by chance 
demonstrating significant association within a single block seemed highly 
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unlikely, we further tested the significance of these data. These and a few 
additional SNP markers were genotyped in an additional 226 (predominantly 
multiplex AGRE) families from the NIMH repository. Single marker PDT analysis 
of resulting genotype data revealed only two of the previously significant markers 
replicated a nominal significance, with hCV11699366 in the CRSP7 promoter 
yielding a P = 0.05, and rs8110418 in SLC35E1 also showing nominal TD (P = 
0.02) in the total dataset (Table 9-7). Single marker association results and 
transmission counts for significant markers can be found in Table 9-7. 
Association analysis in the overall dataset, using FBAT, of all common 
haplotypes yielded no significant association (data not shown). 
. 
Table 9-7. PDT analysis of markers across the 19p13 region. 
Marker 
No.
dbSNP rs#/ 
Celera hCV#
Overall 
PDT (P)
Allele
# of Alleles 
Transmitted
# of Alleles    
Not 
Transmitted
1 0.91
2 0.69
3 0.80
4 0.21
5 0.18
A 540 566
G 78 52
7 0.23
8 0.20
9 0.40
10 1.00
11 0.83
12 0.22
13 0.28
14 0.16
15 0.86
16 0.24
G 712 762
C 592 542
18 0.51
19 0.91
20 0.78
21 0.30
22 0.61
6 0.02
17 0.05
rs8110418/ 
hCV3057319
rs12461684/ 
hCV11699366
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 In a concurrent study, we addressed the alternative to the “common-
disease-common variant” hypothesis by screening for heterogeneous disease-
related alleles. We selected a panel of 24 affected and unrelated individuals from 
families demonstrating evidence for linkage to 19p13, as determined from 
ranking families for the highest multipoint HLOD score at the 40 cM location on 
chromosome 19p13. We sequenced all known CRSP7 and SLC35E1 exons for 
these 24 individuals.  In addition we sequenced 5 overlapping regions 5´ of 
CRSP7 exon one surrounding the putative promoter region and including marker 
hCV11699366 (our most significant marker in the chromosome 19 follow-up 
SNPs). While several variants were rediscovered, one (hCV3057306/rs2287869, 
a synonymous variant in exon 5 of SLC35E1) was observed to be heterozygous 
in 9 individuals and homozygous (for the rarer allele) in 6 individuals within our 
screening panel. This may at first glance seem significant; however, it is most 
likely non-significant given this marker has a dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/) reported minor allele frequency of ~0.40 in 
the general population. Two other markers, 13 (pcr3SNP1) and 16 (pcr2SNP1) in 
Table 9-3 are novel. These novel markers were subsequently genotyped in the 
entire dataset and included in both the single marker and haplotype analysis, but 
yielded no significant association. 
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Discussion 
We identified 19p13 as harboring a putative autism susceptibility locus, 
based on very suggestive linkage to autism detected in a genome-wide survey 
for autism risk loci. A follow-up analysis of these two loci to refine genetic linkage 
was very successful in narrowing linked intervals. In the case of chromosome 
17q, there was a decrease in the observed LOD scores. However, intervals for 
both the primary peak underlying the SLC6A4 locus and a more distal peak at 
17q21 (~70 cM) were substantially narrowed when using a LOD score value of 
1.0 as a cutoff. While the reduction in linkage is somewhat disturbing, other data 
from more recent analyses of linkage to this region suggest that the overall 
evidence for linkage of autism to this chromosome is very strong. The more distal 
peak could correspond to a distinct genetic effect at the integrin β3 (ITGB3) 
locus. Weiss and colleagues recently reported identification of this locus in a 
genome-wide QTL association screen for circulating 5-HT levels in a population 
isolate [199]. The same group subsequently reported a “sex-specific architecture” 
for allelic association at ITGB3 and SLC6A4 for 5-HT levels. That the narrowed 
peak in the current analysis and subsequent analyses remains coincident with 
SLC6A4 also underscores this gene as an attractive candidate.  
Follow-up SNP-based linkage analyses on 19p not only identified a 
narrowed, more significant, peak at 19p13 (~40 cM), but it also suggests a 
second locus at ~55 cM. While this pattern of linkage was present to some 
degree in the initial microsatellite-based genomic screen, addition of the SNP 
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genetic information makes this pattern more clear. The conclusion we can draw 
from these studies is that maximizing genetic information content in a region of 
interest is an important step in, not just refining, but in some cases actually 
defining focused intervals within which gene discovery should be pursued. 
By continuing a biologically unbiased approach in search of autism 
susceptibility genes through SNP-based follow-up, we exploited the availability of 
data spanning the initially-linked interval to perform exploratory association 
analyses. With little a priori likelihood of identifying biologically-relevant 
association, given a sparse (relative to general expectations of linkage 
disequilibrium) ~1-cM grid of markers, we identified an intriguing pattern of 
association in adjacent markers, leading us to further explore the region. This 
strategy led to identification of a haplotype block containing three genes CRSP7, 
SLC35E1, and CHERP.  While these genes co-localize with peak linkage (at ~40 
cM), and thus represent positional candidates for an autism risk locus, these 
genes would not make a priori compelling candidate loci for autism. However, the 
principle underlying this biologically unbiased approach is to allow excess allele 
sharing within a disease population, to lead one to the relevant risk factors.  
Though these genes may not initially make compelling biological 
candidates, it is important to point out their function, if known. CRSP7 encodes a 
subunit of the CRSP co-factor that binds to the C-terminal domain of RNA 
polymerase II to mediate Sp1 transcriptional activation [202]. SLC35E1 is a 
solute carrier of unknown function. CHERP encodes a protein important in 
maintaining Ca++ homeostasis in the endoplasmic reticulum, and is thought to be 
178 
important generally in intracellular Ca++ mobilization, and cellular growth and 
proliferation [203]. Without evidence of specific function for SLC35E1, CHERP, 
which is expressed in the brain based on UniGene expression profiling, may 
represent the most promising of the three genes for predicting functional 
relevance to autism. 
Identification of a total of five SNPs within this block demonstrating 
evidence for association is very compelling but difficult to interpret. Concerns 
regarding multiple testing and Type I error may be reduced somewhat, because 
we were following up an initial observation and more carefully characterizing the 
association in that region. Regardless, given the number of tests performed 
within that block (13) and region (18), hCV11699366 (P = 0.0012) would remain 
significant based on Bonferroni correction. Considering the initial follow-up SNP 
association test, which involved 23 markers, association at hCV11699366 
remains significant following Bonferroni correction for 23 tests.  However, 
analysis of association within this block in a larger dataset containing 384 
combined multiplex and trio families yielded reduced significance; only 
hCV11699366 (P = 0.05) and another previously associated marker (rs8110418; 
P = 0.02) from the original 158 families retain nominal evidence for association.  
It may be important to consider that similar follow-up linkage analysis in the 327 
multiplex families (from the total 384-family dataset), was virtually identical in 
magnitude to that observed in the 158-family dataset. Therefore, the observation 
of reduced significance in tests of allelic association in the CRSP7-SLC35E1-
CHERP haplotype block may not be at all surprising using this entire dataset. 
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Given the additional families examined for association may not be linked to 
chromosome 19, future studies will likely include the examination of the subset of 
linked families for association at these and other markers across the interval.   
In an exploratory manner, the examination of marker hCV11699366 using 
CONSITE revealed plausible evidence this marker may alter a putative 
transcription factor binding site for Spz1. While these findings are initial and 
highly speculative, they demonstrate the usefulness and potential of such tools 
for examination of alleles at markers with unknown functionality. 
Though we did not provide compelling evidence of a common allele at 
this locus to be involved in autism susceptibility, these studies are still in their 
infancy and provide the groundwork for future experiments. Studies to date also 
lack evidence for heterogeneous disease-risk alleles. 
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CHAPTER X 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 Science is in a state of constant evolution, and research into complex 
disease is no exception. Advances have been made not only in the technology 
being used, but also in the basic way we define disease. Complex diseases are 
beginning to be examined as specific traits or phenotypes that characterize a 
particular disease or class of diseases. Scientists are testing whether these traits, 
which may or may not be quantitative, may hold the key to unraveling some of 
the complexity. Even more prominent is the idea of a complex disease having a 
genetic and/or environmental susceptibility landscape.  This idea implies that 
once a given threshold, whether it be genetic or environmental or a combination 
of both, is exceeded a person presents with disease. Understanding this 
susceptibility landscape as well as potential environmental triggers will set the 
stage for preventative and therapeutic research. 
The goals set forth in this body of work were to dissect both genetic and 
phenotypic susceptibility for a severe neurodevelopmental disorder, which is 
characterized by life-long deficits. Autism may be justifiably viewed as one of the 
more complex of the complex diseases. From the complex phenotypic spectrum, 
which includes other known genetic disorders (i.e. Fragile X syndrome, Rett 
syndrome, and tuberous sclerosis), to the male bias seen within the autism 
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spectrum of disorders, to numerous positive yet not replicated molecular and 
genetic findings, and finally to the high potential for gene-gene interactions, gene-
environment interactions, and/or epigenetic and imprinting effects there is 
substantial evidence for complexity. 
To examine the genetic susceptibility landscape we began our genetic 
studies by examining two of the more prominent regions of the genome and then 
expanded to a third region based on new lines of evidence. All of these regions 
arguably harbor potential candidate genes, which have previously been 
discussed. We characterized linkage disequilibrium patterns, haplotype block 
structures, and identified haplotype tag markers where relevant. In addition we 
tested for both single marker associations and multi-marker haplotypes 
associations in our overall dataset as well as different phenotypic subsets. 
Finally, in smaller samples we examined potential functional sequences at 
selected loci through use of molecular screening methods. 
An overall conclusion is that there does not appear to be a common 
variant across any of the loci that is responsible for autism susceptibility in all 
cases or even a majority of cases. This conclusion is not a great surprise given 
the likelihood of both locus and allelic heterogeneity, but further details the 
complexity surrounding this disease. The lack of strong association to a common 
marker at any of the loci does not rule out their involvement in disease, but may 
merely suggest allelic heterogeneity at the locus or allelic interactions of common 
alleles with other loci. We do however detect instances of single marker and 
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haplotype associations in phenotypic subsets. These results provide preliminary 
findings for further study and illustrate the potential usefulness and desire to 
homogenize this diverse dataset. In the very near future, larger sample sizes will 
offset the power issues present with current subsets of the data.  However, 
replication issues may still persist if larger samples sizes are used in the initial 
studies and cannot be found for replication studies. 
Technology is also improving at a great rate. As genotyping throughput 
increases and costs decrease, genome-wide association studies of large autism 
samples will soon offer the potential to detect genes of small to moderate effect 
without requiring hypotheses about pathophysiology or chromosomal location.  
Currently such hypotheses, which can sometimes be quite elaborate, are 
necessary to narrow a large region of suggestive linkage to a manageable 
number of candidate loci. 
Additional technological advances must be made to handle the large 
amount of data now being generated. In addition to the sheer volume of data to 
handle, resources and methods must be created to test for inter-locus 
interactions. With little to no replicable evidence with regard to genes or alleles of 
major effect within autism, there may be numerous allelic interactions that affect 
disease susceptibility. It is a very plausible hypothesis that genes in a common 
biological pathway may interact to yield disease; however, the complexity of such 
a pathway is likely greater than our current understanding. Moreover, strategies 
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to tease apart both locus and allelic heterogeneity must be developed and will 
likely play a key role in examination of complex genetic disease. 
Another potential issue beyond the scope of this project involves 
epigenetic variations. Unknown and unexamined epigenetic differences may 
have a great affect on particular genotypes as they relate to disease risk. It may 
be clearer to see the effects of epigenetics when it comes to diseases that 
present more gradually in the adult. Epigenetic variation may be a necessary and 
specific target for environmental influence, upon which alteration can 
demonstrate adverse effects over time. In the case of developmental disorders 
such variation in developmentally differentiated genes may have more immediate 
irreversible outcomes. Though this is purely speculative, the reality of autism is 
most likely a combination of genetic, interactive, environmental, and epigenetic 
effects that we are only at the tip of understanding.  
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